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Abstract
The aim of the research in this thesis was to discover and validate blood biomarkers
of early Alzheimer’s Disease (AD). Existing and novel datasets from cohort studies
were used for discovery and to attempt validation of previously reported biomarkers.
For example, this thesis presents the first study to investigate associations between
brain amyloid and blood metabolites. Further, this thesis presents the first study to
combine more than one modality of blood biomarker in AD research and the first
study to use a Bayesian methodology in this field.
This thesis begins by aiming to validate candidate protein markers of brain
amyloid burden in a novel proteomics dataset. Secondly, pathway-based methods are
used to investigate the use of gene expression measurements as a potential biomarker
of AD diagnosis. In the fourth chapter I generated a novel metabolomics dataset
to investigate associations between blood metabolites and brain amyloid burden. A
panel is found that predicts dichotomized amyloid burden with reasonable accuracy.
The accuracy is improved by the inclusion of a candidate protein in the model.
The fifth chapter of this thesis is focused on the use of a Bayesian methodology
to predict measurements of amyloid using a variety of omics data. The Bayesian
methodology allows incorporation of historical information by placing informative
priors on demographic variables. No improvement is seen over demographics alone.
The final chapter of this thesis aims to predict amyloid and tau burden using a
polygenic risk score and levels of tau in blood. I have also considered a combined
amyloid and tau pathology endpoint. The blood markers considered here do not
improve predictive ability over demographics alone.
Much of the work in this thesis highlights the importance of demographic factors
in the diagnosis of early AD. The metabolite discovery work shows an improvement
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in predictive ability over demographics alone and warrants further investigation and
replication. The other chapters of this thesis highlight that (in the settings inves-
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Alzheimer’s Disease (AD) was first described in 1906 by Alois Alzheimer (Maurer
et al., 1997). He was faced with the case of a 51 year old woman, Auguste D, whose
symptoms included memory loss, disorientation, hallucinations and psycho-social
incompetence. Alzheimer was unable to reach a diagnosis but was interested in her
condition and monitored Auguste closely. When she passed away Alzheimer per-
formed an autopsy that resulted in the first records of amyloid plaques in the brain.
One hundred and ten years on, many advances have been made in understand-
ing dementia, raising awareness and providing suitable care. However, advances in
treatments for the disease have been few and far between (Corbett & Ballard, 2012).
In modern medicine, AD falls under the umbrella term of neurocognitive disor-
der formerly classified as dementia. Such disorders are characterised by a decline in
cognitive functioning from a level previously attained. In particular, the Diagnostic
and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) defines six cog-
nitive domains: perceptual-motor function, language, learning and memory, social
cognition, complex attention and executive function. DSM-5 diagnosis of probable
AD requires decline in at least two cognitive domains one of which should be mem-
ory and learning (Sachdev et al., 2014). A variety of symptoms are associated with
AD and there is large variation between individuals. Symptoms can include memory
loss, confusion, hallucinations and sleep disturbances eventually leading to complete
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loss of speech, movement and memory. Ferri et al. (2005) estimated the global de-
mentia prevalence at 24.3 million people with 4.6 million new cases developing each
year. With an ageing population the number of people who develop this condition,
and the cost of their care, is rapidly increasing. AD, as the most common form of
dementia, will pose a significant socio-economic burden to the society of the future
(Wimo et al., 2013).
There are two main types of AD: early onset and late onset (or sporadic) AD.
Their combined prevalence in the United States (US) was estimated at 5.3 million
people in 2015 with a projected incidence of 615,000 new cases a year by 2030
(Alzheimer’s Association, 2015).
1.1.1 Early Onset Alzheimer’s Disease
Early onset Alzheimer’s Disease (EOAD) is a Mendelian disorder and is typically
associated with an age of disease onset younger than 65 years. A Mendelian disorder
is one where the presence of a mutation at a specific gene locus guarantees devel-
opment of the disease. In the case of EOAD the cause of disease is an autosomal,
dominant mutation in either the Presenilin 1 (PSEN1 ), Presenilin 2 (PSEN2 ) or
amyloid precursor protein (APP) genes. Although the development of disease is a
given if at least one of these gene mutations is present, several diagnoses could be
made under the International Working Group (IWG-2) criteria (Dubois et al., 2014).
The gene mutations provide evidence of in-vivo AD pathology for pre-clinical states
of AD, typical AD and atypical AD.
In the US it is believed that around 200,000 people have a diagnosis of EOAD
(Alzheimer’s Association, 2015). This is approximately one 25th of the number of
people who have the late onset form of AD.
1.1.2 Late onset Alzheimer’s Disease
LOAD has a much higher prevalence with an estimated 5.1 million people living
with the disease in the US (Alzheimer’s Association, 2015). LOAD has a complex
etiology and is consequently less well understood than EOAD. Presence of LOAD
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cannot be completely determined by one genetic locus or group of loci. It is thought
that the disease process is controlled by a range of genetic and environmental risk
factors each conveying varying levels of risk for disease.
The remainder of this thesis is focused on LOAD, which for brevity will be
referred to as AD from here onwards.
1.1.3 Disease pathology
It has been hypothesised that the cause of AD is a build up of amyloid-β (Aβ)
plaques and hyperphosphorylated tau tangles in the brain. The senile plaques in
the brains of people with AD were first observed by Alzheimer himself in 1906. It
wasn’t until 1984 that Glenner & Wong (1984) identified the plaques to be made
of Aβ protein. Amyloids are insoluble, mis-folded proteins that have been asso-
ciated with several diseases including Huntington’s Disease, Rheumatoid Arthritis
and Amyloidosis (Ramirez-Alvarado et al., 2000). In particular, Aβ is most com-
monly found in its 40 and 42 amino acid forms as a result of cleavage of the amyloid
precursor protein (APP) by α and γ secretase. The normal function of Aβ is not
well understood but Aβ abundances in the brain have been observed to increase
during ageing (Hiltunen et al., 2009). Tau proteins are largely found in neuronal
cells with their primary function being to stabilize microtubules. They are coded for
by the microtubule-associated protein tau (MAPT ) gene, found on chromosome 17,
and when hyperphosphorylated form pathogenic tangles. Tau proteins have been
associated with other neurodegenerative disorders besides AD, including frontotem-
poral dementia (FTD), and are also present in high levels in the cerebrospinal fluid
(CSF) of people who have suffered a traumatic brain injury (Ling et al., 2015).
It is extremely difficult to directly study the causes of AD. Several factors con-
tribute to this, most obviously the inaccessibility of brain tissue in a living human.
Post-mortem studies can be conducted on brain samples but the tissue is incredibly
complex and slow to develop. Furthermore, the heterogeneity of pathology between
individuals is very high. This means large sample sizes are often needed to perform
any meaningful analysis. Bodily fluids such as CSF, blood, urine and saliva are far
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more accessible. However, other than CSF, they are separated from the brain by the
blood-brain barrier (BBB). As this is only a semi-permeable membrane, the chances
of signal passing from the brain into surrounding fluids are reduced. Although, it
has been observed that the BBB weakens with age which may aid us in detecting a
signal in blood (Montagne et al., 2015).
The amyloid cascade hypothesis (Figure 1.1) is a common theory detailing how
the aggregation of Aβ and tau results in AD. It states that Aβ plaques precede tau
tangles and start the process of tau accumulation. The hypothesis states that, given
enough time, the development of this pathology will always lead to AD through
damage to synapses and eventually neurons (Karran et al., 2011). The popular
theoretical model of disease progression suggested by Jack et al. (2013) details our
current understanding of the sequential changes in Aβ, tau, brain structure, mem-
ory and cognitive function over time. This model is consistent with the amyloid
cascade hypothesis as it suggests that the aggregation of Aβ plaques precedes the
presence of other AD pathologies. Other evidence in support of the amyloid cascade
hypothesis includes the fact that Down’s syndrome greatly increases an individuals
risk of developing AD (Wiseman, 2015). Down’s syndrome is caused by trisomy of
chromosome 21, the same chromosome that holds the APP gene.
There are some fundamental questions that challenge the amyloid cascade hy-
pothesis (Morris et al., 2014). In particular, many people with high Aβ burden at
autopsy show no signs of cognitive impairment during their lifetime. It has been
suggested that this is because they did not live long enough for the symptoms of
AD to develop. This may be true but is impossible to verify. Further, the amy-
loid cascade hypothesis has so far failed to provide successes in drug development
and the genetic hits associated with AD suggest a more complex disease mechanism
(Lambert et al., 2013). Nevertheless, it is clear that somehow Aβ is involved in the
etiology of AD. This is even highlighted in theories opposing the amyloid cascade
hypothesis with the main difference being the inclusion of inflammation or tau as
the primary initiator of Aβ accumulation (Goedert, 2004; Morris et al., 2013).
The theoretical model of Jack et al. (2013) also covers the concept of mild cog-
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Figure 1.1: The amyloid cascade hypothesis, reproduced from Karran et al. (2011).
FAD = Familial Alzheimer’s Disease; PHF = Paired Helical Filaments.
nitive impairment (MCI), as a precursor to AD. MCI is characterised as a minor
cognitive deficit particularly seen in the intermediate stages between the normal
cognitive decline of ageing and the quicker, more severe, decline associated with
dementia. Although it can be a precursor for developing AD, MCI can also remain
stable or lead to other dementias. It has been proposed that this is because MCI can
be caused by a range of underlying pathologies; MCI individuals with increased Aβ
and tau burdens are most likely to progress to AD dementia (Okello et al., 2009).
1.1.4 Risk factors for Alzheimer’s Disease
AD has been identified as a complex disease meaning its presence or absence is not
completely determined by one genetic locus or set of loci. It is instead caused by a
variety of environmental and genetic factors.
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1.1.4.1 Non-genetic risk factors of Alzheimer’s Disease
Age is the largest risk factor for LOAD; as an individual gets older their risk of
developing the disease increases substantially up to a doubling in age-specific preva-
lence every 5 years after age 65 (See Figure 1.2) (Alzheimer’s Association, 2015; Qiu
et al., 2009). Further, epidemiological factors also drive AD risk with people who
have lower levels of education having a higher risk of AD (Ra¨iha¨ et al., 1998). It has
been hypothesised that this may be due to ‘brain reserve’ generated through elon-
gated periods of study. As with many diseases, AD has associations with common
conditions such as obesity, cardiovascular disease and diabetes. Cognitive decline
in AD is thought to be faster in individuals living alone. Norton et al. (2014) have
studied the population attributable risk for AD of 7 modifiable risk factors: midlife
obesity and hypertension, physical inactivity, diabetes, smoking, low educational
attainment and depression. They concluded that 28.2% of AD cases worldwide can
be attributed to these risk factors. Matthews et al. (2016) have recently shown a
reduced incidence of AD in British males over 65 years thought to be driven by
changes in these modifiable risk factors.
1.1.4.2 Genetic risk factors of Alzheimer’s Disease
Heritability estimates for AD from twin studies are approximately 50-70% (Gatz
et al., 1997; Pedersen et al., 2004). These studies provide upper-bounds for the
proportion of variability one could expect to explain using genetics. AD is more
common in females than males; some of this risk can be attributed to the longer life
expectancy of females (Vin˜a & Lloret, 2010).
The most well-researched genetic risk factor for AD is the apolipoprotein E
(APOE ) gene on chromosome 19. In the central nervous system the main function
of the protein coded for by the APOE gene is to transport cholesterol and fat soluble
vitamins and minerals to the neurons. There are three main allelic variants of APOE
defined by two single nucleotide polymorphisms (SNPs): rs429358 and rs7412. The
most common APOE variant is 3 making the most common genotype 33. The
risk allele for AD is 4. In comparison to the most common APOE genotype, one
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Figure 1.2: Age-specific AD prevalence (per 100 population) across continents and
countries. * = prevalence of all types of dementia. Reproduced from Qiu et al. (2009).
copy of the risk allele in Caucasians leads to an odds ratio (OR) of 2.6 (24) or
3.2 (34). Homozygosity of the 4 allele results in an OR of 14.9 (Liu et al., 2013).
Overall, APOE is estimated to explain approximately 4-6% of phenotypic variability
(Ridge et al., 2013; Lee et al., 2013). Genetic risk factors are further discussed in
section 1.2.2.
The heritability of the protein pathologies of AD: Aβ and tau, is less well re-
searched. One small twin study (N = 17 twin pairs) found that cognitively normal
co-twins with cognitively impaired probands showed an increased Aβ burden. The
estimated increase of 117-121% indicates that the accumulation of Aβ pathology is
influenced by genetic factors (Scheinin et al., 2011).
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1.1.5 Treatments for Alzheimer’s Disease
There are a handful of drugs available to treat the symptoms of AD. The National
Institute for Health and Care Excellence (NICE) guidelines (2011) for treatment of
dementia recommend the use of Acetylcholinesterase (AchE) Inhibitors (AchEIs) for
management of mild and moderate AD. These drugs block AchE from catalysing
the break down of some neurotransmitters. For patients who cannot take AchEIs,
or for whom the AD diagnosis is severe, memantine can be prescribed. Memantine
blocks N-methyl-D-aspartate (NMDA) receptors stopping excess activity of the neu-
rotransmitter glutamate. However, both these treatment options are only effective
in a subset of people and even then their effect is often moderate, delaying disease
progression by around 6-12 months (Rockwood, 2004).
There are currently no approved disease-modifying treatments for AD, despite
413 AD clinical trials being performed world-wide by 2012 (Cummings et al., 2014).
The majority of these trials were in symptomatic individuals. For example, Bap-
ineuzumab is a humanized anti-Aβ antibody developed by Pfizer and Johnson and
Johnson. Two phase III trials of Bapineuzumab did not meet their primary end-
points; significant difference from placebo in change from baseline in the Alzheimer’s
Disease Assessment Scale - Cognitive Subscale (ADAS-COG) and the Disability As-
sessment for Dementia (DAD) (Salloway et al., 2014). However, it was noted that
approximately 14% of participants in these studies had low Aβ burden. It was
therefore hypothesised that enrichment for participants with high Aβ should be
performed.
A second theory for the lack of successful treatments is that trials are targeting
people who are already showing the characteristic symptoms of AD. It is known
that AD pathology develops over a period of around 20 years meaning at the time
symptoms appear the brain is already damaged, perhaps irreversibly so (Villemagne
et al., 2011; Jack et al., 2013). A solution to this would be to recruit asymptomatic
individuals into preventative trials. This idea motivates the focus of this thesis on
early AD where possible. For this approach to be most effective only people who
are at high risk of developing AD should be enrolled in studies, again suggesting
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the use of Aβ enrichment in recruitment. In the preventative trial setting the use of
high Aβ burden as an inclusion criterion is justified by its presence as the earliest
known pathological change in the disease mechanism of AD (Jack et al., 2013).
Additionally, Aβ is the target of the primary class of novel treatments currently
being developed and tested. Aβ enrichment is being used in the A4 prevention
study and in novel, adaptive trials such as the European Prevention of Alzheimer’s
Dementia consortium (EPAD; www.ep-ad.org) (Sperling et al., 2014). A further
potential enrichment mechanism is the use of genetics. Enriching prevention trials
using genetic biomarkers has previously been shown to be effective for Acute Macular
Degeneration and Type I diabetes (Hu et al., 2013). The APOE gene is a well known
risk factor for AD and could consequently be used to enrich for the likelihood of
developing AD by including participants carrying the 4 risk allele. This approach is
being pursued in the TOMMORROW (www.tommorrowstudy.com) and Alzheimer’s
Prevention Initiative (API) trials.
The primary focus of this thesis is to find biomarkers of Aβ. However, several
disease mechanisms, alongside inhibition and clearance of Aβ, are also being in-
vestigated as potential drug targets. Bapineuzumab, mentioned above, follows an
immunotherapy approach to clearing Aβ; an exciting area with over 10 agents enter-
ing clinical trials. Other approaches include targeting anti-inflammatory processes,
accumulation of tau, APOE and investigation of metabolic dysfunction informed
by discoveries in epidemiology and associations between AD and diabetes (Citron,
2010).
A slightly different approach to drug discovery in AD is the re-purposing of
treatments already approved, or developed and abandoned, in different disease indi-
cations (Appleby et al., 2013). Candidate agents are chosen based on relevant disease
mechanisms. This method of re-purposing has several benefits over developing novel
treatments. In particular, toxicology, safety and pharmacodynamic profiles, as well
as manufacturing procedures, are well established leading to much shorter develop-
ment times. An example of a promising re-purposed agent is metformin; a drug used
to treat type II diabetes (Appleby et al., 2013). Human trials have shown mixed
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results with increased levels of Aβ observed when metformin is administered alone
but decreased levels of Aβ when it is given in combination with insulin.
1.2 Biomarkers of AD and AD pathology
Symptoms of AD partially overlap with other dementias, meaning that a definitive
diagnosis can only be made post-mortem. An accurate diagnosis is especially hard
in early disease when the symptoms, such as mild memory loss and depression, are
particularly non-specific. Both of these factors lead to misdiagnosis of patients.
To protect against misdiagnosis it has been suggested that AD specific biomarker
positivity should be included in diagnostic criteria (Dubois et al., 2014). The US
Food and Drugs Administration (FDA) define a biomarker as a ‘laboratory measure
that reflects the activity of a disease process’ (Katz, 2004). This section introduces
some key biomarkers of AD.
1.2.1 Non-Blood Biomarkers
1.2.1.1 Imaging
AD is a disease of the brain and consequently brain imaging is an obvious place
to start in the search for a biomarker. Many studies have performed structural
magnetic resonance imaging (MRI) scans on people with a diagnosis of probable
AD. They have observed overall brain atrophy and, in particular, a shrinking of the
hippocampus (the region of the brain associated with memory) and medial temporal
lobe (Kehoe et al., 2014). Structural MRI measures have been used in cohort studies
to predict conversion from MCI to AD (Westman et al., 2011). Meanwhile, newer
techniques such as functional MRI are currently being validated as diagnostic tools
for AD; fMRI has the ability to measure changes in the brain by monitoring blood
flow. Although useful, MRI scans seem unable to pick up subtle changes in brain
composition before symptoms arise so provide limited information for diagnosis of
early AD. Furthermore, MRI scans are useful for visualising brain structures but
are not pathology specific; they do not give an indication of the levels or location of
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tau and Aβ (Johnson et al., 2012).
To this end, ligands of the Aβ and tau proteins have been developed for use in
conjunction with positron emission tomography (PET) imaging. The ligands give
an impression of the location and quantity of pathology as measured by fluorescence
and are proving very useful measures in endophenotypic studies of AD. In recent
studies the approved ligands have shown good, but not perfect, correlation with
plaques and tangles at autopsy particularly when using a dichotomized measure of
pathology burden (Clark et al., 2012; Ariza et al., 2015).
1.2.1.2 CSF
CSF is a clear liquid that surrounds the brain and central nervous system. It pro-
tects the brain and spinal chord from damage while performing waste clearance and
homoeostasis. This role makes it a prime candidate to contain substances informa-
tive of the presence of any brain pathology. Studies have shown that Aβ burden in
the brain is strongly, negatively correlated with Aβ in CSF (Landau et al., 2013).
On the other hand, brain tau burden is positively correlated with tau in the CSF.
Due to the imperfect correlation of Aβ and tau between brain and CSF, researchers
have searched a plenitude of other candidate molecules for markers of AD. For exam-
ple, Zu¨rbig & Jahn (2012) review proteomics in CSF while Kaddurah-Daouk et al.
(2011) study metabolites. The metabolite study found alterations in patients with
AD for pathways related to the amino acids: tyrosine and tryptophan, purine, and
vitamin E compound: tocopherol.
1.2.1.3 Cognitive tests
An obvious non-invasive biomarker is the use of cognitive testing. Measures such as
the Mini-Mental State Exam (MMSE), Clinical Dementia Rating scale (CDR) and
the ADAS-COG have been specially formulated to identify characteristics of people
who have dementia (Folstein et al., 1975; Hughes et al., 1982; Rosen et al., 1984).
They are often split into functional categories allowing different symptoms to be
identified and consequently a differential diagnosis to be made. For example, people
with AD are more likely to show obvious deviations from age-associated decline in
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episodic memory, semantic knowledge and some aspects of executive functions than
people with other forms of dementia (Salmon & Bondi, 2010).
1.2.1.4 Limitations
Cognitive testing is not indicative of specific pathology and cannot detect pre-
symptomatic changes. Additionally, collecting CSF measures and performing PET
imaging is expensive and requires specialised facilities and staff. The Amyloid Imag-
ing Task Force estimate that a single PET scan costs approximately $3,000 (Johnson
et al., 2013). Furthermore, internationally, there are mixed views on lumbar punc-
tures with many patients experiencing anxiety and fearing pain. King & Rwegerera
(2014) found that a majority of patients refused a lumbar puncture due to fear of
pain and associated the procedure with paralysis and death. They concluded that
attitudes were improved with education on the purpose, benefits and risks of the
procedure. Meanwhile, Mene´ndez-Gonza´lez (2014) discuss that these preconceptions
are culturally dependent. In Scandinavia lumbar punctures are viewed as routine
procedures while in North America they are considered serious.
It is these reasons that motivate the research detailed in this thesis: Can we find
a cost-effective biomarker of Aβ pathology that is more readily available than CSF
and PET imaging? Ideally, a new biomarker could replace the use of PET scanning
or CSF sampling. However, performance metrics of the test would need to be very
high. For example, a test consistently achieving a sensitivity and specificity of >80%
could be considered clinically useful in that its performance would be comparable
to current markers in CSF (Jellinger et al., 2008). A second possibility would be to
use a new biomarker as a filtering step before performing confirmatory PET scans
or lumbar punctures on those who are deemed at high risk for disease. Such a test
would require slightly lower performance metrics, for example >70% sensitivity and
specificity, and would reduce the number of people subject to the unpleasant and
costly procedures of PET scanning and lumbar punctures.
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1.2.2 Genetic Biomarkers
1.2.2.1 Genome Wide Association Studies
Genome Wide Association Studies (GWAS) test associations between SNPs and
disease aiming to explain disease status using genetic variation. Such studies have
rapidly increased the amount of data available on common genetic variants. Col-
lections such as the National Human Genome Research Institute (NHGRI) Catalog
aim to collate data from these studies (Welter et al., 2014). In April 2016, the
catalog contained 2,423 studies detailing 16,617 unique SNP-trait associations. A
GWAS study in a simple case/control setting comprises multiple univariate logistic
regression analyses, with an association deemed significant if a p-value significance
threshold is reached. Conventionally, genome-wide significance is achieved for a p-
value less than 5 × 10−8 although this varies between studies. GWAS in AD are
beginning to have enough power to identify individual risk SNPs with Lambert
et al. (2013) providing the most comprehensive GWAS to date identifying 20 risk
loci. However, it is estimated that currently identified SNPs can only explain 16-33%
of phenotypic variation (Lee et al., 2013; Ridge et al., 2013, 2016).
GWAS of Aβ and other pathological endpoints provide greater statistical power
by reducing the heterogeneity contributed by controls who may have underlying
pathology in a case/control analysis. Such studies are also highlighting promising
results but sample sizes are considerably smaller so detailed validation is needed
(Kim et al., 2011; Cruchaga et al., 2013). Kim et al. (2011) found four genetic loci
that passed genome-wide significance testing for association with at least one CSF
biomarker (Aβ, total tau or phosphorylated tau). In the larger study from Cruchaga
et al. (2013) three genetic loci were significantly associated with tau.
1.2.2.2 Missing heritability
As genetic analysis becomes cheaper and consequently more readily available we
can begin to investigate the coverage of common SNP chips. Heritability studies of
AD and Aβ show that large amounts of genetic predisposition remain unexplained.
This concept is known as missing heritability and is common across the majority of
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complex diseases. There are several suggestions as to what is causing it. The main
hypothesis is that coverage of commonly available SNP chips is sub-optimal. The
method of next generation whole genome sequencing (WGS) begins to address this
by enabling us to gather information on rare variants that was previously unavail-
able.
1.2.2.3 Whole Genome Sequencing
Next Generation WGS is a modern genetic technique that determines the complete
DNA sequence of an organisms genome. In 2014, Illumina was the first company
to offer this service for an estimated $1,000 per sample (Sheridan, 2014). In AD
research, the first WGS data was made available in 2013 by the Alzheimer’s Disease
Sequencing Project (ADSP) (www.niagads.org). Projects such as 100,000 Genomes
England (www.genomicsengland.co.uk) and the Longevity project are making use of
this method to collect genetic data, alongside clinical and phenotypic information,
for hundreds of thousands of individuals.
Cohort studies such as the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
have been quick to get their samples sequenced. Nho et al. (2013) have used this data
to identify a variant protective of hippocampal atrophy and to discover functional
variants associated with changes in hippocampal volume, in participants with MCI
(Nho et al., 2013, 2015). Due to the novelty of WGS, studies emphasise the impor-
tance of replication in larger cohorts and longitudinal follow-up. Furthermore, WGS
(among other sequencing methods) was used to discover that a T allele of the Trig-
gering Receptor Expressed On Myeloid Cells 2 (TREM2 ) gene (SNP rs75932628)
is associated with AD. It has been estimated based on Icelandic data that the risk
variant occurs in only 0.63% of the population, making it extremely rare. It’s effect
size is second only to APOE (TREM2 odds ratio = 2.92) (Jonsson et al., 2013;
Guerreiro et al., 2013).
New SNP chips named exome chips have been designed to include variants iden-
tified through WGS and exome sequencing. In AD research, Sims et al. (2015) are
beginning work on these chips to explore the idea that missing heritability is likely
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to be explained by rare variants.
1.2.2.4 Polygenic Risk Score
There are three main methods investigating polygenic effects: the polygenic risk
score, linear mixed effect regression models and linkage disequilibrium (LD) score
regression (Purcell et al., 2009; Yang et al., 2010; Bulik-Sullivan et al., 2015). The
polygenic risk score (PGRS) was created to provide an approximate metric repre-
senting the cumulative effect of lower impact risk variants. Risk scores are generated
per person using summary statistics from GWAS by multiplying per risk allele effect
sizes by the number of risk alleles present. This is performed for all SNPs with a
GWAS p-value below a pre-defined threshold. The summation of scores for each
such SNP is used as the final PGRS. The p-value threshold is arbitrary and hence
tools such as PRSice have been developed to investigate the most suitable threshold
for a given analysis (Euesden et al., 2015).
PGRS have proved informative of AD diagnosis and associated phenotypes but
are yet to be included in a multi-modal analysis with other biomarkers of AD
(Sabuncu et al., 2012; Sleegers et al., 2015).
1.2.3 Blood Biomarkers
One approach for finding a biomarker of early AD, that is more readily available
than imaging or CSF measurements, is to search for a marker in blood.
1.2.3.1 Why blood biomarkers?
As blood and CSF interact through the BBB, albeit in a highly regulated manner,
it is possible that a signal reflecting AD pathology could also be detected in blood
(Ballabh et al., 2004). However, due to the distance between brain and blood, it is
likely any signal will be noisier than that seen in the CSF.
Additionally, it is thought that AD may affect the structure of the BBB allowing
abnormal substances, or unusual quantities of compounds, to pass through (Marques
et al., 2013). The break down of the BBB in AD is the subject of much discussion. It
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is well known that ageing leads to a decrease in the bodys ability to supply the brain
with factors needed for normal function and to eliminate toxins. This is exacerbated
in AD. As the BBB is an active barrier, not just a physical block, any problems are
likely to be due to dysfunction rather than a complete barrier break down (Zhao
et al., 2015). On the other hand, Bien-ly et al. (2015) suggest that experimental
drugs are not getting into the brain due to a lack of damage to the BBB. They
explain that this lack of BBB permeability has been shown in several mouse models
of AD and they have observed similar numbers of BBB breaches between human
cases and controls.
Furthermore, the lymphatic system provides a route for signal originating in the
brain to be seen in the blood. The lymphatic system is comprised of a series of
vessels and nodes throughout the body with a primary function to transport lymph,
a fluid containing white blood cells. In doing so, the lymphatic system helps the
body to fight infection and has the secondary function of removing toxins and waste.
More simply, the lymphatic system can be viewed as a drainage system for waste
and toxins to be removed from organs and to exit the body via the blood. In 2014
it was discovered that the lymphatic system is present within the central nervous
system of humans (Louveau et al., 2015). Consequently, it is possible that a process
occurring in the brain, such as build up of amyloid pathology, could be visible as
signal in the blood.
The use of a blood test in disease diagnosis and monitoring is common. For
example, blood glucose measurements have long been used to detect and monitor
diabetes. However, the search for novel blood biomarkers from high-dimensional
omics data has produced very few clinically usable tests, despite interest across a
wide range of clinical areas. In oncology, the Oncotype DX test is a genomic test used
to predict an individuals risk of breast cancer recurrence and response to treatment
(www.oncotypedx.com). Although current evidence supports the conclusion that
the Oncotype DX test is clinically valid, its impact on clinical outcomes is still
being investigated (EGAPP Working Group, 2016). In other areas, omics discovery
studies have been less successful. For example, Hoefer et al. (2015) explore the use
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of omics biomarkers in atherosclerosis while Whiteley et al. (2012) review their use
in predicting stroke. Both studies conclude that the clinical use of omics markers
will depend on the reproducibility of their predictive ability across studies; a concept
that has rarely been demonstrated. The use of blood based biomarkers has shown
promise in research and limited clinical settings, and with improved methodologies
and assays blood biomarkers may well reach clinical utility in the future.
1.2.3.2 Gene expression and pathways
Gene expression is the production of mRNA from a gene. mRNA are the family of
RNA molecules that specify the conversion of genetic code stored on DNA to the
final gene product, usually a protein, at the ribosome. Gene expression is usually
quantified as the amount of corresponding mRNA molecules. By regulating gene
expression a cell can control how much, or how little, of a protein it creates. Gene
expression can be easily quantified in blood using microarray technology and has
consequently been readily explored as a possible biomarker of AD. Han et al. (2013)
state that the blood transcriptome is vital in the disease mechanism of AD. Their
review also highlights the limited replicability at the single marker level with few
transcripts identified as significantly and consistently altered across studies.
Genes can be grouped in to sets according to their biological functions; these
sets can be described as pathways. It is common in genetic and gene expression
analysis to perform a post-hoc pathway analysis to determine which pathways any
differentially expressed gene belongs to. Han et al. (2013) report greater concordance
between studies at the pathway level than at the the single gene level. In studies
of AD and related phenotypes the most common differentially regulated pathways
include mitochondrial dysfunction and immune activation (Lunnon et al., 2012).
1.2.3.3 Proteins
Proteomic analysis is arguably the most well-researched area in the search for a
blood biomarker of AD. This is largely because Aβ and tau are proteins themselves
making blood proteins sensible biomarker candidates. Furthermore, as mentioned in
section 1.2.1.2, the correlations of Aβ and tau between the brain and CSF are high.
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Unfortunately, so far, the correlations observed when studying the blood are much
weaker. This could imply that this disease signal cannot successfully pass through
the BBB or secondly, that we are yet to design an assay sensitive enough to pick
up small, AD related changes in molecular concentrations. Furthermore, amyloid is
produced in the bone marrow and can be deposited in any organ or tissue. If an
amyloid signal could pass through a damaged BBB it would be essential to ensure
relevant signal, originating in the brain, was being detected and not confused by noise
from other sources of amyloid. Consequently, the search began for other proteins in
the blood that may associate with case/control status or disease characteristics such
as cognitive test results, APOE genotype and, of particular interest, Aβ burden in
the brain (Kiddle et al., 2014).
At the beginning of this project (2013) four studies had been published investi-
gating proteins associating with Aβ burden in four different cohorts (Thambisetty
et al., 2012; Kiddle et al., 2012; Burnham et al., 2013; Ashton et al., 2015). Some pro-
teins are significant in multiple analyses making them promising candidates for Aβ
biomarkers; for example fibrinogen gamma chain (FGG) and pancreatic polypeptide
(PPY) (Thambisetty et al., 2012; Kiddle et al., 2012; Burnham et al., 2013; Ashton
et al., 2015). However, replication in larger cohorts, using a variety of technologies
and biological samples is still necessary.
1.2.3.4 Metabolites
Metabolites are the products of any metabolic reaction and include substances such
as vitamins, minerals, hormones and fats. Due to their small size it is thought that
they are the most likely molecules to pass through the BBB, giving the possibility
of a signal originating from the brain being measured in the blood. This effect is
potentially magnified if the BBB is weakened by disease. Furthermore, the well-
known risk gene for AD, APOE, codes for a protein involved in the transportation
of cholesterol. This gives a second link to AD, as cholesterol is a metabolite, and
highlights metabolites as potentially interesting molecules to study.
Metabolite studies have made several novel discoveries of possible markers for
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AD. Ellis et al. (2015) highlight sphingolipid and glutamate metabolism as be-
ing altered in AD. They also highlight the difference in metabolism of molecules
with antioxidant properties (including vitamin C and uric acid) in people with AD
against controls. Several studies have used a case/control design to discover panels
of metabolites associated with disease. For example, Proitsi et al. (2015) discov-
ered a panel of 10 metabolites that differentiated between AD cases and controls.
Further, Mapstone et al. (2014) studied early cognitive impairment in particular by
using a similar 10 plasma metabolite panel to predict conversion from control status
to amnestic MCI. Results from this study failed to replicate in serum samples from
cohorts of a larger size (Casanova et al., 2016). Despite interest in this area, no one
has yet studied blood metabolite markers of Aβ .
1.2.3.5 Multi-modal biomarkers
There are many types of analyte within blood that can be measured and therefore
have potential for use as a diagnostic tool (for example protein, metabolite and
gene expression levels). If they are found to convey independent information on AD
pathology, it is likely that a multi-modal biomarker model will be most accurate
in identifying pre-symptomatic AD patients by offering improved predictive ability
(Bazenet & Lovestone, 2012). However, it is important to study the individual
marker types first, to identify the most promising markers, and to set a benchmark
with which to compare a more costly multi-modal marker (Boulesteix & Hothorn,
2010). The literature to date contains several instances of demographic data (most
commonly age and APOE 4 status) being combined with cognitive scores and one
type of blood biomarker. However, no multi-modal blood biomarkers of AD or
related phenotypes have been researched. It has long been known that AD is a
complex disease with many risk factors and therefore the suggestion of combining




AD is a complex disease with many genetic and environmental risk factors. Ageing
of the wordwide population means the number of people living with AD is sure to
dramatically increase in coming years, presenting a large socio-economic problem.
With no disease-modifying treatments available for AD it is essential to rethink
drug discovery by making use of the 15-20 year period when AD pathology accumu-
lates. As a starting point, AD clinical trial populations can be enriched for people
with high Aβ burden and preventative trials can be performed in asymptomatic
individuals with high Aβ burden. For this enrichment to be successful the relevant
volunteers must be identified; a process that could be aided by the use of a blood
based biomarker. The development of such a marker has been researched but clinical
utility is yet to be achieved.
1.4 Thesis overview
This thesis begins to address the lack of a clinically useable blood biomarker of
AD by investigating the issues of a lack of reproducibility and replicability. It also
presents new methodologies to the field such as Bayesian techniques and multi-
modal approaches to search for new possibilities of blood-based biomarkers of AD.
The cohorts used in this thesis are introduced in each chapter.
1.4.1 Single modality markers
As discussed above, research to discover a blood biomarker of AD is well-established
with the majority of research groups focusing on single modality approaches. Results
frequently differ between studies indicating that replication of results is lacking
and should be the key aim of modern research (Bazenet & Lovestone, 2012). If
replication is not possible, improved methodologies and novel study designs should
be investigated.
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1.4.1.1 Chapter 2: Blood protein markers of neocortical Aβ burden
The paper presented in Chapter 2 has been published in the Journal of Alzheimer’s
Disease (Voyle et al., 2015). It begins to address the replication issues in proteomics
biomarker research by taking a candidate approach to replicating previously identi-
fied blood protein markers of Aβ burden.
1.4.1.2 Chapter 3: A pathway based approach for analysing gene ex-
pression for AD diagnosis
Several gene expression candidates have appeared promising as biomarkers for AD.
However, between studies there is minimal concordance in the markers identified
(Han et al., 2013). The paper in chapter 3 has been published in the Journal of
Alzheimer’s Disease (Voyle et al., 2016a). It investigates the hypothesis that by
creating pathway level scores of gene expression I may create a more robust, and
hence reproducible, biomarker of AD case/control diagnosis.
1.4.2 Multiple modality markers
Although single modality biomarkers have shown some promising associations with
diagnostic and endophenotypic endpoints of AD, nothing has reached clinical util-
ity. In this thesis, I hypothesise that combining independent signal from several
modalities of biomarker may provide potential utility. To test this hypothesis in
AD, multi-modal cohort data has been used to model Aβ and tau burden.
1.4.2.1 Chapter 4: Blood metabolite markers of neocortical Aβ burden
To date, studies of metabolites as possible biomarkers for AD are based only on a
diagnostic endpoint. Due to the heterogenous nature of AD this is often inappro-
priate, particularly as the pathology of disease can develop 15-20 years in advance
of any symptomatic changes. It is therefore imperative that the methodologies used
in these studies are extended to the investigation of an endophenotypic endpoint of
AD. This issue is addressed in chapter 4; the first study to search for associations
between Aβ burden in the brain and metabolite markers in the blood. This study
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has been published in Translational Psychiatry (Voyle et al., 2016b).
In chapter 4 I present a study that is looking to discover a panel of metabolites
to predict Aβ burden in the brain. This paper also presents an enriched panel with
the addition of two reasonably well-replicated proteins: FGG and PPY. On addition
of FGG, accuracy in test data improves by 7% providing evidence that the idea of
multi-modal research warrants further investigation.
1.4.2.2 Chapter 5: Do peripheral markers help to predict amyloid bur-
den in a non-demented population? A Bayesian approach
The paper in chapter 5 focuses on using a PGRS to predict amyloid. A novel,
Bayesian approach was used for this analysis to predict normal and abnormal amy-
loid as measured in CSF. The Bayesian analysis was used to compare models built
using non-informative prior distributions for age, diagnosis and APOE to those
built using informative priors based on results from a meta-analysis by Jansen et al.
(2015). This analysis aims to meet the multi-modal objectives of this project by
combining the PGRS with information from gene expression, protein and metabo-
lite measurements in a subset of individuals as supplementary analysis. This work
is in submission at PLoS Medicine.
1.4.2.3 Chapter 6: Genetic risk as a marker of amyloid-β and tau burden
in cerebrospinal fluid
Chapter 6 presents work focused on predicting a more ‘AD like’ representation of
pathology. I have used a PGRS to predict normal or abnormal amyloid, tau and a
combination of the two pathologies. The latter analysis compares individuals with
normal CSF amyloid and tau to those with abnormal CSF amyloid and tau. This
chapter aims to meet the multi-modal objectives of this project by incorporating
measures of tau in blood plasma in a sub-study. This work has been accepted for
publication at the Journal of Alzheimer’s Disease.
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1.5 Details of methodologies
As this thesis is presented as a series of published or submitted papers, the methods
sections are included within each chapter. In the methodology sections below I
outline some of the more complex methods in more detail.
1.5.1 Statistical methodologies
While completing the work that contributed to this thesis I co-authored a book chap-
ter for Practical Psychiatric Epidemiology, Second Edition (in press). The chapter
(Statistical Methods in Epidemiology: Bio-informatician’s perspective) outlines ba-
sic data handling, exploration and analysis methods vital for psychiatric epidemi-
ology research. A copy of the full chapter can be found in Appendix C and the
following sections are exact replicas of some of the sections I authored (indicated
with quotation marks).
1.5.1.1 Training, testing and validation
‘A common problem of supervised learning methods is over-fitting. An algorithm
can be trained for too long on one particular data set so that it fails to generalise
the information learned to similar data sets. A number of methods are available
for evaluating machine learning results and showing the results are general enough
to be applied to other data (Hand et al., 2001). To successfully train a supervised
learning algorithm, one should aim to generate three data sets from the original
data set.
• A training set: used to train the algorithm.
• A validation set: to track how well the algorithm is generalizing and to perform
parameter tuning.
• A test set: an unseen data set on which the finalised algorithms performance
is tested.
As machine learning algorithms require substantial training data, the usual distri-
bution of the training, validation and testing sets is 2:1:1. However, in the case of
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limited data availability, different cross-validation (CV) methods can be employed.’
1.5.1.2 Cross Validation (CV)
‘In cross-validation the data is divided into a number (n) of ’folds’. Each fold is
treated as the validation dataset in turn, with the remaining n-1 folds being used
as training data. CV is especially useful for smaller datasets (Kohavi, 1995). The
performance of the classifier on each fold is measured and then a final accuracy is
calculated based upon the average of all n folds.’
1.5.1.3 Random Forests (RF)
‘Random forest (RF) is a supervised classifier consisting of multiple decision trees
(Breiman, 2001). The final class assigned to an observation is the modal class se-
lected by the multiple decision trees. RF combines two machine learning methods:
bootstrap sampling and random feature selection. Each tree is created from a boot-
strap sample of the training data. OOB [out of bag] data is used to obtain an
unbiased estimate of the error during the training. However, rather than using all
features, RF randomly selects a subset of input variables to decide what decision
should be made at each node of the tree. Advantages of random forest classifiers
include the fact that the error can be balanced when the class population sizes are
imbalanced and over-fitting can be avoided. There are also good methods available
for handling missing data.’
1.5.1.4 Partial Least Squares (PLS)
‘Partial least squares (PLS) modelling is very similar to PCA [Principal Components
Analysis]. Where PCA looks for orthogonal hyper-planes that explain maximal
variance in the predictors, PLS looks to explain maximal covariance between the
predictors and the outcome (Wold, 2004). It is this reliance on the outcome measure
that means PLS modelling is supervised and is particularly suited for prediction
problems. PLS modelling is useful when the number of predictors is greater than
the number of samples as it reduces the size of the predictor space by creating
components.’
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1.5.1.5 Support Vector Machines (SVMs)
‘Support vector machines (SVMs) are a supervised learning classifier developed by
Cortes & Vapnik (1995). They have been shown to be very accurate in many dis-
ciplines including bioinformatics, benefiting from the ability to handle high dimen-
sional data with a small number of instances, finding a good balance between training
set accuracy and test data error. For a given set of training vectors labelled with
two classes, a SVM can find the optimal linear hyper-plane that maximizes the mar-
gin between the two classes. An example of SVM classification in two dimensions
is given in Figure 1.3. SVMs can be extended to provide non-linear classification
through the application of a kernel function and to multi-class classification but that
is not discussed here.’
Figure 1.3: An example of a SVM classifying between two classes (circles and
crosses). The points acting as support vectors are highlighted. Reproduced from
Practical Psychiatric Epidemiology, Second Edition.
1.5.1.6 Bayesian Logistic Regression
Using a Bayesian methodology enables us to include historical information when
model building. Bayesian statistics is based on the ability to update some prior
beliefs with new data to form posterior beliefs. In many cases, the integrals needed to
perform this calculation can only be estimated using numerical methods. The most
common, and computationally efficient, way to do this is through Markov Chain
Monte Carlo (MCMC) sampling. MCMC draws values from a suggested distribution
forming a Markov Chain meaning each draw depends only on the previous one. In
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this thesis we use a Metropolis sampling method where each value is accepted or
rejected based on some acceptance criteria. It is important to maintain moderate
levels of rejection so the Markov chain explores the posterior distribution. Over
time, the set of accepted values will converge to a distribution that can be used for
inference.
In the case of Bayesian logistic regression analysis, MCMC sampling is performed
to estimate the effect size of each term in a model. The means of the MCMC samples,
after convergence, can then be extracted and used as effect sizes for prediction in
new data. In this thesis we investigated informative prior distributions, derived from
historical data, and non-informative priors. Non-informative priors are designed to
portray minimal information so often have large variances and can be considered
‘flat’. In the studies presented in chapter 5 of this thesis we found that Bayesian
modelling using non-informative priors yielded similar results to a frequentist logistic
regression, as expected.
1.5.2 Scientific methodologies
Chapters 2 and 4 make use of novel quantification techniques for proteins and
metabolites respectively: SOMAscan and LC-MS/MS. More information on these
technologies is given below.
1.5.2.1 SOMAscan technology
The need for advances in proteomic technologies is common across many fields in-
cluding pharmaceutical development, diagnostics and biomarker discovery. Modern
proteomics technologies are generally limited by two main factors: lack of sensitiv-
ity and inability to achieve high-throughput. The SOMAscan platform (SomaLogic
Inc, Boulder, CA) aims to address these limitations through the use of Slow Off-
Rate Modified Aptamers (SOMAmers). SOMAmers are chosen to bind to discrete
molecular targets with improved specificity and are currently being multiplexed at
over 1000 SOMAmers per sample. A more in-depth idea of how the SOMAscan
technology works is given in Figure 1.4 (Kraemer et al., 2011). This details how
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the original protein signal is converted to a nucleotide signal that can be measured
using standard DNA quantification methods.
Figure 1.4: SOMAmer-based assay reagent and assay principles. Reproduced from
Kraemer et al. (2011).
1.5.2.2 Liquid chromatography tandem mass spectrometry (LC-
MS/MS)
LC-MS/MS combines the physical separation properties of liquid chromatography
with the mass analysis capabilities of mass spectrometry. The method provides
high sensitivity to detect a variety of components from a complex mixture such as
serum or plasma. Tandem mass spectrometry comprises two mass analysis steps.
The first step investigates mass of the precursor ion while the second step provides
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fragmentation patterns for the product ions. It is this dual mass analysis that
provides improved sensitivity over MS or LC-MS as well as improved structural
information from the fragmentation patterns. The LC-MS/MS method used in this
thesis has been previously published and can be referred to for more information
(Whiley et al., 2014).
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Chapter 2
Blood protein markers of
neocortical amyloid-β burden: A
candidate study using SOMAscan
technology
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Abstract.
Background: Four previously reported studies have tested for association of blood proteins with neocortical amyloid-! burden
(NAB). If shown to be robust, these proteins could have utility as a blood test for enrichment in clinical trials of Alzheimer’s
disease (AD) therapeutics.
Objective: This study aimed to investigate whether previously identified blood proteins also show evidence for association with
NAB in serum samples from the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL). The study
considers candidate proteins seen in cohorts other than AIBL and candidates previously discovered in the AIBL cohort.
Methods: Our study used the SOMAscan platform for protein quantification in blood serum. Linear and logistic regressions
were used to model continuous NAB and dichotomized NAB respectively using single proteins as a predictor. Multiple protein
models were built using stepwise regression techniques and support vectors machines. Age and APOE "4 carriage were used as
covariates for all analysis.
Results: Of the 41 proteins previously reported, 15 AIBL candidates and 20 non-AIBL candidates were available for testing. Of
these candidates, pancreatic polypeptide (PPY) and IgM showed a significant association with NAB. Notably, IgM was found
to associate with continuous NAB across cognitively normal control subjects.
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Conclusions: We have further demonstrated the association of PPY and IgM with NAB, despite technical differences between
studies. There are several reasons for a lack of significance for the other candidates including platform differences and the use
of serum rather than plasma samples. To investigate the possibility of technical differences causing lack of replication, further
studies are required.
Keywords: Alzheimer’s disease, amyloid plaques, blood, positron emission tomography scan, proteomics
INTRODUCTION
The pathology of AD is characterized by three fea-
tures in the brain: the aggregation of amyloid-! (A!)
into plaques, the presence of hyperphosphorylated tau
in the form of tangles, and the occurrence of neuron
loss leading to brain atrophy [1, 2]. There is debate
as to how these processes interact to cause symp-
tomatic AD. A popular theory is the amyloid cascade
hypothesis: that A! deposition is central to disease
development [3]. Studies show that A! plaques begin
to develop up to 20 years prior to clinical diagnosis
with their growth reaching a plateau as clinical symp-
toms arise [4, 5]. The presence of AD pathology can be
investigated through characteristics that are informa-
tive of AD diagnosis; endophenotypes. Measurements
of analytes in cerebrospinal fluid (CSF) and molecular
imaging by positron emission tomography (PET) scans
are examples of endophenotypes that are biomarkers
for AD. The disadvantages of the procedures involved
in attaining these measurements include their invasive
or expensive nature and that they require specialized
administration.
Existing treatments for AD provide short-term
symptomatic relief, in a subset of patients, and trials
of potential disease modifying treatments are failing
[6]. Two suggestions have been made to address this
shortcoming: the use of A! as a companion diag-
nostic in tertiary prevention trials (those investigating
disease modifying or symptomatic treatments) and in
secondary prevention trials (investigating treatments to
prevent the disease from occurring in the first place).
Firstly, we consider the use of a companion diagnos-
tic in a normal clinical trial. To date, trials of A!
targeting drugs have recruited patients with a clini-
cal AD or mild cognitive impairment (MCI) diagnosis
and unknown brain A! burden [7–10]. As A! PET
scans became more readily available, toward the end
of such trials, A! burden was measured and it was dis-
covered that some of these AD patients had low A!
burden (the target pathology). For example, in a trial
of Bapineuzumab, a humanized anti-A! monoclonal
antibody, approximately 14% of subjects had low A!
burden [9]. Consequently, it has been suggested that
A! PET or CSF measures are used as a companion
diagnostic, with elevated brain A! becoming an eligi-
bility requirement for A!-lowering trials. A panel of
blood biomarkers could enable cost-effective enrich-
ment and identification of trial participants with A!
pathology for subsequent confirmatory A! CSF tests
or PET scans.
A second use of a blood-based biomarker would
be in recruitment for secondary prevention trials. It is
hypothesized that the brains of people recruited with
a diagnosis of AD or MCI are often too damaged for
medication to have an effect. Treatments could have
a higher chance of success in subjects with no clini-
cal symptoms, under the assumption that it is easier
to delay, rather than reverse, the development of AD
pathology. Aisen et al. expand on this idea stating that
there has been no medical advancements in the last
decade in terms of treating AD [11]. They suggest bas-
ing recruitment of patients into clinical trials on the
presence of biomarker defined pre-symptomatic AD;
three such trials had begun by the end of 2014. As
above, using a blood biomarker as an enrichment filter
for PET scans and CSF markers could increase the effi-
ciency of clinical trial recruitment by reducing screen
failures. A simple blood test has the greatest potential
impact in streamlining secondary prevention studies as
screen failure rates due to low A! are expected to be
higher (∼78.1% versus ∼12%) in asymptomatic indi-
viduals than in subjects with AD (Ossenkoppele et al.
and Jansen et al., unpublished results).
Consequently, there is high demand for a blood-
based biomarker of AD pathology [12]. It has been
shown that measures of A! in the brain are highly neg-
atively correlated with those in the CSF [13]. However,
overall, studies of blood A! do not show similar cor-
relations [14]. It is therefore necessary to search for
other analytes within the blood that may be associated
with A! in the brain. Recent studies provide some evi-
dence that proteins in blood show such a link to other
AD endophenotypes and to A! burden in the brain
[15–19]. However, there is a need to investigate these
results further in independent datasets of a larger size,
using different technologies and different biological
samples. We begin to address this here.
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This study aimed to further test findings in the litera-
ture of proteins in blood plasma associating with brain
A! burden [15–17, 19]. We used a radioactive marker
of A!, [11C]-Pittsburgh compound B (PiB), combined
with PET scanning to quantify the amount of brain A!
burden and the SOMAscan proteomics platform [20]
for quantification of protein in blood samples.
With over 1,000 protein analytes, the SOMAscan
proteomics platform has been used in high-throughput
biomarker discovery studies. For example, in AD
research it has been used by Sattlecker et al. and
Zhao et al. to discover potential plasma biomarkers
of AD diagnosis, MRI measures, and/or rate of cog-
nitive decline [18, 21]. In this study we focused our
approach on candidate-based analysis, selecting only
proteins previously found to associate with NAB. This
was done to ensure that there was sufficient statisti-
cal power to detect weaker signal that could have been
missed had the entire SOMAscan panel been used. This
analysis was repeated within just the cognitively nor-
mal control subjects to evaluate whether this test would




AIBL is a prospective, longitudinal study of sub-
jects aged over 60 years. The dual center study recruits
subjects with an AD diagnosis as well as both control
subjects and those with MCI with the aim of identify-
ing factors that lead to subsequent AD development.
Details of study design and enrolment are given else-
where [17]. The present study comprised a subset of
198 subjects from AIBL, enriched for controls.
Proteomics
Blood draws (80 ml) were taken after overnight fast-
ing and serum was collected in Sarsedt s-monovette
tubes. The samples were centrifuged at 1,800 g for
15 min at 20◦C and immediately frozen at −80◦C.
They were stored (long-term) in liquid nitrogen [22].
Protein levels in the blood serum were analyzed using
the SOMAscan platform (SomaLogic Inc, Boulder,
CA). The methods used in this assay are outlined
in detail by Kraemer et al. but, in brief, proteins
were measured using Slow Off-rate Modified Aptamer
(SOMAmer)-based capture arrays using a sample
of less than 10#L per run [23]. SOMAmers are
nucleotides that have been chemically modified to
address two issues: hard to capture proteins and non-
specific binding. Firstly, the nucleotides are given
protein-like properties resulting in high affinity for
hard to capture proteins. Secondly, aptamers with
slow dissociation rates are used allowing disruption
of non-specific binding. These nucleotides are used to
transform a protein signal to a nucleotide signal that
can be quantified using relative florescence on microar-
rays. For full quantification details of this assay, see
Gold et al. [20]. This study used SOMAscan Version
2 which captured information on 1,001 proteins and
protein complexes.
Quality control was performed at the sample and
SOMAmer level, and involved the use of control
SOMAmers on the microarray and calibration samples.
Hybridization controls measured sample-by-sample
variation in hybridization while the median signal over
all SOMAmers measured technical variability. Scale
factors of these two metrics were used to normalize
across all samples with acceptance criteria of 0.4 to
2.5 based on historic trends. SOMAmer by SOMAmer
calibration occurred through the repeated measure-
ment of calibration samples. Historic values were
used to generate a calibration scale factor the accep-
tance criterion for which was: 95% of SOMAmers
must have a calibration scale factor within 0.4 of the
median.
Imaging
The measures of NAB used in this study were
collected by PiB PET scans. The PiB imaging method-
ology is detailed elsewhere [24]. Each scan was
spatially normalized by Rowe et al. to a customized
PiB-PET template in the Montreal Neurological
Institute reference space using Statistical Parametric
Mapping 8 (SPM8; Wellcome Trust Centre for Neu-
roimaging, London, UK). Standardized uptake value
ratios (SUVRs) were then created by computing the
ratio of PiB retention in the whole brain to that in the
grey matter [25].
Identification of candidate blood protein markers
of brain Aβ burden
We identified candidate proteins through a search
of the literature for studies investigating the relation-
ship between blood proteomics and A! burden in the
brain. Any proteins identified as significant in the study
conclusions were selected and matched to the AIBL
SOMAscan data using the UniProt ID.
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Statistical analysis
All statistical analysis was performed in R (version
3.1.1) [26].
Differences in proteomic signal between platforms
and sample types
As the candidates were selected based on their asso-
ciation with NAB in plasma, we aimed to confirm
that serum is an appropriate surrogate by compar-
ing proteomic signal from the SOMAscan platform
between blood plasma and serum samples using age
as an outcome. We also studied differences between
the SOMAscan platform and Myriad’s Rules Based
415 Medicine Multi-analytes Profile (RBM MAP),
one of the discovery proteomics platforms. To do so,
we used proteomic data generated using the RBM
MAP platform from the original publication of a blood
biomarker in the AIBL study; methods described by
Burnham et al. [17].
Menni et al. have studied associations of age with
protein levels from plasma samples using the TwinsUK
cohort and SOMAscan version 3 [27]. Running ran-
dom intercept linear regression, adjusting for family
relatedness, identified proteins associated with chrono-
logical age. We performed a similar analysis using
standard linear regression on our serum samples from
the AIBL cohort. Within each cohort (TwinsUK and
AIBL) the proteins were ranked by p-value from the
regressions and the R package OrderedList was used to
compare the rank of proteins present on both versions
of the platform [28].
To assess the concordance of proteomic signal
between SOMAscan and RBM MAP, we implemented
an identical method. OrderedList was used to compare
lists of proteins ranked according to their associations
with age and gender.
Analysis overview
An overview of the analysis is given in Fig. 1.
Proteins discovered in studies other than AIBL
[15, 16] were analyzed separately to proteins discov-
ered in AIBL using different biological samples (serum
instead of plasma) [17, 19]. This split was implemented
as the association of a non-AIBL candidate with NAB
in AIBL would provide a fully independent replica-
tion of those findings, whereas the association of an
AIBL candidate with NAB would only show that the
marker could also be measured using SOMAmers on
serum samples. Each analysis tested the protein levels
against the continuous endpoint of SUVR as well as a
dichotomized high/low NAB endpoint. A cut off of 1.3
was used to distinguish between high and low NAB
[17]. Use of a continuous endpoint gives increased
power in statistical analysis in comparison to a categor-
ical measure [29]. Additionally, each analysis studied
all samples and control samples alone.
Subjects were randomly split into a training (66%)
and test set (34%) using the createDataPartition func-
tion in the R package caret [30]. The split ensured that
a range of values of NAB were present in each set for
the continuous analysis by splitting the subjects into
groups based on NAB percentiles and sampling within
these groups. For the dichotomized analysis, the split
ensured that the proportion of high and low NAB was
similar between the two sets by sampling within the
high and low groups.
Data pre-processing
Data pre-processing was performed separately for
each analysis. In both cases, all protein data was subject
to a natural logarithm transformation so each protein
followed an approximate normal distribution. Per sam-
ple, per protein outliers were then identified as values
lying outside of 6 standard deviations (SD) of the mean
protein value and were set to missing. Any sample with
more than 20% missing data was removed. Missing
data in the train and test sets was imputed separately
using 10 nearest neighbors.
In some cases, there were multiple SOMAscan
probes available for one UniProt ID. In this instance, a
principal components analysis (PCA) was performed
across these probes and only the first principal com-
ponent (PC1) was included in the analysis. This was
performed on all samples and on control samples alone,
and separately for train and test sets. Additionally, the
colinearity of such probe sets was investigated using
Pearson’s correlation coefficients.
Single protein analysis
Models were built using the training set. The contin-
uous and dichotomized NAB endpoints were regressed
against age, APOE "4 load and each protein in turn
using linear and logistic regression, respectively. Age
and APOE "4 load, defined as the number of "4 alle-
les in a subjects genotype, were included as they were
statistically significant in this population (see Table 2).
In all cases, Benjamini Hochberg corrected p-values
from the full model fit (q-values) were tested against
a significance level of 0.1, to account for false discov-
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Fig. 1. Overview of data analysis.
ery. Although the hypothesis tests performed were not
independent, the Benjamini Hochberg correction gave
an acceptable approximation of the false discovery rate
[31].
Model fit was assessed by exploring the residuals of
each model to ensure normality, constant variance, zero
expectation, and independence. For logistic regression
models, deviance residuals were used.
Each model was used to predict NAB in the test set
and model statistics were calculated. These were R2
and root mean squared error (RMSE) for linear regres-
sion and accuracy, sensitivity and specificity for logistic
regression.Foreachmodel,statisticpermutationtesting
was run with 1,000 permutations of the NAB values,
to create a non-parametric, empirical p-value. In each
permutation, the relationship between NAB endpoint,
age, and APOE "4 load was maintained. Benjamini
Hochberg corrected p-values (q-values) were tested
against a significance level of 0.1.
Multiple protein analysis
The primary multiple protein analysis was paramet-
ric. Models were built using the training set. As in the
single protein analysis, continuous and dichotomized
NAB endpoints were regressed against age, APOE "4
load, and all proteins together (15 non-AIBL candi-
dates and 20 AIBL candidates) using linear and logistic
regression respectively. The models were then sim-
plified using stepwise regression based on Akaike’s
Information Criteria (AIC). Simplified linear regres-
sion models were examined for variable importance
using the Lindemann, Merenda, and Gold (LMG) mea-
sure [32]. This metric represents the R2 of an individual
regressor by averaging over all orders of regressors.
Each model was used to predict on the test set and cre-
ate model statistics with associated empirical p-values,
as detailed previously. Model fit was assessed in the
same manner as for the single protein analysis.
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As a secondary multiple protein analysis we inves-
tigated the possibility of non-linear associations and
interactions by performing a non-parametric multiple
protein analysis using support vector machines (SVMs)
in the R package kernlab [33]. We used an SVM with
radialkernel tobuildmodels in the trainingset.The train
function from the R package caret was used to estimate
model parameters: The kernel parameter (sigma) was
directlyestimatedandregularizationparameter (C)was
tuned using 25 bootstraps. RMSE was used as the opti-
mization metric for continuous NAB while kappa was
used for the dichotomized endpoint. Each model was
used to predict on the test set.
RESULTS
Cohort demographics
For this study, we used SOMAscan data generated
on serum samples from the AIBL cohort. Table 2
summarizes the demographics of this population. As
expected, characteristic features of AD such as Mini-
Mental State Examination score and Clinical Dementia
Rating were significantly associated with continuous
NAB and significantly different between high and low
NAB groups. Age and APOE "4 load (defined as the
number of APOE "4 alleles in a subject’s genotype)
were also significant and hence accounted for in all
analyses.
Overall, demographics in the control population
mirrored those across all samples and hence the same
terms were covaried for in the control only analyses
(see Supplementary Table 1). As expected, measures
of APOE"4 were not significant in this sub-population.
Differences in proteomic signal between platforms
and sample types
We began by comparing proteomic signal associated
with age in plasma samples from the TwinsUK cohort
and serum samples from AIBL. 975 SOMAscan probes
matched between the Twins UK (Version 3, 1,129
SOMAmers) and AIBL (Version 2, 1,001 SOMAmers)
datasets mapped using SOMAscan ID. Comparison of
the protein lists ranked by association with age gave a
significance of similarity p-value of <0.001. The anal-
yses were not adjusted for any covariates.
We also made a comparison between the SOMAscan
platform and RBM MAP platform using samples from
the AIBL cohort. The RBM MAP data contained 151
proteins, 119 of which could be mapped to a UniProt
ID. All 1,001 proteins on the SOMAscan panel were
mapped to a UniProt ID. There were 88 proteins
that overlapped between the two datasets, mapped by
UniProt ID. Comparison of the protein lists ranked by
association with age gave a significance of similarity
p-value of 0.162. An identical analysis with proteins
ranked by association with gender gave a significance
of similarity p-value of 0.201.
Identification of candidate blood protein markers
of brain Aβ burden
We identified four previous studies investigating a
proteomic signal in the blood associated with A! bur-
den in the brain. Previously reported studies used blood
plasma whereas this study uses blood serum samples.
Thambisetty et al. discovered six proteins associated
with brain A! burden in a group of non-demented,
older individuals [15]. Kiddle et al. used data from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
in a discovery analysis to find 16 proteins associated
with brain A! burden [16]. Significant proteins from
these two papers that were also present in the AIBL
SOMAscan data [15] are termed non-AIBL candidates
and are given in Table 1.
Additionally, two discovery analyses have already
been performed on AIBL subjects using different pro-
tein measurement technologies; RBM MAP [17] and
mass spectrometry [19]. Respectively, these studies
highlighted 8 and 17 proteins (a prioritized set) as being
significantly associated with NAB. The proteins that
were also present in the AIBL SOMAscan data [20]
are termed AIBL candidates and are given in Table 1.
See Supplementary Figure 1 for an overview of protein
numbers.
In some cases, there were multiple SOMAscan
aptamers for one UniProt ID: C3 (P01024) had six
matches in the AIBL SOMAscan dataset, APOE
(P02649) had three, and Fibrinogen ([P02671, P02675,
P02679]) had two. All are accounted for in this anal-
ysis using PCA as detailed previously. Eleven of the
41 proteins were not present on the SOMAscan panel.
A!PP was included as an additional protein of interest
as A!1–42 is not present on the SOMAscan panel.
Data pre-processing
There was no observed pattern in the missing data
nor in the demographics of the subjects with data set
to missing so it was assumed the data were missing at
random. No subjects were removed during data pre-
processing.
The protein data was generated in one batch and
the PET scans were performed using one model of
51
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Table 2
Population demographics
Total Overall High NAB Low NAB High/Low
n = 198 p-value n = 107 n = 91 p-value
Gender (% female) 50 0.96 49 52 0.78
APOE status (% of APOE "4 positive) 51 <0.001 61 50 0.004
APOE "4 load (% with loads 0; 1; 2) 49; 43; 8.1 <0.001 39; 48; 13 60; 37; 2.2 0.002
Median age [IQR] (years) 72 [14] <0.001 76 [11] 68 [12] <0.001
Median MMSE score [IQR] 28 [3.0] <0.001 28 [4.0] 29 [2.0] <0.001
Global CDR status (%>0) 44 <0.001 64 21 <0.001
Clinical diagnosis (% with diagnosis 14; 26; 61 0.28 25; 35; 40 0; 15; 85 <0.001
AD; MCI; Control)
Individuals were positive for APOE "4 if at least one APOE "4 allele was seen in their genotype.
APOE "4 load was the number of "4 alleles seen in a subject’s genotype.
IQR, inter-quartile range; MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating.
Overall p-value: Result of the Kendall tau test for dependence between SUVR and the demographics variable.
High/low p-value: Kruskal Wallis Chi-Squared was used to test between high and low groups for continuous data.
High/low p-value: Fishers exact was used to test between high and low groups for categorical data.
Table 3
Candidate proteins of the same UniProt ID
UniProt ID Proteins Minimum-Maximum
Correlation
P01024 C3; C3adesArg; C3b; 0.468 – 0.964
iC3b; C3a; C3d
P02671 Fibrinogen; D-dimer 0.651
P02649 APOE; APOE3; APOE4 0.787 – 0.894
machine. Table 3 gives details of the proteins that
were collapsed into their first principal component, as
detailed previously. In all cases, PC1 accounted for at
least 75% of the total variation. The only probe leading
to correlations of less than 0.75 for UniProt ID P01024
was that of C3d.
Discovery analysis
Discovery analysis was applied across the entire
SOMAscan platform in an attempt to find predic-
tors of dichotomized as well as continuous NAB.
Variable selection techniques that included linear and
logistic regression and SVMs yielded no predictive
models with efficacy of estimating NAB above that
of a model built on age and APOE "4 carriage alone.
The results of linear and logistic regression methods to
predict continuous and dichotomized NAB are given in
Supplementary Table 2.
Single protein analysis
Residual plots indicated a reasonable model fit in
all cases. We outline below single proteins that pass
multiple testing with a q-value of less than 0.1.
Fig. 2. Regression fit for PPY modeling dichotomized NAB in all
samples: training data.
Non-AIBL candidates
When modeling dichotomized NAB, logistic regres-
sion analysis showed that PPY was significantly
associated with PiB positivity across all samples, pass-
ing multiple testing corrections (!= 2.959, p = 0.001,
q = 0.013). Figure. 2 shows the fit of this model in
the training data. See Supplementary Table 3 for full
results.
AIBL candidates
In control samples, IgM was significant in a linear
model with a q-value of 0.044 (!=−0.282, p = 0.002).
Mirroring the non-AIBL candidate results, PPY
53
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Fig. 3. Regression fit for IgM modeling continuous NAB in control
samples: training data.
was significant in a logistic regression model when
considering the dichotomized endpoint in all samples
(q = 0.018). Figures 2 and 3 show the fit of these mod-
els in the training data. See Supplementary Table 4 for
full results.
The analysis of continuous NAB against IgM in con-
trol subjects was repeated including a flag for presence
of diabetes as a covariate (n = 72). IgM had an esti-
mate similar to that previously stated (!=−0.232) and
showed a nominally significant p-value (p = 0.027).
The presence of diabetes flag was not significant
(!= 0.127, p = 0.586).
Multiple protein analysis
Continuous NAB
In linear regression analysis across all subjects mod-
els of both non-AIBL candidates and AIBL candidates
showed improved RMSE (0.490 and 0.497) and R2
(0.245 and 0.226) values over a model of age and
APOE alone (RMSE = 0.500 and R2 = 0.219). The
model of non-AIBL candidates achieved significant
empirical p-values for RMSE and R2 through per-
mutation testing with p-values of 0.041 and 0.043,
respectively. Model statistics achieved in parametric
analysis outperformed those from SVM modeling.
Table 5
Multiple protein analysis: continuous NAB
Population Candidates Method Test data
R2 R2 RMSE RMSE
Empirical Empirical
p-value p-value
All Non-AIBL Linear regression 0.245 0.043 0.49 0.041
[Age, APOE "4 number,
Albumin PPY]
SVM 0.15 – 0.52 –
AIBL Linear regression 0.226 0.061 0.497 0.058
[Age, APOE "4
number, BLC, C4]
SVM 0.15 – 0.53 –
Age and APOE Linear regression 0.219 – 0.5 –
[Age and APOE "4 number]
SVM 0.1 – 0.53 –
Controls Non-AIBL Linear regression 0.241 0.215 0.356 0.226
[Age, APOE "4 number,
vWF, PPY, Plasmingen]
SVM 0.23 – 0.36 –
AIBL Linear regression 0.17 0.371 0.392 0.537
[Age, APOE "4 number,
IgM, BLC, Alpha-2-Macroglobulin,
HRG, Factor B, Hemopexin]
SVM 0.25 – 0.36 –
Age and APOE Linear regression 0.273 – 0.349 –
[Age and APOE "4 number]
SVM 0.02 – 0.41 –
PC1, First Principal Component;
SVM, Support Vector Machine.
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Protein models in control samples created through
regression analysis did not outperform a model of
age and APOE alone. However, all SVM models
showed lower RMSE and higher R2 values than the
demographic only model and in most cases also
outperformed the parametric methods. For further
details of the multiple protein analysis of continuous
NAB, see Table 5.
Dichotomized NAB
In parametric analysis across all subjects, the model
of AIBL candidates gave a higher accuracy (0.612)
than a model of age and APOE alone (0.567). This
was driven by an increase in specificity; 0.583 com-
pared with 0.389 in the age and APOE only model.
Specificity gave a significant permutation p-value of
0.026.
The model of non-AIBL candidates also showed
increased specificity at 0.444 compared to 0.389 in
the age and APOE only model. SVM analysis gave
increased specificity and decreased sensitivity over
parametric analysis in all three models leading to a
marginal increase in overall accuracy.
In control samples, logistic regression analysis of
AIBL candidates gave improved accuracy and sensi-
tivity compared with the model of age and APOE alone
(0.675 and 0.444, respectively, compared with 0.650
and 0.333). The model in non-AIBL candidates also
showed increased sensitivity at 0.500. Non-parametric
analysis showed improved accuracy over regression
analysis in the protein based models driven by an
increase in sensitivity. For further details of the multi-
ple protein analysis of dichotomized NAB, see Table 4.
DISCUSSION
In this study, we investigated blood proteins shown
in the literature to be associated with A! burden in
the brain, using serum samples from AIBL. No pro-
teins were found to pass multiple testing corrections
in a discovery analysis so we implemented a candidate
based approach.
Two candidate proteins (PPY and IgM) showed
association with NAB in the single protein analysis of
the AIBL serum SOMAscan dataset. Both had already
been identified as significant in the AIBL plasma RBM
MAP dataset by Burnham et al. [17].
PPY passed multiple testing corrections for single
protein analysis in all samples for the dichotomized
endpoint. This provides further evidence for claims
made by Chiam et al. who found PPY to be the
most replicated blood protein marker of AD [34].
The direction of association (positive) matched that
of Burnham et al. [17], providing some evidence for
concordance of the SOMAscan platform with RBM
MAP for this protein despite technical differences.
This is also consistent with Sattlecker et al. who used
SOMAscan to show that plasma PPY levels increase
with disease progression in subjects from the combined
AddNeuroMed, Alzheimer’s Research UK/Maudsley
BRC Dementia Case Registry research cohorts [18].
However, the estimate was in the opposite direction to
that described by Kiddle et al. [16]. This could sug-
gest a complex relationship of PPY with NAB that
we may be unable to describe fully with the statistical
approaches applied here. Alternatively, the variation
in direction could be due to lower statistical power
in Kiddle et al. (n = 71) or cohort differences, per-
haps differences between Americans and Australians
or disease stage. Indeed, Lunnon et al. have previ-
ously shown that disease associated markers, albeit
gene expression markers, can frequently change direc-
tion of effect depending on disease stage [35]. The
subjects used by Kiddle et al. from ADNI were at a
much later disease stage (with only three controls) than
the subjects used here.
Doecke et al. have previously shown PPY to be
associated with AD diagnosis in the AIBL cohort
[36]. Similarly, PPY was found to be associated
with diagnosis in ADNI and the Texas Alzheimer’s
Research Consortium [37, 38]. However, there has
been discussion around whether this effect could be
a pharmacological response to the use of acetyl-
cholinesterase inhibitors. Unfortunately, we were
unable to examine this in the AIBL cohort but the
possibility of medication confounding should be inves-
tigated in further studies. Chiam et al. use data from
the AddNeuroMed study to suggest the effect of acetyl-
cholinesterase inhibitor use is not significant on PPY
(Chiam et al., unpublished results).
Additionally, IgM was seen to replicate at the sin-
gle protein level in control samples only. IgM is an
antibody produced by B-cells that appears early in
the course of an infection. This pathway of immune
response has been linked to AD in previous studies
[35]. Furthermore, IgM has been associated with dia-
betes [39]. When a presence of diabetes flag is included
in the IgM model it is not significant. Additionally,
the p-value of IgM remains nominally significant at
0.027 indicating that it is unlikely that this significant
association is a result of disease confounding.
There were 29 candidates that gave non-significant
results. These were: C3, APOE, Fibrinogen, Hap-
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toglobin, Albumin, $1-antitrypsin, $2-macroglobin,
APOA1, C4, Chemokine Ligand 13, Clusterin,
Factor B, Factor H, Gelsolin, Hemopexin, HRG, IgG,
IL13, IL17, IL3, Leptin, MIP1$, MMP9, Plasminogen,
Transferrin, SAP, VCAM1, vWF, and APP.
Some of these proteins showed significant q-values
for model statistics (such as R2 and accuracy based on
permutation testing) although they were not significant
in the parametric model. This indicates that greater
sample size is needed for future studies of this nature
in order to reduce the variation of statistics such as R2
and hence give a more reliable estimate.
Multiple protein models constructed in this study
gave mixed success in explaining variation in brain A!
burden. Although some provided increased accuracy
or R2 over models of age and APOE "4 number alone,
thedifferenceswereminimalandlargelynogreater than
those provided by some single protein models. LMG
variable importance scores from linear regression mod-
elsalsoemphasized that ageandAPOE"4numberwere
the most important variables. Consequently, given a
larger samplesize, ananalysis stratifiedbyAPOEgeno-
typecouldbeused to revealmorecomplex relationships
between APOE and protein markers.
The four studies that contributed candidates for this
analysis used blood plasma samples. However, due to
sample availability, we performed SOMAscan anal-
ysis on blood serum samples. It is possible that this
tissue difference is responsible for the non-replication
of some of the candidates; however, there are studies
suggesting analyte specific consistency across sam-
ple type. O’Bryant et al. show that some blood-based
markers of AD, including pancreatic polypeptide, are
consistent between plasma and serum [38]. Further-
more, our comparison of ranked lists of proteins
associated with age between blood serum (AIBL) and
plasma (Twins UK) showed a high level of concor-
dance on the SOMAscan platform.
Differences between the proteomic approaches used
here (SOMAscan) and in the literature (Myriad RBM,
2DGE, and mass spectrometry) could be driving the
disparity in results between these studies. We see non-
significant p-values for similarity when comparing
ranked lists of proteins associated with age and gender
between SOMAscan and RBM MAP. Due to the simi-
larity in signal between the Twins UK plasma samples
and AIBL serum samples (detailed above), this dif-
ference is likely platform-driven. While SOMAscan
measures the availability of a 3D shape and charge
epitope, mass spectrometry measures mass to charge
ratio. RBM MAP uses antibodies that could be measur-
ing alternative versions or conformations of proteins to
those measured by SOMAscan. It is likely the SOMAs-
can platform would show the highest correlation with
other immunoassays. This is consistent with the obser-
vation that we see the most agreement between AIBL
plasma RBM MAP candidates and our findings here
using serum SOMAscan (PPY and IgM). A study
examining the similarities and differences observed
when running samples across these platforms would
be useful when interpreting results such as these.
Theprimaryanalysisusedinthisstudyfollowsapara-
metric, linear approach following that of three out of
the four studies cited. Burnham et al. used a non-linear,
non-parametric analysis. We investigated the potential
ability to detect interactions and non-linear relation-
ships, and consequently improve model performance,
by building SVM models. These non-parametric mod-
els found slightly improved results suggesting that
non-linearity and interactions could be important in the
relationship between blood proteomics and NAB and
should be considered in further studies.
Throughout the analysis presented here we included
APOE "4 number (0, 1, 2) as a covariate. We did not
include the APOE genotype itself due to small num-
bers of samples in the "2"4 and "4"4 groups. We
investigated whether grouping subjects with an "2"4
genotype with subjects with an "3"4 genotype was
appropriate given that the "2 allele has been found to be
protective and consequently subjects of the two geno-
types could behave differently. Exploratory analysis
of the PPY and IgM results suggest that the general
trend between the "3"4 and "2"4 groups is similar and
consequently it is reasonable to combine them in our
analysis. Supplementary Figures 2 and 3 illustrate this.
It is clear that the sample size used in our analy-
sis limits the power of any conclusions. An additional
factor limiting interpretation of these findings is how
representative the cohort used here is compared to
potential clinical trial recruitment populations, both in
terms of diagnostic groups and prevalence of high A!
burden. Differences in prevalence between this cohort
and the target populations can lead to inflated esti-
mates of positive predictive value, the proportion of
test positives that are true positives [40]. This should
be addressed in further work through study of larger
and more representative cohorts.
A known disadvantage of stepwise regression anal-
ysis is a tendency to over fit to the training data. Several
of the multiple protein models created failed to outper-
form age and APOE "4 number in test data which could
be a suggestion that the stepwise models are over fit-
ting to the training data. Alternatively, this may provide
evidence that the candidates considered here provide
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minimal predictive information on NAB, above that
of age and APOE "4 load, when measured in serum
samples using SOMAscan. Studies of larger cohorts
will allow this to be investigated further.
It is promising that we show for the first time
that IgM predicts NAB in asymptomatic individu-
als. However, we note that the majority of candidates
investigated in this study had been selected from pop-
ulations with a variety of diagnoses. Thus, the lack of
significance of association with NAB for most candi-
dates in asymptomatic subjects was not unexpected.
In further work it would be interesting to perform
a discovery analysis on control subjects alone and
identify proteins that are found to link with A! bur-
den pre-symptomatically. The proteins identified by
Thambisetty et al. are from a control population but of
small sample size (n = 57) [15].
We were surprised to detect a signal for fibrino-
gen from the SOMAscan technology. Currently it is
thought that there should be no fibrinogen present in
blood serum samples. This may reflect issues of speci-
ficity with the fibrinogen SOMAmer or the presence
of low concentrations of fibrinogen in serum sam-
ples beneath detection thresholds of other assays. We
note that this has been reported before in a study of
tuberculosis [41]. As SOMAscan is a relatively novel
protein quantification technology, more work is needed
to qualify how it compares with other platforms and to
identify the binding sites of SOMAmers.
There is a clear link between the development of
A! plaques in the brain and AD but this relation-
ship is not exclusive. That is to say, it is not always
the case that high NAB indicates AD or vice versa;
there are examples of elderly subjects with high A!
burden and no cognitive impairment [42]. While this
could be explained by misdiagnosis and A! starting a
slow AD process in motion, the alternative hypothesis
would be that A! is not causally related to late onset
AD. However, while the focus of AD clinical trials
is predominately anti-A!, it is logical to find mark-
ers relevant to those trials. Furthermore, A! burden is
appearing in new diagnostic criteria for AD [43]. More
work is needed to thoroughly understand the role of
brain A! burden in AD to validate the use mechanistic
action of A!, it would be interesting to study a cohort
of subjects with A! positivity of a model of A! burden
as a diagnostic biomarker. To investigate the prior to
the development of MCI or AD. Unfortunately, the cur-
rent study did not have a sufficient number of samples
(n = 5) meeting this criterion to perform such analysis.
The need for cohorts of this type is clear in order to
advance understanding of the clinical relevance of A!.
If the model statistics achieved in this study
are shown to be robust across relevant, larger, and
independent populations, these models could be ben-
eficial in acting as a cost-effective enrichment filter
between the general population and those predicted to
have high NAB. Using a relevant simple blood test as
a pre-screening tool could reduce the PET and CSF
screening failure rate and hence the cost of trials.
CONCLUSIONS
In this study we investigated blood proteins pre-
viously found to be associated with A! burden in
the brain using serum samples from AIBL and the
SOMAscan proteomics technology. Two candidate
proteins (PPY and IgM) showed association with NAB
in the AIBL serum SOMAlogic dataset. Notably, IgM
was found to associate with continuous NAB across
control subjects, suggesting it may have utility for pre-
dicting A!-positive asymptomatic individuals. There
are several reasons for a lack of significance for the
other candidates including platform differences and the
use of serum rather than plasma samples. To investigate
the possibility of technical differences causing lack of
further replication, further studies are required.
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Abstract.
Background: Recent studies indicate that gene expression levels in blood may be able to differentiate subjects with Alzheimer’s
disease (AD) from normal elderly controls and mild cognitively impaired (MCI) subjects. However, there is limited replicability
at the single marker level. A pathway-based interpretation of gene expression may prove more robust.
Objectives: This study aimed to investigate whether a case/control classification model built on pathway level data was more
robust than a gene level model and may consequently perform better in test data. The study used two batches of gene expression
data from the AddNeuroMed (ANM) and Dementia Case Registry (DCR) cohorts.
Methods: Our study used Illumina Human HT-12 Expression BeadChips to collect gene expression from blood samples. Random
forest modeling with recursive feature elimination was used to predict case/control status. Age and APOE !4 status were used
as covariates for all analysis.
Results: Gene and pathway level models performed similarly to each other and to a model based on demographic
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Conclusions: Any potential increase in concordance from the novel pathway level approach used here has not lead to a greater
predictive ability in these datasets. However, we have only tested one method for creating pathway level scores. Further, we have
been able to benchmark pathways against genes in datasets that had been extensively harmonized. Further work should focus
on the use of alternative methods for creating pathway level scores, in particular those that incorporate pathway topology, and
the use of an endophenotype based approach.
Keywords: Alzheimer’s disease, blood, gene expression, pathways
INTRODUCTION
The most common form of dementia is Alzheimer’s
disease (AD). It is predicted that by 2050, 1 in every 85
people will be living with the disease [1]. No disease
modifying treatments are available for AD and exist-
ing treatments only provide short-term symptomatic
relief in a subset of patients [2]. Additionally, in the
early stages (between 2 and 15 years prior to the devel-
opment of clinical symptoms) the disease is difficult
to diagnose. Villemagne et al. and Jack et al. hypoth-
esize that characteristic AD pathology (the presence
of amyloid-" (A") plaques and hyperphosphorylated
tau tangles in the brain) begins to develop up to 20
years prior to clinical diagnosis [3, 4]. This extended
prodromal stage is an important window in which to
target treatments that may be able to alter the course of
the disease; provided people could be sensitively and
accurately diagnosed. A", tau, and phosphorylated-tau
levels are indicative of AD pathology in this prodro-
mal period and can be measured in cerebrospinal fluid
(CSF) and by positron emission tomography (PET)
imaging [5]. The procedures involved in attaining these
measurements can be invasive or expensive and require
specialized administration, equipment. and expertise.
The development of a less invasive, potentially cheaper
technique, such as a blood test, would offer significant
advantages [6].
Recent studies indicate that gene expression levels
in blood may be able to differentiate AD subjects from
normal elderly controls and mild cognitive impairment
(MCI) subjects with prodromal disease [7–10]. Han
et al. provide an overview of studies of gene expres-
sion associated with AD-related phenotypes [11]. They
state that the blood transcriptome is vital in the disease
mechanism of AD and should therefore be investigated
further in independent studies of a large sample size.
A more general summary of gene expression data in
neurodegenerative diseases is given by Cooper-Knock
et al. [12]. This review emphasizes the dysregula-
tion in neuroinflammation and intracellular signaling
pathways including calcium signaling in AD. The
commonality between these reviews is that they both
highlight limited replicability at the single marker
level. Furthermore, Han et al. report a greater con-
cordance between differentially expressed genes at the
pathway level. A pathway-based interpretation of gene
expression may therefore prove more robust across dif-
ferent sample populations. Such an approach may also
reduce noise and dimensionality. It is important to note
that differential gene expression, as described in these
reviews, does not necessarily identify genes that will
be useful in a classification context.
Although previous gene expression studies in AD
have retrospectively identified pathways altered in dis-
ease [9], this is the first study to use pathway scores for
each individual to build predictive models across the
population. This study used Pathway Level Analysis of
Gene Expression (PLAGE) to estimate pathway vari-
ability across samples in the population by calculating
sample-wise pathway scores [14]. PLAGE outper-
formed other single sample enrichment methods such
as ZSCORE, Gene Set Variation Analysis (GSVA),
and Single Sample Gene Set Enrichment Analysis
(SSGSEA) in a comparison of sensitivity, specificity,
and prioritization by Tarca et al. [15]. PLAGE scores
have been used in univariate t-testing and unsuper-
vised clustering methods to investigate the pathways
involved in oral leukoplakia and those leading to cell
proliferation and migration in leukemia [16, 17]. We
combine, for the first time, PLAGE scoring with a
supervised machine learning approach to build an AD
classifier.
This study used blood expression data from sub-
jects participating in the AddNeuroMed (ANM) and
Dementia Case Registry (DCR) studies to develop
models of clinical diagnosis. The performance met-
rics of gene expression and demographic models is




ANM is a European multi-center study aiming to
develop biomarkers for AD [18]. Subjects with an AD
diagnosis as well as those with MCI and healthy con-
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Fig. 1. Overview of sample numbers in batch 1 and 2 gene expression.
trols were recruited from centers based in Kuopio,
Lodz, London, Perugia, Thessaloniki, and Toulouse.
Details of study design and enrollment are provided
by Lunnon et al. [10]. Subjects for the DCR were
recruited from the Maudsley and Kings Healthcare
Partners, which incorporates the Alzheimer’s Research
UK (ARUK) cohort [19] from whom gene expression
data has not previously been reported.
The present study used data from 748 subjects: 614
subjects from ANM and 134 subjects from DCR.
Gene expression
Whole blood samples (2.5 ml) were collected after
2 h of fasting into Paxgene Blood RNA tubes (BD)
and extracted as in Lunnon et al. [9]. Illumina Human
HT-12 Expression BeadChips were used to analyze
the whole transcriptome according to the manufactur-
ers protocol. The gene expression analysis was run in
two batches at two different sites. Batch 1 contained
samples from 356 ANM subjects run on version 3 of
the BeadChip, as previously described [9, 10]. Batch 2
contained samples from 411 subjects: 134 from DCR
and 277 from ANM run on version 4 of the Bead-
Chip. Samples from 19 subjects were included in both
batches. See Fig. 1 for an overview of sample numbers.
The raw gene expression data are available as GEO
DataSets (Accession number GSE63060 for batch 1
and GSE63061 for batch 2).
Statistical analysis
Data pre-processing
The data pre-processing performed in this study is
different to that used for the original analysis by Lun-
non et al. [9, 10]. The data processing pipeline used
in this study aims to address the effects of technical
data artifacts in gene expression studies [20]. Raw gene
expression data was exported from Illumina’s Genome
studio and processed in R (version 3.1.1) [21] using the
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lumi package [22] and custom in-house pre-processing
scripts (GitHub, http://bit.ly/1vjyKNo). Briefly, raw
expression data was subject to a model based back-
ground correction for bead array [23]. This used
negative bead expression levels to correct for back-
ground noise. The data was then log base 2 transformed
and robust spline normalized in lumi [22]. Outlying
samples were iteratively identified using fundamental
network concepts and removed, following the meth-
ods described by Oldham et al. [24]. To reduce any
batch effects we adjusted for technical categorical
variables using ComBat [25]. Continuous technical
artifacts were accounted for by taking the first prin-
cipal component across housekeeping and undetected
probes and regressing this against technical variables.
Variables significantly associated with the first princi-
pal component were then regressed against expression
for each probe, and the mean adjusted residuals taken
forward for all further analyses. Finally, the data was
reduced to a subset of probes that could be reliably
detected in 80% of samples in at least one diagnos-
tic group. Finally, subjects were excluded where there
were discrepancies between the recorded sex and sex
determined by the XIST (ILMN 1764573), USP9Y
(ILMN 2056795) and EIF1AY (ILMN 1755537 and
ILMN 2228976) X- and Y-linked genes.
Demographic data for the ANM and DCR subjects
was extracted using CohortExplorer [26].
Pathway level analysis of gene expression
(PLAGE)
Gene level expression data were condensed to sam-
ple wise, pathway level scores using PLAGE [14].
PLAGE groups genes into pathways defined by the
Broad Institute Collection of Curated Pathways [27]
and outputs a score, per sample, for each of these sets.
We restricted PLAGE to only include pathways with
between 10 and 500 genes. The generation of PLAGE
scores was implemented through R package ‘GSVA’
and is detailed in Supplementary Methods, section 1
[13].
Data analysis
Clinical diagnosis (AD versus non-demented elderly
control) classification models were built using batch
1 gene expression data. Variable selection was per-
formed using recursive feature elimination (RFE) and
the creation of a tolerance set using the ‘pickSizeTol-
erance’ function in R. This function finds a smaller set
of variables while maintaining model accuracy [28].






Sex (% female) 69 58.9 0.149
APOE status (% of APOE !4 positive) 57 32.7 <0.001
APOE !4 load (% with loads 0; 1; 2) 43; 40; 17 67.3; 29; 3.7 <0.001
Median age [IQR] (years) 76 [10] 73 [9] <0.001
Median MMSE score [IQR] 22 [7.25] 29 [1] <0.001
Median years in fulltime education [IQR] 7 [5] 11 [8] <0.001
Sample collection site 0.011
(% from KPO; LDZ; LND; 32; 15; 7; 21.5; 13.1; 21.5;
PRG; THS; TLS) 26; 12; 8 21.5; 6.5; 15.9
Batch 2
n 118 118
Sex (% female) 63.6 61.9 0.893
APOE status (% of APOE !4 positive) 52.5 24.6 <0.001
APOE !4 load (% with loads 0; 1; 2) 47.5; 39.8; 12.7 75.4; 20.3; 4.2 <0.001
Median age [IQR] (years) 78 [9] 74 [8] 0.001
Median MMSE score [IQR] 21 [8] 29 [2] <0.001
Median years in fulltime education [IQR] 9 [7] 11 [5] 0.001
Sample collection site 0.002
(% from KPO; LDZ; LND; 10.2; 18.6; 35.6; 17.8; 7.6; 51.7;
PRG; THS; TLS) 19.5; 10.2; 5.9 17.8; 3.4; 1.7
Individuals were positive for APOE !4 if at least one APOE !4 allele was seen in their genotype. APOE !4 load was the number of alleles
seen in a subjects genotype. Kruskal Wallis Chi-Squared was used to test between cases and controls for continuous data. Fishers exact was
used to test between cases and controls for categorical data. KPO, Kuopio; LDZ, Lodz; LND, London; PRG, Perugia; THS, Thessaloniki; TLS,
Toulouse.
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of which was a model based on demographic data
alone (demographic model) [29]. The demographic
variables included were those that were significant
in the batch 1 population: sample collection site,
age, years in full time education, and APOE status
(defined as the presence of any number of !4 alleles)
(Table 1). Two further models were built based on these
demographic variables and gene level data (gene
model) or PLAGE scores (pathway model). The pur-
pose of the demographic model is to provide a
comparator for the gene and pathway models. If mod-
els that include blood expression information (as well
as demographics) are no more informative than demo-
graphic variables alone there is no benefit in including
this information. All model building was performed
in the statistical software R (Version 3.1.1) using the
‘caret’ package [28].
Each model was used to predict the diagnostic sta-
tus of subjects in batch 2. Model statistics including
accuracy, sensitivity, and specificity were generated
and compared between the demographic model, gene
model, and pathway model. Receiver Operator Curve
(ROC) analysis was also performed in batch 2 data
using R packages ROCR and pROC [30, 31].
Full details of model building are provided in Sup-
plementary Methods section 2.
Additionally, variable importance (determined as
the change in Gini index) was examined in the pathway
model by permutation testing. The idea of permutation
testing is to break the association between outcome
(in this case diagnosis) and predictor variables. When
the model is re-built based on this permuted data any
significant association is spurious. Therefore, by com-
paring the true variable importance of a pathway to the
variable importances that arise by chance in the per-
muted data we can assess how significant our result
is. To achieve this here we used 1000 permutations of
the demographic variables (including diagnosis) and
for each permutation built a RF model. The impor-
tance measures of each pathway were then compared
to that of the original model to generate an empirical
p-value. A p-value of less than 0.05 was considered
significant.
The validity of the pathways selected in the pathway
model was also investigated in a similar way. A random
set of pathways (of the same size as the final pathway
model) were selected, and used to build a RF model.
The fact that this set is random breaks the association
between predictor variables and outcome. This process
was repeated 1000 times and the accuracies across all
models compared to the accuracy of the true model to
create an empirical p-value.
RESULTS
Cohort demographics
Table 1 gives an overview of the demographics of
subjects included in the two batches of gene expression
data.
Data pre-processing
As a result of pre-processing 12 samples in batch
1 and 49 samples in batch 2 failed quality control
(QC) and were removed. The majority of these samples
failed QC as they were identified as outliers. Addition-
ally, some samples were removed because the sex of
the individual recorded in the clinical database did not
match the biological sample (2 samples in batch 1 and
7 in batch 2).
Samples from 19 subjects were present in both batch
1 and batch 2. Samples from 14 of these individuals
passed QC in both batches; only data from batch 1 was
used and the other was discarded. Correlation between
the two batches was at least 0.9 for all individuals (Sup-
plementary Figure 3). Batch 2 gene expression data
contains subjects from the DCR whereas batch 1 does
not. This study used the same protocols, staff, and facil-
ities as the London sample collection site within ANM.
Principal components analysis (PCA) was performed
across the batch 2 gene expression data from DCR and
ANM subjects from London. The first three principal
components (accounting for >40% of variation) were
linearly regressed against the study the individual was
enrolled in (DCR or London ANM) and found to be
non-significant. Therefore, it was deemed appropriate
to group DCR subjects with London ANM, allowing
the model trained in batch 1 data to be simply applied
to batch 2 data.
After data processing only subjects with either an
AD diagnosis at all visits or control status at all visits
were analyzed further: 207 subjects in batch 1 and 236
in batch 2.
Only gene probes that mapped between the version
3 and version 4 chips used to generate batches 1 and
2, respectively, were used for analysis (5212 probes).
The Broad Institute Collection of Curated Pathways
matched these probes to 834 pathways [27].
Data analysis
Demographic model
The following demographic variables were associ-
ated with case/control status in our cohorts (Table 1):
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Table 2
Random Forest model results in independent test data
Model Accuracy [95% CI] Sensitivity Specificity AUC ROC
Demographic model 0.686 [0.623; 0.745] 0.534 0.839 0.771
Demographic model (no samples collection site) 0.674 [0.610; 0.733] 0.678 0.669 0.761
Pathway model 0.657 [0.592; 0.717] 0.610 0.703 0.729
Gene model 0.657 [0.592; 0.717] 0.568 0.746 0.724
CI, Confidence interval; AUC ROC, Areas under the receiver operating curve.
Fig. 2. ROC curves for Random Forest models in independent test
data. ROC, Receiver Operating Characteristic; AUC, Area under the
curve.
age, sex, APOE status, years in full time education, and
sample collection site. These variables were therefore
used in multivariate modeling using RFE. The optimal
cross-validated accuracy was found when including
all variables; calculation of a tolerance set excluded
the variable representing the Lodz sample collection
site. Variable importance scores showed age as the
most important covariate followed by years in full time
education and then APOE status and sample collection
site. In batch 2 test data the model achieved an accuracy
of 0.69, sensitivity of 0.53 and specificity of 0.84.
The area under the ROC curve was 0.77 (see Table 2
and Fig. 2).
Additionally, a model that did not contain the sam-
ple collection site was built. The aim was to create
a model based on demographics that would be avail-
able to clinicians. This model had a slightly decreased
accuracy in comparison to the demographic model but
outperformed the pathway model and gene model in
accuracy, sensitivity and area under the ROC curve
at 0.67, 0.68 and 0.76, respectively. Interestingly, the
specificity of the model was lower than all others at
0.67 (Table 2).
Gene model
The top 5% of variables from the bootstrapped
variable importance calculations (261 variables) were
carried forward to the RFE model building. The opti-
mal cross-validated accuracy from RFE in the gene
model was found for all of the 261 variables; cal-
culation of a tolerance set reduced this set to only
Table 3
Genes in gene model with variable importance scores
Gene (Illumina ID) Variable importance Gene symbol Entrez ID Gene name
ILMN 2189936 11.9 RPL36AL 6166 Ribosomal protein L36a-like
ILMN 2189933 10.8 RPL36AL 6166 Ribosomal protein L36a-like
ILMN 2097421 10.5 MRPL51 51258 Mitochondrial ribosomal protein L51
ILMN 2237746 10.4 ING3 54556 Inhibitor of growth family, member 3
ILMN 1695645 9.2 CETN2 1069 Centrin, EF-hand protein, 2
ILMN 1784286 7.9 NDUFA1 4694 NADH dehydrogenase (ubiquinone)
1 alpha subcomplex
ILMN 1652073 7.0 LOC653658 653658 Ribosomal protein S23 pseudogene 8
ILMN 1716053 7.0 AK2 204 Adenylate kinase 2
ILMN 1732328 6.5 LOC646200 646200
ILMN 1776104 5.9 NDUFS5 4725 NADH dehydrogenase (ubiquinone)
Fe-S protein 5
ILMN 1753892 5.8 LOC654121 654121
ILMN 1745343 5.4 ZMAT2 153527 Zinc finger, matrin-type 2
ILMN 2048326 4.7 RPS27A 6233 Ribosomal protein S27a
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Fig. 3. Percentage overlap of genes belonging to pathways selected for the Random Forest pathway model.
Table 4
Pathways in pathway model with variable importance scores
Pathway Abbreviation Number of genes in pathway Variable importance
KEGG HOMOLOGOUS RECOMBINATION RECOMB 28 13.6∗
BIOCARTA MCALPAIN PATHWAY MCALPAIN 25 7.8∗
REACTOME APC C CDC20 MEDIATED APC 26 7.5
DEGRADATION OF CYCLIN B
REACTOME TGF BETA RECEPTOR SIGNALING IN TGF 16 7.2
EMT EPITHELIAL TO MESENCHYMAL TRANSITION
REACTOME P75NTR SIGNALS VIA NFKB P75NTR 14 6.9
BIOCARTA UCALPAIN PATHWAY UCALPAIN 18 6.8
REACTOME RNA POL III TRANSCRIPTION RNA POL 33 6.4
BIOCARTA NKT PATHWAY NKT 29 6.0
KEGG NUCLEOTIDE EXCISION REPAIR NUCLEOTIDE 44 5.9
REACTOME IRON UPTAKE AND TRANSPORT IRON 36 5.3
BIOCARTA CCR5 PATHWAY CCR5 20 5.3
KEGG ECM RECEPTOR INTERACTION ECM 84 5.0
REACTOME SIGNALING BY CONSTITUTIVELY ACTIVE EGFR EGFR 18 5.0
REACTOME RESPIRATORY ELECTRON TRANSPORT ATP RESPIRATORY 98 4.4
SYNTHESIS BY CHEMIOSMOTIC COUPLING AND
HEAT PRODUCTION BY UNCOUPLING PROTEINS
∗Nominally significant in permutation testing (p < 0.05).
13, excluding all demographic variables. For a list of
genes, see Table 3.
In batch 2 test data, the gene model accuracy was
lower than that of the demographic model and equal
to the pathway model. The sensitivity, specificity, and
area under the ROC curve of the gene model lay
between the demographic and pathway models at 0.59,
0.75, and 0.72, respectively. (see Table 2 and Fig. 2).
Note that the pathway model showed higher sensitiv-
ity while specificity and AUC ROC were higher in the
demographic model.
Pathway model
The top 5% of variables from the bootstrapped
variable importance calculations (42 variables) were
carried forward to the RFE model building. The opti-
mal cross-validated accuracy from RFE in the pathway
model was found for 40 of the variables; calculation of
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a tolerance set reduced this set to only 16 variables
(Table 4): 14 pathways, age, and years in full time
education.
Permutation tests of variable importance were per-
formed to assess the size of effect relative to that
observed under the null hypothesis of no association.
Of the 14 pathways, two achieved nominal significance
with a p-value <0.05 and are indicated with a ∗ in
Table 4 (Supplementary Figure 5).
Additionally, we compared the model accuracy of
1000 models comprising 16 random variables from
the pathways, age, sex, APOE status, and years in full
time education. This yielded a p-value of 0.082 indicat-
ing that, statistically, the final model does not perform
significantly better than a model of random pathways
(Supplementary Figure 4).
In batch 2 test data, the model accuracy was lower
than that of the demographic model at 0.66, however,
the sensitivity was higher at 0.61. Both specificity
and area under the ROC curve were lower than the
demographic model at 0.70 and 0.73, respectively (see
Table 2 and Fig. 2).
There is minimal overlap in genes between the dif-
ferent pathways included in the final pathway model.
This is illustrated by the sparse percentage overlap
map shown in Fig. 3 and supports the idea that each
pathway is contributing an independent signal to the
model. Of the 13 genes included in the gene model,
only four of them (ILMN 1776104, ILMN 1784286,
ILMN 1695645, and ILMN 2048326) appear in any of
the pathways in the pathway model.
Misclassification
We discovered that 22% of controls used in the
training data had reported memory complaints deemed
not serious enough to reflect a change in diagno-
sis. By studying misclassification rates split by AD
subjects, control subjects, and control subjects with
memory complaints, we see that the most well classi-
fied group in the gene model was those subjects with
memory complaints whereas in the pathway model it
was control subjects (see Supplementary Figure 6). We
also demonstrated that time since disease onset is not
related to misclassification of AD subjects and con-
trol subjects with memory complaints in the test data
(Supplementary Figure 7).
DISCUSSION
In this study we investigated whether AD cases
could be differentiated from control subjects using
gene expression data analyzed at the pathway level.
We were particularly interested in confirming whether
pathway level information created a more robust pre-
dictor of case/control status than expression data
at the gene level as recent reviews of AD stud-
ies have suggested [11]. Our results, using subjects
from the ANM and DCR cohorts, show similar
model performance in a pathway model compared
to a gene and demographic only model. In this
study, we do not find improved prediction of AD
diagnosis using pathway level information using the
PLAGE method to calculate pathway scores. How-
ever, the robustness of pathway based approaches for
AD biomarker discovery should be tested in other
gene expression data from different populations and
platforms.
The fourteen pathways included in the final pathway
model focused around DNA repair, immune response,
and regulation of cellular activities. Of particular inter-
est to AD, two pathways containing genes from the
calpain gene family were included in the final fourteen
pathways. It is thought that amyloid peptides inter-
fere with calpain activity leading to deregulation of
the CDK5 gene and in turn hyperphosphorylation of
the tau protein. This promotes the death of neurons
[27]. It is encouraging that we have seen relevant path-
ways in our final pathway model. Overall, the pathways
are similar to those identified by Lunnon et al. who
studied overall pathway differences using an identical
raw dataset that was processed differently [9]. As we
would expect, 12 out of 13 of the genes in the final
gene model were present in the genes used for mod-
eling by Lunnon et al. The data had been processed
slightly differently emphasizing that these signals
are robust to alterations in processing and modeling
methods.
RF models are commonly used in biomarker studies
[9, 32, 33]. However, it has been shown that they exhibit
variable selection bias being more likely to select con-
tinuous variables or those with many categories [34].
Additionally, the presence of correlated predictors (as
is common in gene expression studies) can add further
bias [35]. Strobl et al. aimed to address these issues
with an ensemble-learning algorithm based on condi-
tional inference trees; Conditional RF (CRF) models
[36, 37]. We attempted to use this methodology in the
present study. We hypothesized that the creation of an
unbiased predictor may highlight different pathways
and genes to those previously discovered, potentially
allowing greater predictive ability. However, the pro-
cess of creating a CRF model was computationally
expensive even when using high performance com-
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puting resources. Model building considering the 834
pathways and 5,212 genes was consequently infea-
sible. Work to improve the efficiency of this method
would be computationally beneficial and would allow
the use of alternative variable importance measures.
Measures such as mean decrease in accuracy and
conditional mean decrease in accuracy would be an
improvement over biased variable importance mea-
sures such as the Gini index, which was used in this
study.
This study used the Broad institute collection of
curated pathways to generate the pathway model and
excluded less well-curated gene sets. This method was
chosen due to its performance in a comparison study
[15] and due to ease of application through the GSVA
R package. It may be beneficial, although potentially
computationally costly, to create pathway level scores
that also reflect pathway topology and thus add further
detail to the model. Such methods have been created
by Pyatnitskiy et al. [38] building on the work of oth-
ers [15, 39]. The method detailed by Pyatnitskiy et
al. does not depend on predefined gene sets as used
in this analysis. However, it is also unable to control
the number of genes in a pathway; a potential bene-
fit of using PLAGE. A further limitation of existing
pathway approaches is that they often ignore informa-
tion on the direction of change for each gene within a
pathway. This would be an interesting area for further
method development.
The creation of a demographic model that excluded
sample collection site led to a drop in accuracy.
Although RNA extraction and analysis were performed
at one site the blood collection may vary by loca-
tion. We aimed to correct for batch effects occurring
in extraction and analysis in the pre-processing. This
highlights that although sample collection sites within
multi-center studies are following the same protocols
major technical differences can still arise and remain
after QC steps including batch correction. As much as
possible, these differences should be quantified dur-
ing extraction. Standardization for future biomarker
development will aid this. It is possible that the sam-
ple collection site effect we see is driven by genetic
differences between sites for some genes (expression
quantitative trait loci). For a biomarker to have clinical
utility it should be robust to such differences. How-
ever, in early exploratory work we are more likely to
find results of interest if technical data artifacts are not
creating a barrier.
The models created in this study all achieved an
accuracy of approximately 70% with the pathway
model having test sensitivity and specificity results of
greater than 60%. The pathway model and gene model
did not outperform a model of demographics alone.
Any potential increase in concordance from the novel
pathway level approach used here has not lead to a
greater predictive ability in these datasets. However,
we have only tested one method for creating pathway
level scores. Further, we have been able to benchmark
pathways against genes in datasets that had been exten-
sively harmonized. It is reassuring to see that pathways
perform similarly to genes and further work is now
needed to see if pathway concordance is more eas-
ily detected using other methodological approaches
and in data generated by independent groups and
platforms.
Furthermore, we found that the heterogeneity of
control subjects may be leading to reduced predictive
accuracy and suggest that the use of an endophenotype
may be beneficial in future work.
CONCLUSIONS
We have used subjects from the ANM and DCR
studies to investigate case/control classification using
gene and pathway level expression data. We hypoth-
esized that a model built on pathway level data may
be more robust than a gene level model and con-
sequently perform better in test data. However, a
pathway level model built using scores and a gene
level model performed similarly to each other and to a
model based on demographic information only. Further
work should focus on the use of alternative methods
for creating pathway level scores, in particular those
that incorporate pathway topology, and the use of an
endophenotype based approach.
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discovery and enrichment using candidate proteins
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We believe this is the ﬁrst study to investigate associations between blood metabolites and neocortical amyloid burden (NAB) in
the search for a blood-based biomarker for Alzheimer’s disease (AD). Further, we present the ﬁrst multi-modal analysis of blood
markers in this ﬁeld. We used blood plasma samples from 91 subjects enrolled in the University of California, San Francisco
Alzheimer’s Disease Research Centre. Non-targeted metabolomic analysis was used to look for associations with NAB using both
single and multiple metabolic feature models. Five metabolic features identiﬁed subjects with high NAB, with 72% accuracy.
We were able to putatively identify four metabolites from this panel and improve the model further by adding ﬁbrinogen gamma
chain protein measures (accuracy = 79%). One of the ﬁve metabolic features was studied in the Alzheimer’s Disease Neuroimaging
Initiative cohort, but results were inconclusive. If replicated in larger, independent studies, these metabolic features and proteins
could form the basis of a blood test with potential for enrichment of amyloid pathology in anti-amyloid trials.
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INTRODUCTION
The most common form of dementia is Alzheimer’s disease (AD), a
neurodegenerative condition that leads to severe cognitive
impairment in later life. Currently, the disease mechanism of AD
is not comprehensively understood, and consequently no
disease-modifying treatments are available. Unfortunately, current
symptomatic treatments only have a moderate effect.1 There is
therefore a desperate need for a disease-modifying treatment
for AD.
A deﬁnitive AD diagnosis can only be made post-mortem;
however, neuropathological biomarkers (amyloid-β (Aβ) plaques
and phosphorylated tau tangles) can be used to help differentiate
AD from other dementias during a person’s lifetime. These can be
used in a clinical trial setting to ensure that all recruited
participants have evidence of the target pathology. In a trial of
Bapineuzumab, an anti-amyloid therapeutic, 14% of subjects had
low amyloid. It was therefore unlikely that these subjects would
see any beneﬁt from the treatment. Furthermore, their involvement
in that study would have reduced the statistical power of ﬁnding a
treatment effect.2 Many trials now test for elevated neocortical
amyloid burden (NAB) as an eligibility requirement.
Elevated NAB is also becoming an eligibility criterion for some
prevention trials, such as the A4 trial.3 This trial aims to assess
whether anti-amyloid therapeutics can delay early cognitive
decline in asymptomatic individuals, a concept that has developed
as a result of research showing that AD has a long prodromal
stage.4,5 The characteristic disease pathology of AD can begin to
develop up to 20 years before any clinical symptoms.6,7 This
provides a window of time for a potential treatment to stop, or at
least slow down, future progression of the disease.
Neuropathological biomarkers are measured by quantifying the
concentrations of Aβ, tau and phosphorylated tau in the
cerebrospinal ﬂuid (CSF) or via positron emission tomography
(PET) imaging. In addition, metabolites in CSF have been studied
as possible biomarkers for AD and related phenotypes.8 However,
the methods used to capture this information are invasive, require
specialized equipment and are often expensive and hence
impractical on a large scale.
Consequently, there is a high demand for a blood-based
biomarker of AD that would be easier and potentially cheaper to
attain.9 Metabolites are typically smaller than other biological
molecules, and therefore have a greater chance of passing
through a possibly weakened blood–brain barrier.10 This increases
the chance that blood metabolites could serve as a biomarker of
AD. A review of AD bioﬂuid metabolite studies has highlighted
sphingolipid and glutamate metabolism as being altered in
AD, besides the metabolism of molecules with antioxidant
properties.11 In addition, Proitsi et al. used a case–control study
design to discover a set of long-chain cholesteryl esters associated
with AD, whereas other studies have aimed to predict conversion
from mild cognitive impairment (MCI) to AD.12–14 Mapstone
et al.13 discovered a lipid panel from peripheral blood that
1MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK; 2Institute of Pharmaceutical
Science, Kings College London, London, UK; 3Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK; 4NIHR
Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK; 5Department of
Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK; 6Proteomics Facility, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
and 7Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA. Correspondence: Dr RJB Dobson or Dr SJ Kiddle, MRC Social, Genetic and
Developmental Psychiatry Centre, King's College London, IoPPN, 16 De Crespigny Park, Denmark Hill, London SE5 8AF, UK.
E-mail: richard.j.dobson@kcl.ac.uk or steven.kiddle@kcl.ac.uk
8Joint senior authors.
9Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within
the ADNI contributed to the design and implementation of ADNI and/or provided data, but did not participate in analysis or writing of this report. A complete listing of ADNI
investigators can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.
Received 18 August 2015; revised 19 October 2015; accepted 30 October 2015
Citation: Transl Psychiatry (2016) 6, e719; doi:10.1038/tp.2015.205
www.nature.com/tp
74
predicted conversion from control status to amnestic MCI or AD
with 90% accuracy. The panel highlighted metabolites involved in
cell membrane integrity and lipids involved in cell signaling, as
also suggested by Whiley et al.15
These studies should now be extended to identify markers of
amyloid pathology. Such markers could then be used to enrich
clinical trials with elevated NAB as an eligibility criterion. Using a
blood test as a ﬁlter before a conﬁrmatory lumbar puncture or PET
scan could improve the efﬁciency of clinical trials by reducing the
cost of recruitment.16
Analogous approaches have already been applied to identify
genetic and protein biomarkers of NAB. A polygenic risk score
trained on AD diagnosis has been shown to associate with CSF Aβ
levels in the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
cohort.17 Similarly, multiple studies have identiﬁed potential
blood protein biomarkers of NAB, as reviewed in Voyle et al.18
Of particular interest are replicated markers of NAB including
pancreatic polypeptide (PPY) and ﬁbrinogen gamma chain
(FGG).16,18
This is the ﬁrst study to investigate associations between blood
metabolites and NAB. Further, we present the ﬁrst multi-modal
analysis of blood markers in AD biomarker discovery. We consider
whether a blood metabolite signal complements that of
previously discovered blood protein biomarkers of NAB.
MATERIALS AND METHODS
Cohorts
UCSF. Subjects were recruited from those enrolled in the University of
California, San Francisco (UCSF) AD Research Centre. Study information has
been given elsewhere.19,20 The study was approved by the UCSF and
Lawrence Berkeley National Laboratory committees for human research.
All subjects provided written informed consent before participating.
ADNI. ADNI is a longitudinal cohort study aiming to validate the use of
biomarkers in AD clinical trials and diagnosis. Data used in the preparation
of this article were obtained from the ADNI database (adni.loni.usc.edu).
The ADNI was launched in 2003 as a public–private partnership, led by
Principal Investigator Michael W Weiner. The primary goal of ADNI has
been to test whether biological markers and clinical and neuropsycholo-
gical assessment can be combined to measure the progression of MCI and
AD. For information, see www.adni-info.org. ADNI was approved by the
institutional review boards of all participating institutions, and written
informed consent was obtained from all participants.
Metabolomics
UCSF. Blood plasma samples were available for 91 subjects enrolled
in the UCSF AD Research Centre. The ultra performance liquid
chromatography-tandem mass spectrometry (UPLC-MS/MS) method used
in this study has been previously published.15 Twenty microliters of plasma
per subject was required for analysis, with sample treatment being
described elsewhere.15,21 The method primarily detects lipids and has
been shown to measure abundances of over 4500 metabolic features. The
instruments included a Waters ACQUITY UPLC and Xevo Quadrupole
Time-of-ﬂight System (Waters, Milford, CT, USA). The Xevo Quadrupole
Time-of-ﬂight System was operated in both negative and positive ion
modes. Samples were analyzed as one batch in a randomized order,
with pooled plasma quality-control (QC) samples run between every
10 samples.
ADNI. Metabolite data were available for 853 blood serum samples.
Twenty-four subjects had two samples included in the study. Targeted
metabolomics analysis was performed using the AbsoluteIDQ p180 assay
(Biocrates Life Sciences, Innsbruck, Austria) requiring 10 μl of serum per
sample. The samples were run in 11 batches with two pooled QC samples
present in each batch: one run before the samples and one afterward.
More information on the assay, sample treatment and instruments can be
downloaded from the ADNI website (adni.loni.usc.edu/).
Candidate protein assays (UCSF only)
The proteomics approach used in this study has been described
elsewhere.16 In short, a set of candidate proteins was quantiﬁed using
single analyte sandwich enzyme-linked immunosorbent assays. In this
study we investigated two proteins that have been replicated as NAB
markers: FGG and PPY.16,18,22,23
NAB measurements
UCSF. Details of PET imaging are given elsewhere.20 All PET scans used
Pittsburgh compound B (11C-PiB) as the radioactive tracer. Scans were
performed using two different scanner types, Biograph TruePoint 6 PET/
computed tomography (N= 9) and Siemens ECAT EXACT HR PET (N= 69),
and were processed using methods described by Lehmann et al.24
We considered two PET outcomes. Two experienced raters who were
blinded to plasma and clinical data rated the scans as either high NAB
or low NAB to give a dichotomous outcome. Second, the 50–70-min
standardized uptake value ratio (SUVR) was used as a continuous
outcome.25
ADNI. Details of PET imaging in ADNI (using both PiB and AV45 markers)
and CSF measurements are detailed elsewhere (www.adni-info.org). PET
end points were dichotomized into high and low NAB at the SUVR
thresholds previously used in ADNI (1.5 for PiB and 1.11 for AV45). CSF
measures of amyloid were taken from the data set ‘UPENNBIOMK2’
available on the ADNI website. The CSF measures were dichotomized at
the previously published threshold (192 pg ml− 1). We combined the three
amyloid end points into a combined amyloid end point to maximize
sample size. A subject was classiﬁed as NAB-positive if at least one
measurement indicated high brain amyloid burden, and classiﬁed as NAB-
negative otherwise.
Statistical analysis
All statistical analyses were performed in R version 3.1.1.26
Data pre-processing
In UCSF, metabolic feature data were extracted from netCDF ﬁles using the
R package ‘XCMS’.27 The package performed ﬁltration and peak identiﬁca-
tion before matching peaks across samples and performing a retention
time correction. Following data extraction, the negative- and positive-
mode data were processed separately using the pipeline detailed in
Supplementary Text 1. ADNI data were also processed using this pipeline.
The processing included outlier removal, normalization through autoscal-
ing and a log base 2 transformation as well as batch correction using the
empirical Bayes method, ComBat.28
After pre-processing, the UCSF data collected in negative and positive
modes were merged.
Protein data were subject to a natural logarithm transformation and
screened for per sample, per protein outliers deﬁned as values outside of 6
s.d.'s of the mean (as above). Each protein was autoscaled.
Single metabolic feature analysis
Single metabolic feature analysis was performed in UCSF for both NAB
outcomes for each of the 2760 metabolic features detected. SUVR was
linearly regressed against each metabolic feature in turn with APOE ε4
status and age included as covariates in the model. The APOE ε4 status is
deﬁned as 1 if a subject’s genotype contained any ε4 alleles and 0
otherwise. Similarly, logistic regression was performed for the dichotomous
outcome. In both cases, a Benjamini–Hochberg correction of the false
discovery rate was applied.
Multiple metabolic feature analysis
Multiple metabolic feature analysis was performed on UCSF data using the
R package ‘caret’.29 Partial least squares (PLS) and PLS discriminant analysis
were used for the continuous and dichotomized outcomes, respectively.
Ideally, we would have split the data into a training and test set; however,
owing to relatively small sample size, this was not possible and a
cross-validation (CV) approach was taken instead. All metabolic features,
age and APOE ε4 status were included in the model building. The number
of components to include was tuned using ﬁve-fold CV through the ‘train’
function. Recursive feature elimination was used to select a subset of
variables using ﬁve-fold CV. The subset sizes considered varied from 2 to
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99 in steps of 1 and from 100 to the total number of covariates in steps
of 100. In PLS modeling, the lowest root mean squared error (RMSE) was
used to select the best model, whereas for PLS discriminant analysis the
highest accuracy was used. The function ‘pickSizeTolerance’ was then
applied in an attempt to ﬁnd a smaller subset of variables that maintained
RMSE or accuracy to within 5% of the best model. We also built models
using the 10 most important predictors, the maximum number of
metabolic features we could feasibly identify. Model statistics resulting
from ﬁve times CV within recursive feature elimination are presented in
this report.
For comparison, we used ﬁve-fold CV to build a model based on age and
APOE ε4 status alone using the ‘train’ function to tune the number of
components as above. This method was used, despite the small number of
predictors, to ensure continuity between modeling techniques. We
checked that the results were consistent with those gained from a linear
regression model. This model is referred to as the demographic-only
model throughout.
Metabolic feature and protein joint analysis
The ﬁnal multiple metabolic feature models were updated by adding
proteins. Model building followed that of the demographic-only model
detailed above. FGG and PPY were included both together and separately.
We also modeled PPY and FGG (with and without age and APOE ε4 status)
against continuous and dichotomized NAB without metabolic features for
comparison.
Putative metabolite identiﬁcation
Putative identiﬁcation of selected metabolic features from statistical
analysis was attempted using the median m/z and their corresponding
retention time, initially using an in-house database and the Human
Metabolome Database.21,30 To enable the conﬁrmation of features from
the database-matching, fragmentation patterns were analyzed using level-
two MS spectra.
Replication in ADNI
We searched the ADNI metabolite data for any of the metabolic features
putatively identiﬁed in UCSF. Logistic regression models of the combined
amyloid end point were built using individual metabolites as predictors,
covarying for age and APOE ε4 status.
Code availability
All R codes used to generate this analysis are available from the
corresponding author on request.
RESULTS
Data pre-processing
UCSF. The R package ‘XCMS’ extracted data for 248 metabolic
features from negative ionization mode and 2807 metabolic
features from positive ionization mode. We ran UPLC-MS/MS in
the positive mode on 91 subject samples and 11 pooled QC
samples. In the negative mode, data were available for 90 samples
and 10 pooled QC samples.
ADNI. Data were available for 141 metabolites in 853 samples.
This included 22 pooled QC samples and 24 replicates. As no
documentation of technical replicates was given by ADNI, the ﬁrst
value was taken. This reduced the sample size to 829, including
the 22 QC samples.
Figure 1 gives an overview of the pre-processing steps. In UCSF,
this processing resulted in 78 subjects with dichotomous NAB and
76 subjects with continuous NAB. We had a total of 2760
metabolic features: 240 from the negative mode and 2520 from
the positive mode. In ADNI, the processing resulted in 531
subjects with the combined amyloid end point and 116 metabolic
features.
Cohort demographics
An overview of demographics for subjects included in the
dichotomous NAB analysis is given in Table 1. The subjects used
here have a wide range of diagnoses that can be grouped into
four categories: AD, fronto-temporal dementia, MCI and healthy
controls. Of these 78 subjects, 2 did not have SUVR available,
reducing the number of subjects in the continuous analysis to 76.
The demographics of this subpopulation are given in
Supplementary Table 1. It is important to note that the population
is relatively balanced in terms of age and scanner type between
high and low NAB groups.
An overview of demographics for subjects included in the ADNI
replication analysis is also shown in Table 1.
Single metabolic feature analysis
For both continuous and dichotomized NAB, no metabolic
features passed a q-value threshold of 0.1. Supplementary
Tables 2 and 3 give full results.
Multiple metabolic feature analysis
Continuous NAB. The multiple metabolite model with the lowest
error was found for 100 predictors, all of which were metabolic
features (CV RMSE= 0.53, CV R2 = 0.10). A tolerance set was
generated to maintain error (that is, CV RMSE) within 5% of the
UCSF Positive mode UCSF Negative mode ADNI
Metabolic features identified
Metabolic features (p) = 
2807
Samples (N) = 91
Metabolic features (p) =
248
Samples (N) = 90
Metabolic features (p)
= 141
Samples (N) = 831














Identify per sample, per metabolic feature outliers and set to missing 
















Test normality of each metabolic feature
Log base 2 transformation
Adjust for batch effects using ComBat
Use probabilistic principal component analysis to ensure QC samples 
cluster
Impute data using 10 nearest neighbors








UCSF: Remove samples with missing continuous NAB from continuous NAB 
analysis





Figure 1. Overview of pre-processing steps affecting the number of
metabolic features and samples.
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value achieved by the optimal model (0.53). The reduced model
contained 17 of these metabolic features (CV RMSE= 0.55, CV
R2 = 0.07).
The 10 predictor models contained only one component (CV
RMSE= 0.56, CV R2 = 0.05). Cross-validated model statistics are
given in Table 2, illustrating that the models including metabolic
features do not outperform age and APOE in this training data. For
information on the metabolic features included in the ﬁnal models
see Table 3.
Addition of the proteins FGG and PPY to the 17-metabolic-
feature model increased cross-validated R2 to 0.57, explaining
more variation in NAB than metabolic features or proteins alone
(R2 = 0.07 and 0.21, respectively).
Dichotomized NAB. The best model and tolerance set model
were the same, both containing ﬁve-metabolic-feature predictors
(CV accuracy = 0.72, CV sensitivity = 0.65, CV speciﬁcity = 0.76).
Model statistics for the ﬁnal models are given in Table 2. We see
an improved accuracy of 72% compared with age and APOE alone
at 58%. For information on the ﬁve metabolic features included in
the ﬁnal model see Table 3.
The addition of the protein FGG to the ﬁve-metabolic-feature
model increased accuracy to 79%, with sensitivity and speciﬁcity
both above 70% (71% and 84%, respectively). The two
protein models (FGG and PPY only) gave an identical accuracy
to the ﬁve-metabolic-feature model at 72%, driven by a high
speciﬁcity (93%).
Putative metabolite identiﬁcation. We aimed to putatively identify
the ﬁve metabolic features that were included in the ﬁnal model
of dichotomized NAB (Figure 2). We were able to identify four of
these ﬁve metabolic features. No suitable surrogate metabolic
feature was available for the unidentiﬁed metabolite.
Table 1. Cohort demographics
UCSF Total (N= 78) Low NAB (N= 48) High NAB (N=30) P-value
Median NAB SUVR (IQR)a 1.3 (0.9) 1.2 (0.1) 2.3 (0.4) —
Plasma sample median days in storage 1354.5 (560.8) 1400 (432.8) 1247 (835.3) 0.435
Median number of days' difference between sample
collection and scan (IQR)
18.5 (69.8) 18.5 (62.3) 16 (101.5) 0.963
Median age (IQR) 65.5 (10.7) 65.8 (9.1) 63.1 (12.7) 0.472
Median MMSE (IQR) 25.5 (6.0) 27 (4.3) 22.5 (9.8) o0.001
Scanner type (%)
Biograph 9 (11.5) 6 (12.5) 3 (10.0) 40.999
Siemens 69 (88.5) 42 (87.5) 27 (90.0)
Gender (%)
Female 32 (41.0) 18 (37.5) 14 (46.7) 0.482
Male 46 (59.0) 30 (62.5) 16 (53.3)
APOE ε4 status (%)
0 57 (73.1) 38 (81.2) 18 (60.0) 0.065
1 21 (26.9) 10 (18.8) 12 (40.0)
Diagnosis (%)
AD 24 (30.8) 2 (4.2) 22 (73.3) o0.001
FTD 48 (61.5) 42 (87.5) 6 (20.0)
HC 4 (5.1) 3 (6.3) 1 (3.3)
MCI 2 (2.6) 1 (2.1) 1 (3.3)
ADNI N= 531 N= 265 N=266
Median age (IQR) 75.1 (8.70) 75.8 (8.60) 74.3 (8.78) 0.497
Gender (%)
Female 213 (40.1) 110 (41.5) 103 (38.7) 0.536
Male 318 (59.9) 155 (58.5) 163 (61.3)
Median years in education (IQR) 16 (4) 16 (4) 16 (4) 0.505
APOE ε4 status (%)
0 279 (52.5) 115 (43.4) 164 (61.7) o0.001
1 252 (47.5) 150 (56.6) 102 (38.3)
Median MMSE (IQR) 27 (5) 26 (6.75) 28 (4) 0.001
Diagnosis (%)
Other 88 (16.6) 36 (13.6) 52 (19.5) o0.001
Dementia 157 (29.5) 101 (38.1) 56 (21.0)
MCI 172 (32.5) 80 (30.2) 92 (34.6)
HC 114 (21.5) 48 (18.1) 66 (24.8)
Abbreviations: AD, Alzheimer’s disease; ADNI, Alzheimer’s disease neuroimaging initiative; FTD, fronto-temporal dementia; HC, healthy control; IQR,
interquartile range; MCI, mild cognitive impairment; MMSE, mini mental state exam; NAB, neocortical amyloid burden; SUVR, standardized uptake value ratio;
UCSF, University of California, San Francisco. aThis is based on those subjects with SUVR available (N= 76; low NAB N= 48; high NAB N= 28). Kruskal–Wallis Χ2
was used to test between high and low groups for continuous demographic variables. Fisher’s exact was used to test between high and low groups for
categorical demographic variables.
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One of the four metabolic features was discovered in negative-
mode UPLC-MS/MS (median m/z= 775.68) and has been identiﬁed
as a phosphatidylethanolamine (PE 39:7). The remaining metabolic
features were discovered in the positive mode. The metabolic
feature with median m/z= 647.59 and an isotope (median
m/z= 648.59) are likely to be anandamide (linoleoyl ethanolamide
(2M+H)).31 As expected, these isotopes are highly correlated
(Pearson’s correlation coefﬁcient = 0.966). Fragmentation patterns
of the metabolic feature with the median m/z= 778.63 suggest a
phosphatidylcholine (PCaa 36:6).
Replication in ADNI. One of the four putatively identiﬁed
metabolites from UCSF was found in the ADNI data: PCaa 36:6.
In the logistic regression model of the combined amyloid end
point, PCaa 36:6 had an estimate of − 0.729 (P= 0.066).
DISCUSSION
To the best of our knowledge, this is the ﬁrst study to investigate
associations between blood metabolites and amyloid burden in
the brain. We have used non-targeted metabolomics to predict
NAB in subjects from the UCSF AD research center. We also
present the ﬁrst analysis to combine protein and metabolite data
in the search for a biomarker for AD.
We found a panel of ﬁve metabolic features that predicted
amyloid positivity with an accuracy of 72%. If the model speciﬁcity
(76%) seen here is maintained in a replication study, it could be
Table 2. Multiple metabolic feature analysis
Continuous NAB models R2 RMSE
Tolerance set (17 metabolic features) 0.07 0.55
10 Metabolic features 0.05 0.56
Age and APOE status 0.12 0.55
Tolerance set (17 metabolic features) with FGG 0.57 0.37
Tolerance set (17 metabolic features) with PPY 0.57 0.38
Tolerance set (17 metabolic features) with FGG and PPY 0.57 0.37
FGG and PPY 0.21 0.49
FGG with APOE status and age 0.09 0.53
PPY with APOE status and age 0.01 0.54
FGG and PPY with APOE status and age 0.08 0.52
Dichotomized NAB models Accuracy Sensitivity Speciﬁcity
Five metabolic features 0.72 0.65 0.76
Age and APOE status 0.58 0.10 0.88
Tolerance set (ﬁve metabolic features) with FGG 0.79 0.71 0.84
Tolerance set (ﬁve metabolic features) with PPY 0.75 0.58 0.86
Tolerance set (ﬁve metabolic features) with FGG and PPY 0.78 0.65 0.89
FGG and PPY 0.72 0.43 0.93
FGG with APOE status and age 0.70 0.43 0.90
PPY with APOE status and age 0.58 0.26 0.83
FGG and PPY with APOE status and age 0.65 0.39 0.86
Abbreviations: FGG, ﬁbrinogen gamma chain; NAB, neocortical amyloid burden; PPY, pancreatic polypeptide; RMSE, root mean square error. Table shows cross-
validated model statistics for continuous NAB.
Table 3. Metabolic features included in the multiple metabolic feature models
Continuous NAB tolerance set model Continuous NAB 10 predictor model Dichotomized NAB model
Mode Median m/z Median retention
time (min)
Mode Median m/z Median retention
time (min)
Mode Median m/z Median retention
time (min)
Positive 184.10 2.85 Positive 184.10 2.85 Positivea 647.59 10.69
Positive 370.41 11.51 Positive 370.41 11.51 Positivea 648.59 10.69
Positive 565.64 18.24 Positive 565.64 18.24 Negativea 775.68 16.38
Positive 700.62 17.09 Positive 700.62 17.09 Positivea 778.63 14.94
Positive 718.65 17.20 Positive 718.65 17.20 Negative 829.66 16.52
Negative 726.62 18.54 Negative 774.62 18.38
Positive 755.64 13.93 Negativea 775.68 16.38
Negative 774.62 18.38 Negative 775.63 18.38
Negativea 775.68 16.38 Positive 776.66 18.53








Abbreviation: NAB, neocortical amyloid burden. aIdentiﬁed metabolic feature.
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useful in a screening setting where a large proportion of subjects
would have high amyloid burden. As the metabolite panel
correctly identiﬁed subjects with low amyloid levels, 76% of the
time it could be useful in reducing the number of patients with
low amyloid burden unnecessarily subjected to further proce-
dures. Interestingly, no metabolic feature model retained age or
APOE ε4 status. This population appeared relatively balanced with
respect to these two variables, possibly accounting for the lack of
inclusion. Alternatively, effects of age and APOE, which are well
known to be associated with amyloid burden, could be accounted
for in surrogate metabolic feature variables.6,7 Analysis of single
metabolic features gave no signiﬁcant results. However, low
statistical power in the current study means that this approach
should not be ruled out in further study of larger cohorts.
We were able to putatively identify four of the ﬁve metabolic
features included in the model of dichotomized NAB. Of those
identiﬁed, one was a phosphatidylcholine compound (PCaa 36:6).
PCs are a group of compounds previously implicated in AD by
Whiley et al. and others.12,15 In particular, PCaa 36:6 was included
in the 10-lipid panel suggested by Mapstone et al. to predict
conversion to amnestic MCI or AD with 90% accuracy. The
association is in the opposite direction to that seen here, which
could be explained by differences in disease stage between the
cohorts. PCs are phospholipids that form a substantial component
of biological membranes, and in this study show increased
abundance in subjects with high NAB. Chung et al. state that PCs
improve memory in mouse models, corresponding with the
direction of association seen by Mapstone et al.13 However, a
Cochrane review has surmised that there is not sufﬁcient evidence
to extend this conclusion to humans.33
We were able to test associations of PCaa 36:6 in the ADNI
cohort. We saw a direction of association concurrent with that
seen by Mapstone et al. but opposite to that seen in the UCSF
cohort.32 Subjects in the ADNI cohort are diagnostically more
similar to those used by Mapstone et al., which could account for
this similarity. Further, as we could only test the one metabolite, it
is possible that this discrepancy is because we could not include
the other four metabolites. ADNI is currently the only other cohort
that has both metabolite and amyloid data available, and
consequently this is the maximum extent of replication we can
perform. It is essential that further attempts at replication are
made in larger, independent studies.
We were also able to identify a PE (39:7). PEs are also a subtype
of phospholipids that can be found in biological membranes.
Interestingly, in humans they are largely found in tissues of
the central nervous system and when methylated yield
phosphatidylcholines.34 PEs are also implicated in prion disease,
where they cause aggregation of the prion protein.35 In this study
PE 39:7 was reduced in subjects with high NAB. PEs are also
substrates for the synthesis of the ﬁnal metabolic feature we were
able to identify: anandamide.36 Anandamide is an endogenous
cannabinoid neurotransmitter that, on connection with receptors
in the cell membrane, reduces the release of other neurotrans-
mitters in the brain.37 Anandamide is fat soluble, allowing it to
pass through the blood–brain barrier and is made in areas of the
brain important in memory. It is hypothesized that anandamide is
involved in the creation and deletion of short-term connections
between nerve cells.38 In support of this theory, the presence of
anandamide has been shown to impair memory in rats.38 In this
study anandamide is reduced in subjects with high NAB. This
Figure 2. Boxplots showing metabolic feature levels between high and low neocortical amyloid burden (NAB) groups for the ﬁve metabolic
features included in the ﬁnal model of dichotomized NAB. Student’s t-test was used to generate a P-value.
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supports ﬁndings by Jung et al.39 who see an Aβ-dependent
association of anandamide with cognitive decline in samples of
brain tissue.
This study shows for the ﬁrst time that the addition of candidate
proteins (FGG and PPY) to metabolic feature models improves
results. These results are promising and warrant further study
while reinforcing the idea that a multi-modal approach may be
more effective in AD biomarker discovery than single modality
approaches.
Although the results we present here are interesting, and we
are reassured by the fact that the ﬁndings make biological sense,
this study does have limitations—in particular, a lack of test data
and the difference of direction of association for PCaa 36:6 in
ADNI. Without a full independent test set it is likely that model
statistics will be inﬂated, and therefore the results should be
interpreted cautiously. Our preference would have been to split
the data into a training and test set; however, the relatively small
sample size made this suggestion infeasible. Instead, we choose to
use a ﬁve-fold CV approach in this study. It is essential to validate
this work in independent cohorts of a larger size, for example, in
an asymptomatic cohort with high amyloid levels, to reﬂect the
populations eligible for trials such as the A4 trial.3 A further issue
caused by small sample size is a lack of statistical power. This
could be causing the substantial differences in R2 seen in the
continuous NAB analysis and provides further rationale for this
work to be replicated in larger cohorts.
A further limitation of this study is the confounding factor of
diagnosis: the majority of subjects with high NAB have AD,
whereas the majority of subjects with low NAB are diagnosed with
fronto-temporal dementia. It is therefore impossible to tell
whether the markers we identify here differentiate between high
and low NAB or AD and fronto-temporal dementia. Both
applications are important and interesting; however, it is vital
that we aim to understand this confounding in future studies
perhaps through similar analysis in an AD-only cohort.
In further research, targeted metabolite analysis would be
beneﬁcial. With an increased annotation, the biological under-
standing of any ﬁndings would grow, potentially deepening our
knowledge of the disease mechanism of AD. Metabolite
identiﬁcation using the current methods is time-consuming, often
inconclusive and can only be conﬁrmed when the pure standard
compounds are available. Further, the presence of annotated data
would enable pathway analysis and more ready replication of
ﬁndings. The data available in ADNI begin to work toward this.
CONCLUSION
This study used metabolomic information to predict NAB in
subjects from the UCSF AD Research Centre. Five metabolic
features identiﬁed subjects with high NAB with 72% accuracy.
We were able to identify four metabolic features from this panel
(PCaa 36:6, PE 39:7 and Anandamide and an isotope) and improve
the model further with the addition of FGG protein measures
(accuracy = 79%). If replicated in large, independent studies, these
metabolic features and proteins could form the basis of a
blood test with potential for enrichment of amyloid pathology
in anti-amyloid trials.
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Chapter 5
Do peripheral markers help to
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Abstract22
INTRODUCTION: In this study we investigate the association between A  levels in cerebrospinal23
fluid (CSF) and genetic risk in a non-demented population. This paper presents the first analysis to use a24
Bayesian methodology in this area.25
METHODS: Data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the EDAR* and26
DESCRIPA** studies was used in a Bayesian logistic regression analysis. We modeled CSF A  burden using27
age, diagnosis (healthy control or mild cognitive impairment), APOE and a polygenic risk score (PGRS)28
associated with Alzheimer’s Disease (AD). We compared models built using informative priors on age,29
diagnosis and APOE with non-informative priors on all variables.30
RESULTS: The use of informative priors did not improve model performance in the majority of cases.31
Models using only age, diagnosis and APOE genotype showed the best predictive ability.32
DISCUSSION: A previous study indicated that a PGRS of AD case/control status was associated with33
CSF A  burden in healthy controls. The current study suggests that this association does not lead to models34
that are more predictive of amyloid positivity than already known factors such as age and APOE.35
* ‘Beta amyloid oligomers in the early diagnosis of AD and as marker for treatment response’36
** ‘Development of screening guidelines and criteria for pre-dementia Alzheimers disease’37
KEYWORDS: Amyloid; Alzheimer’s Disease; Multi-modal; Polygenic Risk Score; Bayesian; Gene38
Expression Risk Score; Blood; Biomarker; Protein; Metabolite.39
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1 Introduction40
It is hypothesized that late onset AD is caused by the presence of A  plaques in the brain tissue and41
hyperphosphorylated tau tangles in the neurons [1]. Hypothetical models and longitudinal studies indicate42
that A  pathology begins to develop up to 20 years prior to symptomatic changes [2, 3, 4]. This provides43
a window of opportunity for disease-modifying treatments, provided accurate and sensitive diagnostic tools44
are available. Existing tools for identifying the presence of pathology include measurements of amyloid45
and tau in CSF or in brain by the use of positron emission tomography (PET) imaging. Although these46
tests are reasonably accurate they are invasive and expensive. Peripheral biomarkers are sought as an47
intermediate step to provide cost-e↵ective enrichment of people with high risk profiles for clinical trials,48
particularly secondary prevention trials of anti-amyloid therapeutics. In this study we aimed to address49
this by investigating the degree to which a genetic risk score was predictive of CSF A  in a non-demented50
population.51
AD has been identified as a complex disease meaning its presence or absence is determined by environ-52
mental and genetic risk factors. Heritability is estimated to be 50-70% [5, 6, 7]. Over 20 risk loci have been53
identified for AD with Lambert et al. providing the most comprehensive Genome Wide Association Study54
(GWAS) to date [8, 9, 10, 11, 7]. However, it is estimated that currently identified SNPs can only explain55
16-33% of phenotypic variation [9, 10, 7]. GWAS of A  endpoints are also highlighting promising results56
but sample sizes are considerably smaller so validation in larger numbers is needed [12]. An approach to57
consolidating the combined e↵ect of several smaller genetic contributions to disease is found in polygenic58
risk scores (PGRS). A PGRS is calculated as a weighted sum and represents the cumulative e↵ect of these59
smaller genetic e↵ects . They have been shown to be informative in understanding genetic contributions to60
phenotypes beyond AD clinical diagnosis. For example, Sabuncu et al. found an AD case/control PGRS61
associated with A  burden in healthy controls (p < 0.0001). It has not been assessed whether this would62
provide predictive utility for enriching populations for prevention trials [13, 14, 15].63
It is well known that model estimates, and often predictive ability, become more reliable as the number64
of individuals included in an analysis increases. However, in AD research the amalgamation of studies to65
create large datasets is often unfeasible due to di↵erences in study populations and data collection methods.66
Initiatives such as the European Medical Information Framework (EMIF) are aiming to rectify this, but large67
populations with both multi-modal biomarker data and amyloid pathology measures are not yet available68
(www.emif.eu).69
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However, there is substantial information available on the associations between demographic variables70
and prevalence of A  burden, as discussed in meta-analyses by Jansen et al. and Ossenkoppele et al. [4, 16].71
The former of these studies concentrated on persons without dementia (N=7583). The study concluded that72
age, APOE genotype and presence of cognitive impairment were associated with A  burden. No equivalent73
studies are available for tau pathology and consequently this work focuses on amyloid alone.74
The present study uses data from the ADNI, EDAR and DESCRIPA cohorts, to investigate genetic risk75
as a blood biomarker of A  burden using a Bayesian methodology [17]. This study includes older individuals76
who do not have a clinical diagnosis of AD and are at a variable risk of developing the disease. This is77
the first study to use a Bayesian framework in AD blood biomarker research with the aim of investigating78
genetic risk as a marker in blood that could support strategies for identifying individuals at high risk of79
developing disease for recruitment into clinical trials. The models created combine age, diagnosis (control or80
MCI) and APOE genotype with a PGRS. A previous study has shown a case/control PGRS associated with81
A  in healthy controls. We aim to investigate whether this association translates to predictive ability. We82
hypothesized that by informing estimates for demographic variables using the large meta-analysis presented83
by Jansen et al. we would create more robust models. The Bayesian methodology used here has been made84




EDAR is a prospective, longitudinal study with centers at multiple European sites. The study aims to89
examine and evaluate biomarkers of early AD and treatment response [17]. For more information see90
www.edarstudy.eu. Our access to samples and clinical and phenotypic information from the EDAR study91
was enabled by EMIF.92
2.1.2 DESCRIPA93
DESCRIPA is a prospective, multi-center study based in Europe and coordinated by the European AD94
Consortium. The study focused on collecting data from non-demented subjects with the aim of developing95
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screening guidelines and clinical criteria for AD in non-demented subjects. Further details of this study can96
be found in Visser et al. [18].97
2.1.3 ADNI98
ADNI is a longitudinal cohort study aiming to validate the use of biomarkers in AD clinical trials and diag-99
nosis. Data used in the preparation of this article were obtained from the ADNI database (adni.loni.usc.edu).100
The ADNI study was launched in 2003 as a public-private partnership, led by Principal Investigator Michael101
W. Weiner, MD. The primary goal of ADNI has been to test whether biological markers and clinical and102
neuropsychological assessment can be combined to measure the progression of mild cognitive impairment103
(MCI) and AD. For information, see www.adni-info.org. ADNI was approved by the institutional review104
boards of all participating institutions, and written informed consent was obtained for all participants.105
The ADNI study comprises three stages. ADNI 1 is the initial study (target N = 800). ADNI GO106
contains a subset of the controls and MCI participants from ADNI 1 and is supplemented by additional107
individuals with MCI (target N = 700). ADNI 2 enhances ADNI 1 and ADNI GO further with the inclusion108
of new participants in all diagnostic groups (target N = 1350).109
This study uses data from ADNI 1 and the ADNI 2 and ADNI GO sub-groups, referred to as ADNI 2110
from here onwards.111
2.2 Genetics112
Samples from EDAR and DESCRIPA were genotyped on the Illumina HumanOmniExpressExome-8v1.2113
BeadChip and processed together (N = 336) [19]. This BeadChip contains 960,919 markers of which 273,000114
represent functional exomic markers. This is the first publication to present genotype information for EDAR115
and DESCRIPA. The data was processed in Genome Studio (as described at bit.ly/1VpRclH) before being116
run through the rare variant caller Zcall [20] (as described here: bit.ly/1YKHYhK). ADNI 1 samples were117
run on the Human610-Quad BeadChip (N = 818) while ADNI 2 and ADNI GO samples were run on the118
Illumina HumanOmniExpress BeadChip (N = 432). The HumanOmniExpress BeadChip is similar to that119
used in the EDAR and DESCRIPA studies but does not include exomic markers, while the Human610-Quad120
BeadChip is older. Details of the genotyping protocols followed in ADNI are given elsewhere [21].121
The cohorts were subject to quality control and imputation separately, as described in Coleman et al.122
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[22]. In short, the data was filtered to ensure a minor allele frequency of greater than 5% for all SNPs before123
removal of rare variants and subjects with high levels of missing data. SNPs that di↵ered significantly (p124
< 0.00001) from the Hardy-Weinberg equilibrium were removed. The data was pruned for SNPs in linkage125
disequilibrium and for genetically similar individuals. Finally, the data was imputed using reference files126
from the 1000 Genomes Project. [23]127
2.3 Amyloid measurements128
Throughout this study amyloid measurements in cerebrospinal fluid (CSF) are used as the endpoint of129
interest. All A  measurements were dichotomized as detailed in the meta-analysis from Jansen et al..130
The distribution of amyloid burden in all studies was bimodal (as expected) making this dichotomization131
biologically relevant. Low CSF A  is referred to as ‘abnormal’ A  burden while high CSF A  is referred to132
as ‘normal’. The details for each study are as follows:133
2.3.1 EDAR134
Details of CSF collection and analysis can be found at www.edarstudy.eu. In brief, CSF measurements were135
collected using the Alzbio3 Luminex assay in one batch at the end of the study. CSF amyloid measurements136
were dichotomized at the previously published threshold of 389pg/ml.137
2.3.2 DESCRIPA138
Details of CSF measurements in DESCRIPA have been described elsewhere [19]. In brief, CSF measurements139
were analyzed in one laboratory and collected using single-parameter ELISA kits (Innogenetics, Ghent,140
Belgium). CSF amyloid samples were dichotomized using the previously published threshold of 550pg/ml.141
2.3.3 ADNI142
For ADNI, datasets used to extract CSF measures of amyloid were chosen to maximize sample size. The143
dataset ‘UPENNBIOMK2’ was used for ADNI 1 and ‘UPENNBIOMK6’ for ADNI 2 and ADNI GO. Both144
datasets contain CSF measurements collected using the xMAP Luminex platform and Innogenetics im-145
munoassay kits. The CSF measures were dichotomized at the previously published threshold (192 pg/ml).146
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2.4 Statistical analysis147
All statistical analysis was performed in R version 3.1.1 [24]. Models were built in ADNI 1 data and tested148
in data from EDAR, DESCRIPA and ADNI 2. We built models including age, diagnosis (healthy control149
or MCI) and APOE genotype as covariates (‘basic model’) and models including these variables with the150
addition of a PGRS (‘PGRS model’). The predictive ability of each model was quantified using accuracy,151
sensitivity, specificity and area under the Receiver Operating Characteristic (ROC) curve [25, 26, 27].152
2.4.1 PGRS153
PGRS were created using the software package PRSice [28]. E↵ect sizes from stage 1 of the International154
Genomics of Alzheimer’s Project (IGAP) case/control GWAS were used as the weights to generate the risk155
score (N = 54,162, number of SNPs = 7,055,881) [8]. We used 0.5 as the p-value threshold for inclusion in156
the PGRS. This threshold showed the most significant association with case/control diagnosis in the large157
IGAP PGRS study [15]. The genetic region coding for APOE was removed from all scores and included as158
a covariate in modeling.159
2.4.2 Data analysis160
This study aimed to predict dichotomized amyloid burden using genetic risk in a Bayesian logistic regression.161
The method was implemented using the R function ‘MCMClogit’ in the ‘MCMCpack’ package [29]. Models162
were built using a Metropolis sampler with 100,000 MCMC iterations, with the first 3,000 discarded as163
burn-in. This number of iterations ensured the ratio of standard deviation to Monte Carlo Standard Error164
(MCSE) was less than 5% for all parameters.165
The variables included in the ’basic model’ were chosen based on the meta-analysis published by Jansen166
et al. [4]. The study used generalized estimating equations (GEEs) to predict amyloid burden from age,167
diagnosis (control or MCI) and APOE ✏4 status (defined as the presence or absence of any number of ✏4168
alleles). Age is centered at 70 years. In this study we only consider healthy controls and people with a169
diagnosis of MCI. The best model identified by Jansen et al. was:170
Final model : A  ⇠ Age+Diagnosis+ APOE+Age ⇤Diagnosis+Age ⇤APOE171
We have used the estimates from this meta-analysis to inform the regression estimates of variables in this172
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study where possible. It can be shown that the estimates from GEEs are normally distributed [30] and hence173
we included these estimates as priors using a multivariate normal distribution (see Table 1). The PGRS had174
a non-informative multivariate normal prior with mean 0 and variance 100. We also created models where175
all variables had the non-informative Normal(0,100) priors for comparison.176
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Diagnosis = Control -0.964 0.0793
APOE status = 0 -1.493 0.0772
Age * APOE status = 0 -0.021 0.0079
Age * Diagnosis = Control 0.019 0.0081
SE = Standard error.
MCI is used as the reference diagnosis.
APOE status 1 (at least one ✏4 allele) is used as the reference level.
177
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The tuning parameter of each model was adjusted to achieve an acceptance rate in the Metropolis sampler178
of approximately 0.35. This tuning was performed over the 3,000 burn-in samples. This acceptance rate is179
slightly higher than advised in the literature as lower acceptance rates were causing reduced mixing [31].180
2.4.3 Graphical User Interface181
The analysis methods used in this study have been packaged into a user-friendly application through Rshiny182




In the ADNI cohort the genetic data was imputed from 479,073 and 599,526 SNPs in ADNI 1 and ADNI187
2 respectively, to 8,799,802 and 6,336,499 SNPs. In EDAR and DESCRIPA the data was increased from188
619,609 SNPs to 5,409,779 by imputation. The PGRS was standardized by subtracting the mean and dividing189
by the standard deviation, per cohort.190
3.2 Cohort demographics191
The demographics given below are from the individuals in ADNI 1, ADNI 2, EDAR and DESCRIPA with192
CSF and GWAS data available.193
In ADNI 1 (training data) there is 1 point di↵erence in median MMSE between subjects with normal194
and abnormal A  (28 vs. 29). However, the larger sample size of ADNI 1 (compared to ADNI 2, EDAR195
and DESCRIPA) means this di↵erence is statistically significant. Diagnosis and APOE genotype also show196
significant di↵erences between groups, as we would expect. We see a significant di↵erence (p-value < 0.05)197
in the PGRS between groups. Similar associations are seen in the data from EDAR and DESCRIPA with198
age also being nominally significantly associated with normal and abnormal A . ADNI 2 data shows no199

































































































































































































































































































































































































































































































































































































































































































































































































































































































The test data indicated that, in most cases, the addition of informative priors on age, diagnosis and APOE204
genotype did not improve the predictive ability of models. Furthermore, no model including a PGRS showed205
higher accuracy than the basic models. The basic model with non-informative priors achieved the highest206
accuracies at 54% and 49% with a high sensitivity of 81% and 63%, but low specificity (23% and 41%). See207
Table 3 for full results.208
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Table 3: Test data results
Model Informative priors? Accuracy [95% CI] Sensitivity Specificity AUC ROC
EDAR and DESCRIPA
Demographics No 0.535 [0.445; 0.624] 0.806 0.233 0.412
Demographics Yes 0.543 [0.453; 0.632] 0.776 0.283 0.412
PGRS No 0.457 [0.368; 0.547] 0.657 0.233 0.391
PGRS Yes 0.394 [0.308; 0.484] 0.493 0.283 0.394
ADNI 2
Demographics No 0.488 [0.333; 0.645] 0.625 0.407 0.458
Demographics Yes 0.488 [0.333; 0.645] 0.625 0.407 0.461
PGRS No 0.465 [0.312; 0.623] 0.625 0.37 0.396
PGRS Yes 0.442 [0.291; 0.601] 0.5 0.407 0.4
CI = Confidence Interval; AUC ROC = Area under the Receiver Operating Characteristic Curve;




This study shows that the predictive ability of models including age, diagnosis and APOE genotype is not211
improved by the addition of a PGRS despite previous studies showing an association [13]. The PGRS used212
in this analysis was trained on a case/control endpoint. As GWA studies of amyloid endpoints become213
available the predictive ability of a PGRS trained using this information is likely to improve [33].214
This paper presents the first analysis to use a Bayesian methodology in AD blood biomarker research. We215
aimed to inform estimates of well-researched risk variables (age, APOE status and control or MCI status)216
by including prior information from a large meta-analysis [4]. In this study we see that this approach does217
not improve predictive ability of models over those without informative prior information. However, we have218
only used one type of Bayesian methodology. There is a risk that if ill-fitting priors are used in combination219
with small sample sizes, model fit may be driven by the prior distributions. It is possible that the priors220
used here are not optimal as our population demographics are slightly di↵erent from those seen by Jansen et221
al. [4]. However, we believe informing model estimates with information from previous literature is likely to222
reduce false positives in biomarker studies of a small size. Bayesian analysis is one way of doing that; other223
methods should also be investigated.224
The creation of the PGRS also created some limitations for this study. Firstly, the PGRS used here225
only utilizes common genetic variation. This is because rare genetic variants, such as TREM2, may not226
be significantly associated with disease in small populations. As larger studies become available inclusion227
of such variants should be investigated. Further, the PGRS was created using a simple additive method.228
This simplistic method is likely to be sub-optimal and as new methodologies for creating PGRS become229
available they should be investigated in this setting. Additionally, the platforms used to measure genetics230
di↵ered between the discovery and test cohorts used in this study. It is well documented that there can be231
inconsistencies between omics platforms which could have contributed to the reduced predictive ability seen232
here [34, 35, 36, 37].233
It is important to bear in mind in all further research that di↵erences in normal/abnormal CSF A 234
cut-o↵s can make replication and research in other cohorts di cult. Work is being done to investigate these235
values with an aim of standardization [38]. This study also has the limitation that the IGAP data (used236
to generate the PGRS) is not independent of the training and test data, as ADNI was included in IGAP.237
However, we believe the benefit of larger sample size outweighs this. Finally, the cohorts used in this study238
are still of a relatively small size. Although we tried to address this through the use of Bayesian methods,239
97
studies of larger sample sizes will be vital for further investigations of blood based biomarkers of A .240
This study also presents opportunities for further work. Firstly, it is possible that markers identified in241
case/control studies are associated with other AD related phenotypes such as tau burden. If large meta-242
analyses of the risk factors a↵ecting tau burden, and other endophenotypes, become available it would be243
interesting to perform similar Bayesian analysis on these alternative endpoints. Secondly, in the setting of244
preventative clinical trials the most common way to measure brain amyloid burden is through the use of a245
PET scan. In this study we have used CSF. However, it has been shown that measurements from CSF and246
PET are highly correlated meaning markers identified for one can reasonably be tested to see whether they247
are transferable to the other. In this study the use of CSF allowed us to maximize the sample size with248
measurements of amyloid and genetics. If promising blood markers of CSF measures are identified, future249
studies should perform similar analysis using a measurement of A  derived from a PET scan. Furthermore,250
the e↵ect of a measure of brain reserve on model accuracy could be investigated. It is well-known that some251
people with high levels of brain amyloid burden at autopsy show no cognitive deficit during their lifetime. It252
has been shown in recent studies that levels of ‘brain reserve’ may be driving the di↵erence between people253
who have high levels of pathology and no symptoms and those who show symptoms [39]. This is motivating254
a theory that increased brain reserve may prevent development of symptoms even if pathology is present.255
Although brain reserve itself may be hard to quantify it may be possible to measure and model associated256
lifestyle, environmental and psychological factors such as social networks.257
Although there are further candidates and alternative methods to be considered in the search for a blood258
biomarker of amyloid burden it is imperative that appropriate populations are used. As in this work, the259
search in asymptomatic individuals is likely to have the biggest impact for enrichment of clinical trials.260
Furthermore, rigorous testing of biomarkers is essential. Without replication it is probable that model261
performance is overestimated.262
5 Conclusions263
This paper presents the first analysis to use a Bayesian methodology in the search for a blood biomarker of264
AD. We see that the Bayesian approach does not improve predictive ability in this setting, and that omics265
measurements do not improve the predictive ability of models above that of demographics alone. We have266
been unable to demonstrate any additional benefit over age diagnosis and APOE genotype by including267
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Abstract.
Background: The search for a biomarker of Alzheimer’s disease (AD) pathology (amyloid- (A) and tau) is ongoing,
with the best markers currently being measurements of A and tau in cerebrospinal fluid (CSF) and via positron emission
tomography (PET) scanning. These methods are relatively invasive, costly, and often have high screening failure rates.
Consequently, research is aiming to elucidate blood biomarkers of A and tau.
Objective: This study aims to investigate a case/control polygenic risk score (PGRS) as a marker of tau and investigate blood
markers of a combined A and tau outcome for the first time. A sub-study also considers plasma tau as markers of A and
tau pathology in CSF.
Methods: We used data from the EDAR*, DESCRIPA**, and Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohorts
in a logistic regression analysis to investigate blood markers of A and tau in CSF. In particular, we investigated the extent to
which a case/control PGRS is predictive of CSF tau, CSF amyloid, and a combined amyloid and tau outcome. The predictive
ability of models was compared to that of age, gender, and APOE genotype (‘basic model’).
Results: In EDAR and DESCRIPA test data, inclusion of a case/control PGRS was no more predictive of A, and a combined
A and tau endpoint than the basic models (accuracies of 66.0%, and 73.3% respectively). The tau model saw a small increase
in accuracy compared to basic models (59.6%). ADNI 2 test data also showed a slight increase in accuracy for the Abeta
model when compared to the basic models (61.4%).
Conclusion: We see some evidence that a case/control PGRS is marginally more predictive of A and tau pathology than
the basic models. The search for predictive factors of A and tau pathologies, above and beyond demographic information,
1These authors are joint senior authors.
2Data used in preparation of this article were obtained from
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
(http://adni.loni.usc.edu). As such, the investigators within the
ADNI contributed to the design and implementation of ADNI
and/or provided data, but did not participate in analysis or writ-
ing of this report. A complete listing of ADNI investigators can
be found at http://adni.loni.usc.edu/wp–content/uploads/how to
apply/ADNI Acknowledgement List. pdf.
∗Correspondence to: Richard J.B. Dobson and Steven J. Kiddle,
SGDP Centre, IoPPN, 16 De Crespigny Park, Denmark Hill,
London SE5 8AF, UK. Tel.: +44 020 7848 0924; Fax: +44 020
7848 0866; E-mails: richard.j.dobson@kcl.ac.uk (Richard J.B.
Dobson), steven.kiddle@kcl.ac.uk (Steven J. Kiddle).
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is still ongoing. Better understanding of AD risk alleles, development of more sensitive assays, and studies of larger sample
size are three avenues that may provide such factors. However, the clinical utility of possible predictors of brain A and tau
pathologies must also be investigated.
*‘Beta amyloid oligomers in the early diagnosis of AD and as marker for treatment response’
**‘Development of screening guidelines and criteria for pre-dementia Alzheimer’s disease’
Keywords: Alzheimer’s disease, biomarker, blood, multi-modal, polygenic risk score, tau
INTRODUCTION
The hallmark pathologies of Alzheimer’s disease
(AD) are amyloid- (A) plaques and phosphory-
lated tau tangles in the brain. Although diagnostic
criteria for AD focus on pathological evidence of A,
tau levels in cerebrospinal fluid (CSF) are also con-
sidered [1]. Jack et al. provide a theoretical model
for the progression of AD based on existing evidence
that is consistent with the popular amyloid cascade
hypothesis [2, 3]. This hypothesis states that the build
up of tau is triggered by increasing levels of A in
the brain.
The search for a biomarker of AD pathologies (tau
and A) is ongoing with the best markers currently
being measurements of tau and A in the CSF and
via positron emission tomography (PET) scanning.
These methods are relatively invasive and often have
high screening failure rates meaning a high propor-
tion of individuals that are scanned have low levels
of these pathologies. Additionally, PET scanning in
particular is an expensive procedure costing around
$3,000 per scan [4]. There are only approximately
2,380 (http://www.imvinfo.com, August 2016) PET
scanners in the United States meaning access to facil-
ities is limited [5]. The lumbar puncture needed to
access CSF is also considered a high-risk proce-
dure in many western countries [6]. To address these
shortcomings, research is aiming to elucidate blood
biomarkers of AD pathologies (A and tau) [7]. One
motivation for discovering a blood-based biomarker
of AD pathology comes from clinical trial recruit-
ment. For example, when recruiting into a trial of an
anti-amyloid therapeutic, a blood-based biomarker of
A could act as a filtering step to identify individu-
als with abnormal levels of A before performing a
confirmatory PET scan or lumbar puncture. As such
a test is likely to be cost-effective, we could reduce
the cost of screening while also reducing the number
of individuals subject to the invasive lumbar punc-
ture and PET scanning procedures. So far, research
into a blood marker has largely focused on A brain
burden, rather than tau pathology. However, some
studies have investigated genetic markers of tau [8].
This study aims to further this research by investigat-
ing markers of a combined A and tau outcome for
the first time.
Genome wide association studies (GWAS) of AD
to date have identified over 20 risk loci explaining
approximately 16–33% of genetic variability in the
disease [9–13]. Compared to the predicted heritabil-
ity of 50–70%, this is fairly low [13–15]. Modern
technologies including next generation sequencing
and the development of high coverage, exome chips
are beginning to address this issue of missing her-
itability. Meanwhile polygenic risk scores (PGRS)
are aiming to combine genetic risk from variants of
lower effect size [16]. To date, PGRS in AD have
only been trained on case/control endpoints as GWAS
studies of pathological outcomes are relatively small
(for example, N = 1,269 [17]). Studies have shown
case/control PGRS are associated with AD-related
phenotypes but few have investigated their predictive
ability in test data [18, 19]. When we studied the pre-
dictive ability of a PGRS for A burden, we saw that
the case/control PGRS used was no more predictive
than demographics (age, gender) and APOE geno-
type alone (Voyle et al., in submission). However,
we hypothesize in the current study that the PGRS
may be more predictive of a combined A and tau
outcome; a more ‘AD-like’ phenotype.
This study aims to investigate the predictive ability
of a case/control PGRS on CSF A and tau. A sub-
study will also consider plasma tau as a predictor.
We use individuals from the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI), EDAR, and
DESCRIPA studies to investigate these associations
and compare all models to those of demograph-
ics (age, gender) and APOE genotype [20, 21]. We
hypothesize that blood markers of AD will perform
better when predicting a combined pathology (tau and
A) endpoint over tau and A individually. The com-
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MATERIALS AND METHODS
Cohorts
EDAR was a prospective, longitudinal study which
aimed to examine and evaluate biomarkers of early
AD and treatment response [21]. In particular, the
study focused on A oligomers and the effect of
genetic variants on these oligomers. For more infor-
mation see http://www.edarstudy.eu. Our access to
samples and clinical and phenotypic information
from the EDAR study was enabled by the European
Medical Information Framework and has been previ-
ously described (Voyle et al. in submission).
DESCRIPA was also a prospective, multi-center
study. It was coordinated by the European AD
Consortium and focused on collecting data from
non-demented subjects with the aim of developing
screening guidelines and clinical criteria for AD.
Further details of this study can be found in Visser
et al. [20].
ADNI is a longitudinal cohort study aiming
to validate the use of biomarkers in AD clinical
trials and diagnosis. Data used in the prepara-
tion of this article were obtained from the ADNI
database (http://adni.loni.usc.edu). The ADNI study
was launched in 2003 as a public-private partnership,
led by Principal Investigator Michael W. Weiner, MD.
The primary goal of ADNI has been to test whether
biological markers and clinical and neuropsycho-
logical assessment can be combined to measure the
progression of mild cognitive impairment (MCI) and
AD. ADNI was approved by the institutional review
boards of all participating institutions, and written
informed consent was obtained for all participants.
This study uses data from ADNI 1 and the ADNI 2
and ADNI GO sub-groups, referred to as ADNI 2
from here onwards.
Genetics
Samples from EDAR and DESCRIPA were geno-
typed on the Illumina HumanOmniExpressExome-
8v1.2 BeadChip (N = 336) [22]. The data has
previously been reported on by Voyle et al. (in
submission). The HumanOmniExpressExome Bead-
Chip has been optimized to tag SNPs that capture a
large amount of common genetic variation. In total,
the chip contains 960,919 markers of which over
273,000 correspond to functional exomic markers.
ADNI 1 samples were run on the Human610-Quad
BeadChip (N = 818), which has since been discontin-
ued. The chip provides coverage of 924,000 randomly
selected SNPs. ADNI 2 and ADNI GO samples were
run on the Illumina HumanOmniExpress BeadChip
(N = 432). This chip is similar to the HumanOm-
niExpressExome BeadChip used in the EDAR and
DESCRIPA studies but does not include the exomic
markers. In total, the chip contains 713,599 mark-
ers. Details of the genotyping protocols followed in
ADNI are given elsewhere [23]. Details of the data
processing are briefly outlined below.
The cohorts were subject to quality control and
imputation separately, as described in Coleman et al.
[24]. In short, the data was filtered to ensure a minor
allele frequency of greater than 5% for all SNPs before
removal of rare variants and subjects with high lev-
els of missing data. SNPs that differed significantly
(p < 0.00001) from the Hardy-Weinberg equilibrium
were removed. The data was pruned for SNPs in
linkage disequilibrium and for genetically similar
individuals. Finally, the data was imputed using ref-
erence files from the 1000 Genomes Project [25].
CSF Measurements
This study focuses on total tau (tTau) and A
measurements in CSF. The analysis considered three
endpoints: dichotomized A, dichotomized tTau, and
a binary representation of overall pathology. For the
latter analysis, referred to as total CSF burden, each
cohort was reduced to those individuals with normal
A and normal tTau, or abnormal A and abnormal
tTau. The distributions of tTau and A were similar
between cohorts in terms of shape but not in absolute
value. Consequently, this work focused solely on a
dichotomized outcome.
EDAR
Details of CSF collection and analysis can be found
at http://www.edarstudy.eu. In brief, CSF measure-
ments were collected using the Alzbio3 Luminex
assay in one batch at the end of the study. CSF A
and tTau measurements were dichotomized at the
previously published thresholds of 389 pg/ml and
98 pg/ml, respectively.
DESCRIPA
Details of CSF measurements in DESCRIPA have
been described elsewhere [22]. In brief, CSF mea-
surements were analyzed in one laboratory and
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(Innogenetics, Ghent, Belgium). CSF A and tTau
samples were dichotomized using the previously
published thresholds of 550 pg/ml and 375 pg/ml,
respectively.
ADNI
For ADNI, datasets used to extract CSF measures
of A and tau were chosen to maximize sample size.
The dataset ‘UPENNBIOMK2’ was used for ADNI 1
and ‘UPENNBIOMK6’ for ADNI 2 and ADNI GO.
Both datasets contain CSF measurements collected
using the xMAP Luminex platform and Innogenetics
immunoassay kits. The CSF measures of amyloid and
tTau were dichotomized at the previously published
thresholds (192 pg/ml and 93 pg/ml, respectively).
Plasma Tau (ADNI 1 only)
Plasma tau was investigated as a potential blood
biomarker of A and tau in a sub-study. ADNI 1 was
the only cohort with such data available. Plasma tau
was analyzed by the Single Molecule Array (SIMOA)
technique and the Human total tau assay using a com-
bination of monoclonal antibodies. Samples with a
plasma tau concentration below the lower limit of
quantification (<1.0 pg/ml) were removed (N = 36).
Outliers, identified as values greater than 6 standard
deviations from the mean, were removed (N = 2) and
the data was subject to a natural logarithm transfor-
mation.
Statistical analysis
All statistical analysis was performed in R version
3.1.1 [26].
The three endpoints of interest (dichotomized amy-
loid, dichotomized tTau, and total CSF burden) were
modeled using logistic regression models covarying
for age, gender, and APOE genotype. An individuals
APOE genotype was coded as 1 if at least one4 allele
was present and 0 otherwise. Models were also built
using only the demographic variables age, gender,
and APOE genotype, for comparison. Throughout
this study these models are referred to as ‘basic
models’.
Two analyses were performed to study these three
endpoints of interest:
1. PGRS: Models were built in ADNI 1 data (A
and tau N = 363; Total CSF burden N = 244) and
tested in data from EDAR and DESCRIPA (A




Outcome ADNI 1 (N) EDAR and ADNI 2 (N)
DESCRIPA (N)
Dichotomized amyloid 363 250 44
or tTau
Total CSF burden 244 135 37
PGRS and plasma tau analysis




ADNI 2 (A and tau N = 44; Total CSF burden
N = 37).
2. PGRS and plasma tau: Models were built
and tested in ADNI 1 using 5 fold cross-
validation (A and tau N = 323; Total CSF
burden N = 219).
The sample sizes of each dataset used in these
analyses are given in Table 1.
All models including a PGRS co-varied for
the first three genetic principal components to
account for population structure. The predictive
ability of each model was quantified using
accuracy, sensitivity, specificity and area under
the receiver operating characteristic (ROC) curve
[27–29].
PGRS
PGRS were created within each cohort using
PRSice [30]. Effect sizes from stage 1 of the Inter-
national Genomics of Alzheimer’s Project (IGAP)
case/control GWAS were used as the weights to
generate the risk score [9]. We used 0.5 as the p-
value threshold for inclusion in the PGRS. This
threshold showed the most significant association
with case/control diagnosis in the large IGAP PGRS
study [31]. The genetic region coding for APOE was
removed from all scores and included as a separate
covariate due to its strong influence. The PGRS was
standardized by subtracting the mean and dividing
by the standard deviation, per cohort. This aims to
account for the scores including different SNPs due to
availability on the different SNP chips. It is important
to note that APOE genotype is included as a covari-
ate in modeling and not in the PGRS. Therefore, the
PGRS is only exploring variation above and beyond
APOE. This is different to the focus of the IGAP
PGRS study which included APOE within the PGRS
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Table 2
Cohort demographics – Dichotomized A
ADNI 1 (N = 363) ADNI 2 (N = 44) EDAR and DESCRIPA*
(N = 250)
Demographic Normal Abnormal p-value Normal Abnormal p-value Normal Abnormal p-value
CSF A CSF A CSF A CSF A CSF A CSF A 
(N = 112) (N = 251) (N = 27) (N = 17) (N = 99) (N = 151)
Median age [IQR] 74.4 [8.35] 75.3 [8.55] 0.825 67.8 [12.55] 75.2 [11.1] 0.049 66 [12] 69 [13] 0.136
Gender (%) 0.487 0.359 0.052
Female 36.6 40.6 51.9 35.3 38.4 51.7
Male 63.4 59.4 48.1 64.7 61.6 48.3
Median years in education [IQR] 16 [4.25] 16 [4] 0.748 16 [4] 16 [4] 0.825 11.5 [8] 10 [7] 0.133
Median MMSE [IQR] 29 [3] 26 [4] <0.001 29 [2] 27 [3] 0.058 27.5 [4] 26 [5] 0.009
Diagnosis (%) <0.001 0.247 0.001
Dementia 6.3 33.5 0 5.9 34.3 45.0
MCI 40.1 51.0 74.1 82.4 43.4 41.1
SCI 0 0 0 0 5.1 10.6
CTL 53.6 15.5 25.9 11.7 17.2 3.3
APOE status (%) <0.001 0.225 <0.001
0 85.7 33.5 66.7 47.1 74.7 38.4
1 14.3 66.5 33.3 52.9 25.3 61.6
Kruskal Wallis chi-squared was used to test between normal and abnormal groups for continuous demographic variables. Fishers exact
was used to test between normal and abnormal groups for categorical demographic variables. APOE status is 1 if an individual’s genotype
contains any 4 alleles, and 0 otherwise. IQR, Inter-quartile range; CSF, cerebrospinal fluid; MMSE, Mini-Mental State Exam; MCI, mild
cognitive impairment; SCI, subjective cognitive impairment; CTL, control. ∗One individual has missing diagnosis, 2 have missing education
information, and 3 have missing MMSE.
whether information from a SNP chip adds anything
above APOE. Furthermore, generally, APOE is not
well measured on SNP chips so APOE genotype is
determined by targeted genotyping.
The datasets used for model testing (EDAR and
DESCRIPA) were not included in the IGAP study.
Furthermore, although some samples from ADNI
were included in IGAP, the majority were only
included in the training, not testing, stages.
RESULTS
Cohort demographics
Table 2 shows demographics against normal and
abnormal CSF A while Table 3 is against CSF
tTau. Demographics for the sub-population used in
the total CSF burden analysis are given in Supple-
mentary Table 1. Demographics for the sub-group of
ADNI 1 individuals with plasma tau measurements
is given in Supplementary Table 2.
In ADNI 1 training data and EDAR/DESCRIPA
test data, there is a significant difference between
normal and abnormal A in MMSE, diagnosis, and
APOE genotype as we would expect. Similar asso-
ciations are also seen with dichotomized tTau. The
smaller sample size of the ADNI 2 test data (N = 44)




The PGRS was not significant in any of the logis-
tic regression models (p-values of 0.995, 0.929,
and 0.796 for tTau, A, and total CSF burden
respectively). The inclusion of the PGRS marginally
improved the predictive ability of tTau models over
the basic models. The accuracy of the Abeta model
was also marginally improved by inclusion of the
PGRS in ADNI 2 test data. The models of total CSF
burden had the highest accuracies (72% and 65%).
See Table 4 for full results.
Genetic risk and plasma tau
When modeling CSF tTau no model outperformed
the basic model at an accuracy of 66%. Similarly,
when modeling total CSF burden the inclusion of a
PGRS and plasma tau did not improve predictive abil-
ity above the basic model (77%). The only model to
see an improvement over the basic model was when
modeling A. Inclusion of plasma tau measurements
marginally improved accuracy from 71% to 74% and
the area under the ROC curve from 0.658 to 0.697.
See Table 5 for full results.
DISCUSSION
The aim of this study was to investigate blood
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Table 3
Cohort demographic - Dichotomized total tau
ADNI 1 (N = 363) ADNI 2 (N = 44) EDAR and DESCRIPA*
(N = 250)
Demographic Normal Abnormal p-value Normal Abnormal p-value Normal Abnormal p-value
CSF tau CSF tau CSF tau CSF tau CSF tau CSF tau
(N = 203) (N = 160) (N = 30) (N = 14) (N = 150) (N = 100)
Median age [IQR] 75.2 [8] 74.45 [10] 0.642 67.85 [10.7] 76.75 [12.68] 0.051 66.55 [13] 70.5 [12] 0.032
Gender (%) 0.234 >0.999 0.094
Female 36.5 43.1 46.7 42.9 42.0 53.0
Male 63.5 56.9 53.3 57.1 58.0 47.0
Median years in education [IQR] 16 [4] 16 [5] 0.064 16 [4] 16 [4] 0.7 10 [6] 9 [8] 0.032
Median MMSE [IQR] 28 [3] 26 [4] <0.001 29 [1.75] 27 [3.75] 0.153 28 [4] 26 [4] <0.001
Diagnosis (%) <0.001 0.38 <0.001
Dementia 15.8 36.9 0 7.1 26.7 62.0
MCI 45.8 50.0 76.7 78.6 47.3 34.0
SCI 0 0 0 0 12.7 2.0
CTL 38.4 13.1 23.3 14.3 13.3 2.0
APOE status (%) <0.001 0.191 0.001
0 63.5 31.9 66.7 42.9 59.3 43.0
1 36.5 43.1 33.3 57.1 40.7 57.0
Kruskal Wallis chi-squared was used to test between normal and abnormal groups for continuous demographic variables. Fishers exact
was used to test between normal and abnormal groups for categorical demographic variables. APOE status is 1 if an individual’s genotype
contains any 4 alleles, and 0 otherwise. IQR, inter-quartile range; CSF, cerebrospinal fluid; MMSE, Mini-Mental State Exam; MCI, mild
cognitive impairment; SCI, subjective cognitive impairment; CTL, control. ∗One individual has missing diagnosis, 2 have missing education
information, and 3 have missing MMSE.
Table 4
PGRS: Test data results
Outcome Model Accuracy Sensitivity Specificity AUC ROC
EDAR and DESCRIPA
tTau Demographics only 0.584 0.570 0.593 0.625
A Demographics only 0.660 0.788 0.465 0.686
Total CSF burden Demographics only 0.733 0.750 0.716 0.801
tTau Demographics and PGRS 0.596 0.560 0.620 0.609
A Demographics and PGRS 0.616 0.768 0.384 0.692
Total CSF burden Demographics and PGRS 0.719 0.702 0.702 0.748
ADNI 2
tTau Demographics only 0.636 0.571 0.667 0.655
A Demographics only 0.546 0.765 0.407 0.527
Total CSF burden Demographics only 0.649 0.583 0.680 0.693
tTau Demographics and PGRS 0.659 0.571 0.700 0.671
A Demographics and PGRS 0.614 0.647 0.593 0.590
Total CSF burden Demographics and PGRS 0.649 0.583 0.680 0.683
AUC ROC, area under the receiver operating curve; PGRS, polygenic risk score.
(A and tau). We modeled levels of A and tau in
CSF using a PGRS and a sub-study considered mea-
surements of tau in blood plasma. We also studied a
total CSF burden endpoint for individuals with abnor-
mal tau and A, or normal tau and A. The results
shown here highlight that a case/control PGRS and
plasma tau do not substantially outperform demo-
graphics (age, gender) and APOE genotype. The
highest model accuracies were seen when modeling
the total CSF burden phenotype.
Several studies have focused on identification of
blood biomarkers of A [17, 32, 33]. However, few
have achieved successful replication. The hypothesis
tested in this study was that a combined tau and A
endpoint would be closer to an AD case/control phe-
notype and consequently easier to predict. This study
supports this hypothesis, although the improvements
in accuracy are minimal. Further, this accuracy of pre-
diction was achieved by the basic model and the two
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Table 5
PGRS and plasma tau: Five fold cross-validation results
Outcome Model Accuracy Sensitivity Specificity AUC ROC
tTau Demographics only 0.656 0.691 0.628 0.659
tTau Demographics and PGRS 0.638 0.665 0.617 0.641
tTau Demographics and plasma tau 0.650 0.587 0.700 0.644
tTau Demographics, PGRS and plasma tau 0.653 0.608 0.689 0.649
A Demographics only 0.709 0.787 0.530 0.658
A Demographics and PGRS 0.697 0.769 0.532 0.650
A Demographics and plasma tau 0.743 0.813 0.582 0.697
A Demographics, PGRS and plasma tau 0.725 0.813 0.523 0.668
Total CSF burden Demographics only 0.772 0.742 0.816 0.779
Total CSF burden Demographics and PGRS 0.763 0.735 0.804 0.769
Total CSF burden Demographics and plasma tau 0.758 0.765 0.748 0.756
Total CSF burden Demographics, PGRS and plasma tau 0.772 0.780 0.756 0.768
AUC ROC, area under the receiver operating curve; PGRS, polygenic risk score.
and plasma tau, did not improve model accuracy in
the majority of cases.
Firstly, this could be explained by the PGRS being
trained on a case/control endpoint. As individuals can
often be misdiagnosed with AD the case/control phe-
notype can be misleading. GWAS are beginning to be
large enough to detect risk SNPs associated with A
and tau. When sample sizes in these studies increase
further they should be used to train PGRS. Intuitively,
they may achieve improved predictive ability than
models based on a case/control PGRS. Furthermore,
due to the relatively small sample size of this study,
the PGRS only utilizes common variation excluding
loci such as TREM2. As larger studies become avail-
able the inclusion of such rarer variants in genetic risk
scoring should be considered.
In the sub-study, it is interesting that plasma tau is
no more predictive of CSF tau than age, gender, and
APOE genotype. Furthermore, plasma tau achieves a
higher accuracy when modeling CSF A. The lack
of ability to predict CSF tau indicates the need for
further assay development to detect still more sen-
sitive measurements. Furthermore, research into the
permeability of the blood-brain barrier will help the-
orize as to how much pathology signal from the brain
and CSF is likely to be seen in blood.
This study has shown the importance of replication
in independent datasets; models that perform well in
training data often do not replicate. It is particularly
important to test replicability when standardized pro-
tocols for assays do not exist [34]. For example, this
analysis highlights the difference between EDAR,
DESCRIPA, and ADNI in the assays and cut-offs
used to define high and low pathology burden. The
CSF A cut-off for high/ low burden ranges between
192 pg/ml and 550 pg/ml. Efforts are being made to
standardize such metrics for future research [35, 36].
It is important to point out the limitations of
this study. Firstly, there are differences in sam-
ple collection methods, assays and data processing
pipelines between ADNI 1, ADNI 2, EDAR, and
DESCRIPA. In particular, the GWAS platforms used
differ between the studies. The models in this study
are trained in ADNI 1, which uses a slightly older Illu-
mina chip (Human610-Quad) than ADNI 2, EDAR,
and DESCRIPA. Although this means that the data
from the other cohorts may not be fully utilized, it
is unlikely to cause a lack of replicability. However,
it is possible that some replicability is lost due to
differences in sample collection methods and data
processing. Furthermore, the use of the older SNP
chip (Human610-Quad in ADNI 1) may have lead
to reduced SNP content and sub-optimal imputation
within the ADNI 1 cohort. It is also of note that the
ADNI study was included in IGAP, effect sizes from
which were used to create the PGRS. We believe
that the benefit of a larger sample size for train-
ing outweighs any negative impact. Despite the use
of well-characterized cohorts in this study, we must
point out that the sample size considered is still rela-
tively small. In future work, this could be addressed
by the use of longitudinal aging studies instead of the
case/control cohort studies used here.
Finally, we have shown that the multi-modal
approach used in the sub-study investigating plasma
tau, did not improve predictive ability above the basic
model. We used a simple additive model and more
complex methods such as OmicKriging may be use-
ful in this setting [37]. Furthermore, the standard for
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PET imaging. Generally, PET imaging and CSF mea-
surements are used interchangeably but any results
should be replicated using imaging based outcomes.
In combination with a pathological endpoint more
closely related to an AD phenotype, such as the total
CSF burden used here, the suggestions presented in
this discussion could improve the predictive ability
of proposed markers of A and tau.
CONCLUSIONS
This study has used data from the EDAR,
DESCRIPA, and ADNI cohorts to investigate blood
markers of A and tau. We see that a case/control
PGRS is no more predictive of pathology than age,
gender, and APOE genotype. A sub-study shows that
model accuracy is not improved by the addition of
plasma tau measurements. These results emphasize
that the search for predictive factors of A and tau,
above and beyond demographic and APOE informa-
tion, is still ongoing. Better understanding of AD risk
alleles, development of more sensitive assays, and
studies of larger sample size are three avenues that
may provide such factors. However, the clinical util-
ity of possible predictors of brain A and tau must
also be investigated.
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7.1 Summary of findings
In this thesis I aimed to identify blood-based biomarkers of AD and it’s associated
phenotypes, in particular Aβ and tau burden. I have studied a variety of components
in blood including genetics, gene expression, proteomics and metabolomics using
data from several cohort studies to explore single and multi-modal biomarkers of
AD.
7.1.1 Single modality markers
7.1.1.1 Chapter 2: Blood protein markers of neocortical amyloid-β bur-
den
In the search for a blood biomarker of AD, replication of existing discoveries was
an essential first step. Forty-one proteomic markers of Aβ were identified from
the literature: 15 candidates discovered in AIBL and 20 from other cohorts. Two
of these candidates (IgM and PPY) met a pre-defined significance threshold and
were hence deemed replicable in our SOMAscan data from AIBL subjects. This
replication adds evidence to the association of IgM and PPY with brain amyloid
burden despite technical differences between studies, such as biological fluid and
platform. However, it is possible that the lack of replication of other candidates was
also due to these technical differences.
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7.1.1.2 Chapter 3: A pathway based classification method for analyzing
gene expression for AD diagnosis
In chapter 3, I hypothesised that combining gene expression levels to create a path-
way level score may improve the ability of a model to differentiate between AD
cases and controls. The work in AddNeuroMed concluded that the pathway level
models were no better than gene expression or indeed demographic only models in
the available data. Independent validation of this work is essential. This is the only
chapter of this thesis that discusses a case/control endpoint and an endophenotype
based approach may be beneficial for future work in this area.
7.1.2 Multiple modality markers
7.1.2.1 Chapter 4: Blood metabolite markers of neocortical amyloid-β
burden
The motivation for studying metabolites as blood markers of AD is driven by their
intuitive link with the disease. In particular, the fact that a major risk gene for
AD, APOE, codes for a protein that transports fats and fat soluble vitamins which
are both metabolites. This chapter should be viewed as a pilot study due to the
small number of subjects. It provides encouraging evidence for associations be-
tween metabolites and amyloid which warrant further investigation and attempts
at replication. Furthermore, this chapter provides evidence for the potential pre-
dictive ability of multi-modal biomarkers, exemplified by the addition of protein
measurements to the metabolite model.
7.1.2.2 Chapter 5: Do peripheral markers help to predict amyloid bur-
den in a non-demented population? A Bayesian approach.
In Chapter 5, I present a Bayesian methodology that aims to incorporate histori-
cal information on demographic variables into the prediction of amyloid in a non-
demented population. The hypothesis that this method would improve predictive
ability was not shown by the results. Further, the focus of the study was using
demographics and a PGRS to predict CSF amyloid. The inclusion of the PGRS
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did not improve predictive ability over demographics alone. Furthermore, I hy-
pothesised that inclusion of multiple modalities of omics data in modelling would
improve predictive ability; this was not shown by the results of this analysis.
7.1.2.3 Chapter 6: Genetic risk as a marker of amyloid-β and tau burden
in cerebrospinal fluid.
The final chapter of this thesis aims to examine a PGRS as a marker of tau levels in
CSF. Additionally, I investigate the PGRS as a marker of a combined amyloid and
tau endpoint representing a more ‘AD-like’ phenotype. In the populations studied,
the PGRS was not significantly associated with AD pathologies and did not improve
predictive ability over demographics. Further, I performed a sub-study with the
inclusion of plasma tau as a predictor. Similarly, no improvements in predictive
ability were seen.
7.2 Implications of findings
7.2.1 Clinical
Due to the lack of replication of the biomarkers presented in this thesis the current
clinical implications are minimal. For a biomarker of AD or pathology burden to
have clinical utility it would need to be replicable across independent cohorts. This
level of reproducibility and consistency has not yet been shown for any biomarkers
discussed in this thesis. Nevertheless, the replication of two candidate proteins and
discovery of a 5-metabolite panel whose predictive ability is improved by the addition
of FGG, indicates that these methods warrant further investigation and could lead
to clinical utility in the future.
Additionally, the results outlined in this thesis could provide insight into possible
disease mechanisms of AD or Aβ accumulation. Conventionally, to find biomarkers
of a disease one would target compounds that are thought (or known) to be in-
volved in the causal process behind the disease but in AD no such process is known.
Therefore, we can look to inform existing theories using the associations shown in
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this thesis. It is of course vital to ensure that these associations are not interpreted
as causal mechanisms. With this in mind it is equally important for negative results,
as well as positive findings, to be communicated to clinicians. Such dissemination
ensures all evidence is available to key decision makers.
7.2.2 Research
In comparison to the clinical implications the impact for research is more obvious.
Firstly, I have shown that associations of some proteins (IgM and PPY) with Aβ
seem to replicate across technical platforms and studies. Of particular interest is the
association of IgM with Aβ burden in a non-demented population showing promise
for use as a filtering step for enrichment in secondary prevention clinical trials.
Furthermore, I have shown associations of a metabolite panel with Aβ burden in a
largely demented population. This work was performed in a relatively small number
of subjects and provides a basis for further research. Others have shown replication
of protein markers between blood fractions and using different proteomic platforms
(O’Bryant & Xiao, 2014). This method of systematic alteration of technical factors
builds the evidence for association of specific markers with AD phenotypes. Further,
we can begin to address which set of technical factors gives rise to the best biomarker.
For example, O’Bryant & Xiao (2014) find that markers in blood serum are more
predictive of AD cases than equivalent markers in blood plasma.
Secondly, this thesis provides some evidence for the use of a multi-modality
approach when using omics data in the search for a biomarker of Aβ. Chapter
3 is the first published piece of work to exemplify this although the theoretical
idea has been developing for some time (Bazenet & Lovestone, 2012; Snyder et al.,
2014). Chapters 5 and 6 challenge this idea as the addition of multiple modalities
of omics data did not lead to improvement in the predictive ability of models. As
highlighted in the individual chapters this could be due to the PGRS being trained
on a case/control endpoint or the selection of candidate protein and metabolite
markers. As more cohorts with a variety of omics data become available this avenue
will hold lots of research potential. For example, the European Medical Information
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Framework (EMIF) 1000 core is a dataset that aims to have PET scanning and blood
omics measurements available for 1000 individuals by the end of 2016 through EMIF
funding. Furthermore, the development of methods to more effectively combine the
independent signal seen in each modality will be vital.
More generally, the work in this thesis highlights the importance of replication
in all discovery work, not just within omics analysis or AD. Through Chapters
5 and 6 I have shown that model metrics (in particular accuracy, sensitivity and
specificity) decrease substantially when models are tested on independent datasets
with previously un-modelled noise. This was also exemplified by Casanova et al.
(2016) who failed to replicate a metabolite signature of AD published by Mapstone
et al. (2014).
7.3 Limitations
This section details some research limitations that affect the whole thesis. More
specific limitations related to each analysis are given in individual chapters.
A limitation that has recurred throughout this work is a lack of statistical power
largely driven by a small number of participants in each analysis. This is particularly
true of Chapter 4 (N = 78, metabolic features = 2760). In all analyses I have aimed
to maximise sample sizes where possible, for example by using the measurement
of Aβ with largest sample size available. Furthermore, the Bayesian method em-
ployed in Chapter 5 was motivated by the relatively small size of current AD omics
studies. Lower participant numbers are largely due to a small overlap in the people
with amyloid measurements and omics data. Additionally, in the gene expression
analysis I chose to study as clean a phenotype as possible by only including cases
and controls that had maintained diagnosis at all visits. Overall, larger studies are
needed to ensure any significant associations are real and to minimise the number of
false negative associations. It is becoming more likely that these larger sample sizes
will originate from population studies of health cohorts rather than cohort studies
of individuals with AD and other dementias. For example, the PROTECT study
(www.protectstudy.org.uk) is recruiting individuals over the age of 50 with no diag-
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nosis of dementia (N ∼ 5000). It aims to follow them for 10 years to elucidate factors
that influence changes in the brain during ageing. A sub-group of individuals will
have blood measurements collected and will provide an interesting asymptomatic
discovery population.
The power available in AD cohort studies is also limited by the presence of
mixed pathologies. Although I have focused on modelling associations with Aβ
(and in some cases tau) pathology we cannot be certain that there are not other
confounding factors such as presence of other forms of dementia. For example, in the
UCSF cohort used in Chapter 4 a large number of individuals were diagnosed with
fronto-temporal dementia. Furthermore, it is possible that biomarkers investigated
in this thesis are confounded by medications the participants are taking. This was
difficult to investigate in several of the cohorts used in this thesis as medication
information was not available. However, Tao et al. (2015) have shown no significant
confounding of treatment for several gene expression and protein biomarkers. I am a
co-author on this paper for providing the processed gene expression data generated
in chapter 3 of this thesis (Appendix A).
Across the field of AD research there is a lack of knowledge of the functional role
of amyloid in ageing and AD. In particular, there are distinct examples of Aβ not
always causing dementia symptoms, with people who have high amyloid burden at
autopsy having shown no cognitive impairment during their lifetime (Morris et al.,
2014). Current theories hypothesise that this could be because they have not yet
accumulated enough pathology or because factors such as cognitive reserve influence
the effect of any pathology. This raises the question that even if we can predict Aβ
burden using a biomarker, will anti-amyloid treatments necessarily lead to improve-
ments in cognition? At least one clinical trial to date saw improvements in Aβ levels
measured by PET imaging but no significant changes in cognitive symptoms (Liu
et al., 2015). This lack of improvement could be explained by the fact that PET
imaging measures the plaque formations of Aβ but not the oligomeric amyloid which
is thought to be the toxic form. If methods are developed to measure this oligomeric
form answers to this question could be found through further studies.
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Finally, across science there is a tendency to publish positive results more often
than negative findings, leading to publication bias (Song et al., 2010). This can mean
that a sample of studies is unrepresentative of all analysis that has been performed in
the research area. One solution to prevent publication bias is to enforce (or at least
recommend) registration of all studies to some central database. As such, several
individuals have called for detailed registries of biomarker studies to be established
(Andre et al., 2011; Altman, 2014). If implemented, these registries would better
inform evidence based medicine in the field of AD biomarker research.
7.4 Further work
With the research implications outlined above in mind there are several avenues
that should be investigated further.
Firstly, work in this thesis has demonstrated that multi-modal analysis is possible
(Chapters 4, 5 and 6). However, it has not always improved the predictive ability
of a model and in all cases simple additive modelling techniques have been used. It
would be interesting to develop more sophisticated methods that could ensure any
information included by an additional modality is independent and hence potentially
useful. Furthermore, interactions between modalities should be investigated. The
work in this thesis has not implemented feature selection across modalities. Without
these developments there is a risk of creating models that over-fit to the training
data with minimal additional benefit. Furthermore, economic cost-benefit analyses
will become even more important at this stage. We need to ensure that any potential
blood-test that is developed will be more cost-effective than the current standard
for measuring Aβ and tau (a PET scan or lumbar puncture). As we add more
modalities to our modelling this becomes less likely.
Chapter 4 presents the first study to investigate associations between Aβ and
metabolites. I was able to putatively identify the metabolites of interest through
comparisons with the Human Metabolome Database and in-house tables. To be
more confident in this identification we could purchase standards of these metabo-
lites (where available) and compare their LC-MS/MS spectra with that seen in
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our study. This non-putative identification would allow targeted analysis to be
performed using a variety of platforms in the future. Furthermore, the levels of
metabolites in each individual were calculated using the R package ‘XCMS’. By
performing semi-quantification (measuring the area under the chromatogram peak
by hand) for the metabolic features of interest, we could be more certain of their
levels and hence the associations we have seen in Chapter 4. The metabolite study
is the only study in this thesis to contain a population that predominantly contains
people with AD or FTD. This was well documented in the chapter itself and it pro-
vides opportunity for further study in a non-demented population; the population
that could see most benefit from such a blood test being used as a filtering step.
This notion is applicable to all research in this area: the early stages of disease
development are vital and consequently research should focus on these populations.
In further work it would be interesting to covary for novel factors that are ap-
pearing in the literature to be associated with Aβ and tau burden. For example, it
has been shown in recent studies that levels of ‘brain reserve’ may be driving the
difference between people who have high levels of pathology and no symptoms and
those who show symptoms (Bauckneht et al., 2015). This is motivating a theory that
increased brain reserve may prevent development of symptoms even if pathology is
present. Although brain reserve itself may be hard to quantify it may be possible
to measure and model associated psychological factors such as social networks.
There are also some more general research questions that if addressed would im-
prove the validity and replicability of work in this area. Firstly, it is well documented
that a wide range of cut-offs are used to differentiate individuals who have high levels
of pathology from those that have low levels, particularly in CSF (Mattsson et al.,
2010). This is largely due to differences in assays but has also been shown to be
influenced by technical differences in processing methods. A standardised protocol,
and potentially assay, would alleviate this problem and specialised working groups
are discussing this currently (Zwan et al., 2015). This is an area that should be
closely monitored by the AD biomarker research community and any recommended
practise implemented as soon as possible. This lack of comparability between assays
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also extends to the majority of omics platforms (Mattsson et al., 2010). For exam-
ple, Casanova et al. (2016) failed to replicate a set of predictive metabolite markers
discovered by Mapstone et al. (2014). It was suggested that this failed replication
was due to differences between blood plasma and serum. However, high correlations
between metabolites in blood plasma and serum in other studies make this unlikely
(Casanova et al., 2016). Several other factors were also altered between the studies,
for example processing methods. Therefore, we cannot be sure what is driving this
lack of replication. If omics studies were standardised it would be easier to compare
findings and elucidate which factors were driving any difference in results.
The majority of the work described in this thesis focuses on a single measurement
of amyloid that in most cases is then dichotomised to either high or low. This is
well justified by the bimodal distribution of amyloid burden across a population.
However, it is well known that there are other pathologies and processes associated
with development of AD. I believe an important next step is to find biomarkers of
these pathologies and combinations of them with Aβ burden. I began to address
this by studying possible markers of tau and a combined Aβ and tau endpoint in
Chapter 6. As tau imaging tracers are now becoming available I think this would be
an increasingly interesting endophenotype to study. Additionally, a distributional
measure of the spread of pathology in the brain may be more informative than an
overall Aβ or tau burden metric. Analysis of the spread of pathologies in the brain
have shown this area of research could hold promise (Thal et al., 2014).
If robust and replicable blood biomarkers are discovered they could have im-
mediate impact in trials such as the European Prevention of Alzheimer’s Dementia
(EPAD) trial. EPAD is an adaptive trial meaning many potential treatments are
tested against each other and against placebo at the same time. At pre-specified
interim analyses researchers can determine whether certain treatments should be
removed from the trial. Novel treatments can also be added. Recruitment into the
EPAD trial is largely through registries from existing cohort studies. However, indi-
viduals eligible to participate must undergo brain imaging to ensure they have the
amyloid pathology many of the experimental treatments will target. The use of a
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blood biomarker has the potential to significantly reduce the cost of this screening
step. Furthermore, blood biomarkers could be used to monitor amyloid burden at
the interim analyses again, potentially reducing the cost of longitudinal monitoring
in the study.
The research in this thesis, amongst other literature, highlights that there is
still a long way to go in the discovery of a blood based biomarker for AD. The
data analysis methods used throughout this thesis have consistently been shown to
achieve good performance in other areas (Touw et al., 2012). I therefore suggest
that the main areas of opportunity to improve discoveries in this field come in the
form of data quality and quantity. The quality of omics data currently available is
limited by technical variability in collection and processing methods (O’Bryant et al.,
2015). Techniques to reduce such variability should be developed and implemented
in future studies. Furthermore, even when technical variability is controlled the
assays available are often sub-optimal. For example, the specificity of methods
such as SOMAscan is largely unknown and sensitivity of methods including MS can
be low. New methodologies such as SIMOA begin to address this by measuring
quantities by counting single molecules. Further novel assay development will be
vital in finding a blood based biomarker for AD.
Data quantity in cohort studies is also a limiting factor to AD blood biomarker
discovery. With a large number of variables, often in the thousands, the bene-
fit that larger numbers of individuals bring is unquestionable. Initiatives such
as the EMIF core 1000 are beginning to address this. However, to make the
most of this opportunity it is essential that such studies are well planned. For
example, the overlap in samples with different types of data collected should be
as large as possible. This will maximize the number of individuals with mul-
tiple measurements to enable the study of combinations of omics markers. Fi-
nally, the use of longitudinal data will provide invaluable information. The
deep and frequent phenotyping study will be one of the first resources to pro-




Global dementia prevalence has been estimated at 24.3 million people (Ferri et al.,
2005). With an ageing population AD, as the most common form of dementia, poses
a significant socio-economic burden to society. Evidence indicates that pathological
changes leading to AD can occur up to 20 years prior to symptom development.
This provides a window of opportunity to target disease-modifying treatments yet,
to date, none are available. To improve the likelihood of finding a suitable treatment
clinical trials are being enriched for individuals with high levels of Aβ pathology as
quantified by PET imaging or measurements in CSF. These methods of measur-
ing pathology are often sub-optimal being invasive and expensive procedures that
require specialist services. Consequently, this thesis presents work searching for a
blood-based biomarker for use as a filtering step prior to a confirmatory PET scan
or lumbar puncture.
No biomarkers identified this far have reached clinical utility. However, I have
shown that there is validity in using omics data to look for associations with AD
pathology, in particular amyloid, in the search for a biomarker. Further, the use of
a combination of markers from multiple modalities warrants more research. Work
throughout this thesis demonstrates the need for replication. This will become
increasingly possible in the near future as larger cohorts with a variety of omics
data become available.
If biomarkers of AD, and in particular Aβ burden, can be identified there is great
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Abstract.
Background: There is an urgent need to discover Alzheimer’s disease (AD) biomarkers that are both easily measured and reliable.
Research into blood-based biomarkers for AD using transcriptomics and proteomics has been an attractive and promising area
of research. However, to date researchers have not looked into the possibility of AD medication being a confounding factor in
these studies.
Objective: This study explored whether acetylcholinesterase inhibitors (AChEIs), the main class of AD medication, are a
confounding factor in AD blood biomarker studies.
Methods: The most promising blood transcriptomic and proteomic biomarkers from two recent studies were analyzed to
determine if they were differentially expressed between AD subjects on AChEIs and subjects that were not.
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Results: None of the gene or protein biomarkers analyzed were found to be significantly altered between subjects in either
group.
Conclusion: This study found no evidence that AChEIs are a confounding factor in these published AD blood biomarker studies.
Further work is needed to confirm that this is also the case for other proposed biomarkers.
Keywords: Alzheimer’s disease, blood, cholinesterase inhibitors, gene expression, microarray, protein, proteomics
INTRODUCTION
Alzheimer’s disease (AD) is a common, costly,
and fatal neurodegenerative disorder. It manifests in
the form of progressive cognitive decline, includ-
ing memory loss, executive dysfunction, psychiatric
symptoms, and behavioral disturbances [1]. Currently,
a definitive diagnosis of AD can only be obtained
after postmortem dissection of brain tissue. AD diag-
nosis therefore relies on robust clinical evaluation,
sometimes including assessment of pathology using
cerebrospinal fluid (CSF) biomarkers [2], or pathol-
ogy measures from brain scans; usually magnetic
resonance imaging (MRI) or positron emission tomog-
raphy (PET) [3, 4].
Despite these efforts, diagnosis of AD remains dif-
ficult, especially in areas where access to advanced
neuroimaging equipment remains limited. A lumbar
puncture to acquire CSF for analysis is also relatively
invasive and inappropriate in certain clinical environ-
ments. It has been suggested that up to two-thirds of
dementia patients go undiagnosed [5], and that by the
time an AD diagnosis is made, the underlying patho-
logical processes have been developing for around 20
years [6]. There is therefore an urgent need to develop
investigative techniques that are cost effective, easy to
administer, and capable of aiding the diagnosis of AD
in its early stages. Though undoubtedly challenging,
this may prove useful for enriching clinical trials for
subjects whose pathology is less advanced.
Recently, the analysis of blood samples to develop a
blood-based diagnostic test has been an attractive area
in AD biomarker research. Blood samples of AD sub-
jects can be collected with relative ease, and analyzed
to determine differences in protein or messenger RNA
(mRNA) quantity that might elucidate underlying bio-
logical changes in the disease state [5]. Studies such
as Booij et al. [7], Fehlbaum-Beurdeley et al. [8], and
more recently Lunnon et al. [9] have demonstrated that
whole-blood profiling of mRNA can generate evidence
of AD associated differences in gene expression. Sim-
ilarly, studies such as Ray et al. [10], Doecke et al.
[11], and Sattlecker et al. [12] have analyzed blood
protein quantities to identify proteins with significantly
altered blood levels in AD. Zurbig and Jahn [13], Lista
et al. [14], Kiddle et al. [15], and Chiam et al. [16]
have also recently reviewed the blood-based proteins
most commonly associated with AD, finding a mod-
est degree of replication between studies. Given the
prospect of a cheap and convenient diagnostic test
should success be achieved, it is likely that research
into blood-based biomarkers, while not without limi-
tations, will continue to be an appealing avenue in AD
biomarker discovery [17, 18].
Although there has been a significant amount of
research generated in the field, very little has been
done to look into the potential effects of medica-
tion as a confounding factor in blood-based biomarker
discovery. This is important as the medication an indi-
vidual is receiving depends largely on their diagnosis.
Medication could potentially affect the composition
of biological molecules in the blood. For example,
AD patients are often placed on a wide range of
psychotropic drugs and recent evidence suggests that
psychotropic drugs affect the expression of AD related
genes in blood [19].
There are currently two classes of drugs used
to treat the cognitive symptoms of AD, acetyl-
cholinesterase inhibitors (AChEIs) and memantine (an
NMDA receptor antagonist). Of these, AChEIs are the
most common class of drug used in the treatment of
AD [20]. These drugs act by inhibiting the enzyme
acetylcholinesterase. This prevents the breakdown of
the neurotransmitter acetylcholine at synapses, thus
increasing the strength of neural transmission in the
brain [21, 22]. Treatment with AChEIs has been
found to modulate the expression of pro- and anti-
inflammatory cytokines in the blood of AD patients
[23]. Given the high prevalence of AChEI use among
AD subjects, it is therefore pertinent to determine if
the potential gene and protein blood biomarkers iden-
tified in studies are indeed due to biological changes
as a result of AD and not due to the effects of these
drugs.
This study seeks to build on the results from Lunnon
et al. [9] and Sattlecker et al. [12] by analyzing the most
promising gene and protein biomarkers identified in
AD subjects by both studies and determining if the use
of AChEIs confounds the association between these
blood-based biomarkers and AD.
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METHODS AND MATERIALS
Samples and clinical data from the AddNeuroMed
cohort
As described in Lunnon et al. [9] and Sattlecker et
al. [12], blood samples were obtained from subjects
participating in the AddNeuroMed (ANM) study
[24–26]. Subjects were located at six different study
sites across Europe, namely London, Lodz, Toulouse,
Perugia, Kuopio, and Thessaloniki. Informed consent
was appropriately taken according to the Declaration
of Helinski (1991) and ethical approval was obtained
at each site. A diagnosis of AD was attained using
the NINCDS-ADRDA criteria [27] and the Diag-
nostic and Statistical Manual of Mental Disorders
(DSM-IV).
All subjects went through a semi-structured inter-
view in order to collect the necessary demographic and
medical information. This included an array of neu-
ropsychological assessments such as the Mini-Mental
State Examination [28], Global Deterioration Scale
[29] and the Alzheimer’s Disease Assessment Scale-
Cognitive subscale [30]. Information regarding the
kind of neuropsychiatric medication each subject was
currently prescribed was also obtained.
Blood samples were drawn from subjects by
venipuncture and collected in PAXgen vacutainer tubes
(Qiagen) for RNA analysis and EDTA glass tubes for
proteomic analysis.
Relevant demographics and clinical data for these
subjects were extracted from the AddNeuroMed
database using CohortExplorer [31].
Gene expression study
Blood samples collected from the ANM cohort were
analyzed to determine mRNA gene expression profiles.
Full details of the data collection and preprocessing
procedure can be found in Lunnon et al. [9] and Voyle
et al. (manuscript in preparation), and is only discussed
briefly here.
Data collection
The vacutainer tubes containing blood samples for
RNA analysis were inverted 8–10 times and stored
at –24◦C for 24 h before lowering the temperature
to –80◦C until RNA extraction. RNA was extracted
using the PAXgene blood RNA kit (Qiagen), follow-
ing the manufacturer’s protocol. The 2100 Bioanalyser
(Agilent Technologies) was then used to evaluate the
quality of the extracted RNA. Only RNA samples that
exceeded a RNA integrity number (RIN) of 7.0 were
used in the analysis.
Microarray processing was conducted at the Univer-
sity of California in Los Angeles. The RNA samples
were processed on Illumina Human HT-12 v3 Expres-
sion BeadChips (Illumina), each containing 48,803
probes. RNA was amplified using the Illumina Total-
Prep RNA Amplification Kit (Ambion) and gene
expression values were obtained using the Lumi pack-
age within the R Bioconductor project [32].
Preprocessing
Raw gene expression data was subject to a model
based background correction for bead array [33]. Neg-
ative bead expression levels were used to correct for
background noise. The data was then log base 2 trans-
formed and robust spline normalized before outlying
samples were iteratively identified by fundamental
network concepts and removed [32, 34]. To remove
any batch effects, we adjusted for technical categor-
ical variables using ComBat [35]. The first principal
component across housekeeping probes was taken and
regressed against technical variables and phenotype in
order to account for the principal component across
housekeeping probes. Variables significantly associ-
ated with the first principal component where then
regressed against expression for each probe, and the
mean adjusted residuals taken forward for all further
analyses. Finally, the data was subset to probes that
could be reliably detected in at least 80% of sam-
ples in each diagnostic group. Subjects were excluded
if lab-based investigations highlighted discrepancies
between recorded sex and sex determined by the XIST
gene.
Probe selection
Probes that had a significant difference in signal
between AD subjects and controls were identified from
Lunnon et al. [9]. The most significant probes were
identified through a dual-criteria. Firstly a Bonferroni
correction was applied to the p-values reported by Lun-
non et al. [9] (!= 0.05/19,161). Any probe that met the
corrected threshold of p-value <! and had an absolute
fold change of >0.5 was identified for further analysis.
Subject selection
In Lunnon et al. [9], a total of 356 samples (116 con-
trol, 127 mild cognitive impairment (MCI), 113 AD)
were put through RNA microarray processing. Of this
a subset was extracted for analysis in our study, as
described below. Of the 113 AD subjects, 100 had com-
plete demographic data for medication, age, gender,
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Mini-Mental State Examination (MMSE) score, and
APOE status. It was decided that subjects on meman-
tine, another form of AD cognitive drug would be
excluded as there were too few subjects to conduct
a conclusive analysis. Therefore 5 subjects on meman-
tine and 6 subjects on both AChEI and memantine were
excluded. This resulted in a total of 89 AD subjects for
gene expression analysis.
Proteomic study
Similar to the gene expression analysis described
above, blood samples collected from the ANM cohort
were analyzed to determine protein quantities. A
detailed account of the data collection and preprocess-
ing procedure can be found in Sattlecker et al. [12] and
is described only briefly here.
Data collection
EDTA tubes with the blood samples were cen-
trifuged at 2,000 rpm at 4◦C for 10 min within
approximately 2 h of collection. The resulting plasma
supernatant was then collected and divided into
aliquots before being frozen at –80◦C until protein
measurement.
Protein quantities were measured using the new
Slow Off-rate Modified Aptamer (SOMAmer)-based
capture array known as “SOMAscan” (SomaLogic,
Inc). Chemically modified nucleotides are used to
transform a protein signal into a nucleotide signal [36].
Microarrays were then used to quantify the signal using
relative fluorescence. A total of 1,001 human proteins,
representing different molecular pathways and gene
families, were quantified this way.
Preprocessing
Hybridization controls on the microarray were used
to monitor sample-by-sample variability in hybridiza-
tion, while the median signal across all SOMAmers
was used to monitor overall technical variability. Using
both the resulting hybridization and median scale
factors, data across samples was normalized. An accep-
tance criterion of 0.4–2.5 was used for values based
on historic trends. SOMAmer-by-SOMAmer calibra-
tion was established through the repeated measurement
of calibration samples. A calibration scale factor is
then generated using historic values of these calibra-
tion samples. The acceptance criterion for calibrator
scale factors is that 95% of SOMAmers must have a
calibration scale factor within± 0.4 of the median [12].
All measurements obtained were log 2 transformed.
Seven sample outliers were identified using principal
component analysis in R and were thus removed from
downstream processing [12].
Probe selection
Sattlecker et al. [12] had previously identified four
proteins (prostate-specific antigen complexed to !1-
antichymotrypsin, clusterin, pancreatic prohormone
and fetuin B) that were found to have significantly
altered levels (q-value <0.05) in AD subjects when
compared to healthy elderly controls. These four pro-
teins were selected for the analysis.
Subject selection
In Sattlecker et al. [12], a total of 415 ANM samples
(110 control, 109 MCI, 196 AD) underwent SOMAs-
can proteomic analysis. Like in the gene expression
portion of the study, a subset of this was extracted for
data analysis using the same criteria. Of the 196 AD
subjects, 189 had complete demographic data for med-
ication, age, gender, MMSE score, and APOE status.
After 8 subjects on memantine and 13 subjects on both
AChEI and memantine were excluded, a total of 168
AD subjects were selected for the proteomic portion
of the study.
Statistical power calculations
Power calculations were performed using the
‘pwr.f2.test’ in the ‘pwr’ R package, based on the
approach of Cohen [37]. Based on the recommen-
dation by Cohen f2 = 0.02, 0.15, and 0.35 were used
to indicate a small, medium, and large effect size,
respectively. A statistical significance level of 0.005
was required, to represent a Bonferroni multiple testing
correction for 10 markers (midway between number of
gene expression and protein markers studied).
Data analysis
All data analysis was performed using R. The AD
subjects that were selected for either the gene expres-
sion study or the proteomic study were further split
into two groups based on the type of cognitive enhanc-
ing AD medication they were on. The first group
comprised those on AChEIs, while the second group
comprised those subjects not on any form of cogni-
tive enhancing AD medication (non-AChEI). The gene
expression study had 72 subjects in the AChEI group
and 17 subjects in the non-AChEI group. Similarly,
the proteomic study had 129 subjects in the AChEI
group and 39 subjects in the non-AChEI group. For
both studies, an analysis was then conducted between
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the AChEI group and non-AChEI group to see if there
was any significant difference in gene expression and
protein quantity.
Firstly the demographic data was analyzed to ensure
that confounding variables could be identified. Dis-
crete variables such as gender and APOE "4 allele
status were analyzed using Fisher’s exact test. Con-
tinuous variables such as age and MMSE score were
analyzed using linear modeling. A threshold of p-value
<0.05 was set to identify if any of the variables differed
between both AChEI and non-AChEI groups.
An analysis was then conducted on the genes and
proteins that were pre-selected to determine if there
was a significant difference in gene expression or pro-
tein levels between AD patients on AChEIs and those
that were not. This was conducted using linear model-
ing with study site added as a covariate in the analysis.
The p-values obtained were then adjusted for multiple
testing by applying the false discovery rate (FDR). A
threshold of q-value <0.05 was used to identify dif-
ferentially expressed genes and differences in blood
protein quantity. Box plots were created for genes or
proteins of interest and for these, 111 controls (non-
AD subjects) from the ANM cohort were included to




To examine our ability to detect small, medium, and
large effects of AChEIs on blood marker levels, we
performed statistical power calculations using a sig-
nificance level of p = 0.005. Figure 1 shows that the
gene expression study (n = 89) has ∼2.3%, ∼47%, or
∼96% statistical power to detect a small, medium, or
large effect of AChEIs on blood gene expression mark-
ers. It also shows that the proteomics study (n = 168)
has∼5%,∼89%, or∼100% statistical power to detect
a small, medium, or large effect of AChEIs on blood
protein markers. It also shows that even a study with
a sample size of 500 would only have ∼30% power to
detect a small effect of medication on a blood marker.
Gene expression study
To investigate the effect of AChEIs on blood gene
expression markers of AD, we examined gene expres-
sion levels in 89 AD subjects with gene expression,
demographic, and medication data. No significant dif-
ferences in gender, age, APOE status, or MMSE scores
Fig. 1. Statistical power curves for the detection of the effect of
AChEIs on 10 blood markers (midway between number of genes
and proteins investigated). Points indicate statistical power for dif-
ferent effect sizes (small, medium, and large) in a model with 6
degrees of freedom for the numerator. Black lines indicate sam-
ple size of the gene expression study (n = 89) and the proteomics
study (n = 168). A significance threshold of p < 0.005 was used to
correspond to a p < 0.05 significance level after Bonferroni multiple
testing correction for 10 markers/tests.
were seen between the AChEI group and the non-
AChEI group (p < 0.05; Table 1). As a result, none of
the demographic variables were factored in as covari-
ates in the analysis of probe signal between both
groups.
When a Bonferroni correction was applied, 23
probes were identified that passed the dual-criteria that
had been set (p-value <! and absolute fold change
>0.5). These 23 probes were thus selected for analysis
(Table 2).
After multiple testing correction was applied, none
of the 23 probes analyzed showed any significant
difference in signal strength between the group on
AChEIs and the group without (q-value <0.05).
Table 1
Demographic information for subjects included in the gene expres-
sion analysis
AChEI Non-AChEI p-value
Total Number 72 17 –
Males/Females 25/47 3/14 0.25
Median Age (IQR) 76 (9.25) 75 (9) 0.89
Median MMSE (IQR) 22 (7) 22 (6) 0.76
APOE "4 Status (0/1/2) 29/29/14 9/7/1 0.40
AChEI, Group taking acetylcholinesterase inhibitors; Non-AChEI,
Group not on any AD cognitive enhancing medication; MMSE,
Mini-Mental State Examination.
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Table 2
Results for the gene expression analysis showing the 23 probes analyzed with details of the gene name,
coefficient value, standard error, p-value and q-value
Probe ID Gene Name Coefficient Standard p-value q-value
Error
ILMN 2097421 MRPL51 0.35 0.27 0.20 0.29
ILMN 1784286 NDUFA1 0.40 0.26 0.13 0.21
ILMN 1776104 NDUFS5 0.37 0.27 0.17 0.26
ILMN 1726603 ATP5I 0.34 0.28 0.22 0.30
ILMN 2187718 COX17 0.29 0.28 0.31 0.36
ILMN 2128128 SHFM1 0.22 0.27 0.41 0.43
ILMN 1799030 CMTM2 0.34 0.29 0.24 0.30
ILMN 1703538 AIF1 0.23 0.28 0.41 0.43
ILMN 2166865 ENY2 0.46 0.27 0.095 0.2
ILMN 1732328 LOC646200 0.40 0.25 0.12 0.21
ILMN 1680314 TXN 0.53 0.28 0.058 0.15
ILMN 1726239 TBCA 0.51 0.26 0.054 0.15
ILMN 2232936 UQCRH 0.53 0.27 0.048 0.15
ILMN 1746516 RPS25 0.42 0.26 0.11 0.21
ILMN 2189936 RPL36AL 0.071 0.26 0.79 0.79
ILMN 1791332 ATP5O 0.62 0.26 0.022 0.15
ILMN 1792528 LOC401206 0.50 0.26 0.055 0.15
ILMN 2189933 RPL36AL 0.31 0.26 0.24 0.30
ILMN 2225887 ATP5EP2 0.58 0.27 0.036 0.15
ILMN 1661945 C14orf156 0.62 0.27 0.027 0.15
ILMN 1745343 ZMAT2 0.54 0.27 0.045 0.15
ILMN 1680967 CIP29 0.51 0.28 0.07 0.16
ILMN 1652073 LOC653658 0.57 0.25 0.025 0.15
Six probes (UQCRH, ATP5O, ATP5EP2, C14orf156,
ZMAT2, and LOC653658) were found to be nomi-
nally significantly (p < 0.05) associated with the use of
AChEIs (Table 2). The box plots for these six probes
are shown in Fig. 2. Only two of these—LOC653658
and C14orf156—were still nominally associated with
medication use when presence or absence of APOE
"4 (and its interaction with medication use) was also
accounted for in the model. Visually there does not
appear to be a significant difference in expression of
these genes between groups.
Proteomic study
For the 168 AD subjects with proteomic, demo-
graphic, and medication data, no significant differences
in gender, age, APOE status, or MMSE scores were
observed between the AChEI group and the non-
AChEI group (p < 0.05; Table 3). None of these
variables were thus factored in as covariates for the
proteomic analysis.
The four proteins analyzed showed no significant
difference in quantity between both groups in a linear
model, with none passing significance thresholds either
at the nominal (p < 0.05) or multiple testing corrected
(q < 0.05) threshold (see Table 4).
Table 3
Demographic information for subjects included in the proteomic
analysis
AChEI Non-AChEI p-value
Total Number 129 39 –
Males/Females 48/81 9/30 0.12
Median Age (IQR) 77 (10) 78 (9.5) 0.45
Median MMSE (IQR) 21 (8) 21 (8) 0.63
APOE "4 Status (0/1/2) 55/48/26 19/18/2 0.074
AChEI, Group taking acetylcholinesterase inhibitors; Non-AChEI,
Group not on any AD cognitive enhancing medication; MMSE,
Mini-Mental State Examination.
DISCUSSION
The analysis conducted shows that none of the
biomarkers studied are differentially expressed in
subjects taking AChEIs. Our sample had reasonable
statistical power to detect large effects on gene expres-
sion markers, and both medium or large effects on
protein markers. This implies that AChEIs are not a
large confounding factor affecting the most promising
gene or protein biomarkers identified in the studies by
Lunnon et al. [9] and Sattlecker et al. [12]. If AChEIs
had been found to be a large confounding factor,
it would have undermined the diagnostic/enrichment
potential of the biomarkers identified in those studies.
The results of this study, though small in scope and by
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Fig. 2. Box plots of the six nominally significant genes found in the gene expression analysis. AD subjects on acetylcholinesterase inhibitors
(AChEI) are compared with AD subjects not on AChEIs (Non-AChEI) and control subjects without AD (CTL). There do not appear to be a
significant difference in gene expression between AD subjects with and without AChEIs.
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Table 4
Results for the proteomic analysis showing the four proteins analyzed with details of the UniProt ID, coefficient value, standard error, p-value
and q-value. ∗q-values are approximately equal, exact equality of these q-values is an artifact of the approximation method used by the R function
‘p.adjust’
UniProt ID Protein Name Coefficient Standard Error p-value q-value
P07288, P01011 PSA-ACT –0.049 0.19 0.80 0.80∗
Q9UGM5 Fetuin B 0.083 0.19 0.66 0.80∗
P10909 Clusterin 0.12 0.19 0.54 0.80∗
P01298 Pancreatic Prohormone 0.17 0.19 0.37 0.80∗
PSA-ACT, prostate specific antigen complexed to !1-antichymotrypsin.
no means comprehensive, are therefore encouraging
and strengthen the validity of these studies. As the first
study to examine the possibility of AD blood biomark-
ers being confounded by AChEIs, it also highlights a
previously neglected potential confounding variable.
In this study the sample size of both groups tested
was notably imbalanced. The number of subjects in
the group not on any AD medication was significantly
smaller than the group on AChEIs in both the gene
expression and proteomic analysis. This is understand-
able since most AD patients would be expected to have
some sort of cognitive enhancing medication as treat-
ment. It would also have been interesting to include
an analysis of subjects using memantine, the other
main class of AD cognitive drugs. Yet in this study too
few subjects were on memantine to allow a thorough
investigation of this. This limitation could be overcome
should larger studies be conducted in the future.
While in this study AChEIs were considered as a
single class of drug, three separate AChEIs (donepezil,
galantamine, and rivastigmine) are the mainstay in AD
therapy [20]. Though all three drugs work similarly
by inhibiting acetylcholinesterase and preventing the
breakdown of acetylcholine at the post-synaptic cleft,
it is likely that that there are subtle differences in their
effects on underlying biological processes. Therefore
if an adequate sample size is available in future studies,
all three drugs should be studied individually for their
effects on AD blood biomarkers. This is pertinent since
studies revealing differences in gene expression as a
result of AChEI use have studied AChEIs individually.
Specifically, Reale et al. [23] investigated the effects
of donepezil on blood inflammatory markers in AD
patients, while Andin et al. [38] investigated the effect
of rivastigmine on the glutamate transporter rEAAC1
blood mRNA expression in mice models, both reveal-
ing significant effects by the drugs on gene expression.
One possible way of improving the sample size in
future studies is to ensure the collection of appropriate
medication information in any research cohort, as some
subjects were excluded from our study due to incom-
plete demographic data. Furthermore with hindsight,
medication could have been included as a covariate
in the discovery stage of biomarker studies, instead
of analyzed post-hoc. We have not seen this approach
applied in any of the discovery studies to date and this
should therefore be considered for future biomarker
studies.
Besides drugs that improve cognitive symptoms,
many AD patients are also on other medications to
manage the non-cognitive symptoms of the disease.
People with dementia are far more susceptible to
psychiatric conditions such as mood disorders and
psychosis [39]. In such cases, drugs such as antidepres-
sants, neuroleptics, sedatives, and hypnotics are often
required for treatment [19, 40]. Citalopram, an antide-
pressant, has been found to affect gene expression in
AD lymphocytes [41]. Thus it is possible that other
psychotropic medications could prove to be a con-
founding factor in blood biomarker studies and should
be explored in future studies. Given that each subject
could potentially be on multiple medications, it may
also be possible to conduct multivariate analyses to
determine if a combination of medications would yield
a significant difference in gene expression, although
larger cohorts would be needed to identify this.
This study considered promising biomarkers indi-
vidually, looking at whether the expression of single
genes or proteins are affected by AChEIs. However,
Sattlecker et al. [12] and Lunnon et al. [42], as well
as other researchers, have also proposed multivariate
biomarker models of AD. These multivariate models
could also be investigated to determine if AChEIs, or
any other medications, affect their potential utility.
It is also important to consider the possible effects
of medication on other potential blood biomarkers.
For example, many other potential biomarkers of AD
have been highlighted in recent reviews of blood gene
expression [17] and protein levels [16].
CONCLUSION
Overall this exploratory study has found no evi-
dence that AChEIs are a large confounding factor
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for the most promising AD blood-based biomarkers
identified in both studies. This gives an encouraging
indication that the use of AChEIs is unlikely to affect
the validity of these biomarkers in potential diagnosis
or enrichment applications. However, more compre-
hensive studies need to be conducted to explore the
full effects of AChEIs on these and other proposed
blood-based biomarkers of AD.
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1. Introduction 
This chapter walks through the basic statistical methods needed to explore, analyse 
and interpret data collected in epidemiological studies. We begin with raw data, 
highlighting essential data visualisation and cleaning steps before providing intuitive 
explanations for some of the most commonly used modelling tools from statistics and 
bioinformatics. We end by outlining the importance of testing results in independent 
data sets, where possible, and suggest other methodologies where this is not possible. 
After studying this chapter you should have a comprehensive idea of how to perform 










2. Data collection 
The first stage of any analysis is to collect data from a well-designed study. We begin 
by looking at the raw data that arises from epidemiological studies and highlighting 
the first stages in creating clean data that can be used to draw informative conclusions 
through analysis. We move on to describe big data and associated challenges before 
emphasising the importance of reproducibility in research. 
2.1 Data formats 
Raw data can come in many different types and formats, ranging from hand-written 
lab sheets and unformatted excel files, to images. In order to analyse and explore data 
it is vital to fully understand the structure and content of your raw data set. Depending 
on its nature, and the type of analyses you would like to run, an initial pre-processing 
step is recommended or even unavoidable. Examples of pre-processing steps include 
transforming qualitative data into machine-readable categories or using an image 
analysis pipeline to extract important features of an image and cast them into a 
structured, tabular format. 
2.2 Data exploration 
The aim of data exploration is to use descriptive methods to get a statistical and visual 
impression of the data (Sayad, 2011). Exploratory statistics allow quantification and 
visualisation of qualitative variables, such as categorical data, as well as continuous 
variables. Perhaps most importantly, data exploration is the first step in identifying 
new patterns and/or associations. Data exploration is of particular importance in large 
data samples where a preliminary impression of the data helps to identify potential 
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confounding factors, anomalies and missing data (Podsakoff et al., 2003). 
 
2.3 Data cleaning  
Data collection and aggregation into a master data set can result in irregularities and 
missingness. Human error during data collection or participant-dropouts during a 
longitudinal study are examples that can result in the former. The process of removing 
or accounting for these impurities within the data set is known as data cleaning. 
The extent of data cleaning depends on the specific method that you are aiming to 
apply and ranges from basic methods to advanced pre-processing. Amongst the most 
common mistakes that lead to impure data sets is failure to look at the data at all, or in 
tabular form only. Basic data exploration and plots can easily identify missing values, 
label switching and unit mismatches. A further advantage of exploratory plots is an 
indication of skewness that can reveal biases within the data (Kuhn and Johnson, 
2013). These can then be accounted for before applying additional analyses. 
2.4 Missing data 
Missingness in statistics is defined as the lack of data for a variable in an observation. 
It is a common phenomenon in the realm of data analysis and is grouped into three 
categories: missing completely at random (MCAR), missing at random (MAR), and 
missing not at random (MNAR), also known as informative missingness (van Buuren, 
2012). 
- MCAR: the probability of being missing is equal for all observations. In other 
words, the cause for missingness is unrelated to the data. 
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- MAR: the probability of being missing is equal for a particular observation 
only.  
- MNAR: the probability of being missing varies depending on another 
observation. 
An example of MNAR would be an increasing dropout rate in a clinical trial based on 
the administered concentration of an experimental drug. Even though the data exhibits 
increasingly more missingness, it is highly informative on drug adherence in patients 
(Kuhn and Johnson, 2013). 
Treating missingness is a challenging topic that can range from simple data removal 
to application of prediction models for imputation. Depending on the nature of the 
data, as well as the type and extent of missingness, different methods should be 
applied (Schafer and Graham, 2002). The exact intricacies of treating missingness in 
data are beyond the scope of this chapter. 
2.5 Big data 
Big data is vaguely defined. However, the most commonly cited definition of big data 
is by Laney (2001) from Gartner as “high volume, velocity and variety information 
that demand cost-effective, innovative forms of information processing for enhanced 
insight and decision making”. Additionally, variability within a data type is an 
important characteristic of big data and should be added to the definition. There is no 
clear boundary to when conventional data turn into big data, however any 
combination of complexity, size, and advanced analytics technology satisfies the 
definition by Laney (2001). In fact, data sets do not even need to be particularly big, 
just complex, to be considered big data.  
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2.6 Reproducibility 
Reproducibility allows re-running an analysis and always obtaining the same result 
when applied to the same data set. This is particularly important for the validity and 
generalisability of your analysis should you want to publish your results. 
Unfortunately, reproducing complex analyses is associated with challenges, such as 
software updates that change the outcome of an analysis, incomplete or non-existent   
documentation, and failing to record intermediary results.  
Detailed documentation and scripted analyses are a great way to ensure that your 
research is reproducible. This will not only benefit you but also the community of 
psychiatric epidemiology. 
2.7 Classification vs. regression 
It is likely that the data collection and cleaning covered above has been to answer a 
specific research question. Before moving forward it is important to identify whether 
the question you are answering is a classification or regression question: 
- Classification: Allocation of an observation to one of several groups. For 
example, classifying a brain scan as positive or negative for a defined 
pathology. 
- Regression: Predicting a continuous outcome for an observation. For example, 
predicting hippocampal volume from an MRI scan. 
Throughout this chapter we will refer to classification however, most methods can 
also be applied in a regression setting. 
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3. Feature identification and selection 
Once a data set has been processed (if not before) an analysis plan needs to be 
created. Conventional statistical methods (not covered in this chapter) require the 
number of variables in the data set to be less than the number of samples. However, 
machine learning algorithms do not have such a limitation. Machine learning 
algorithms use induction to learn; they aim to improve prediction based on the data 
provided. Although they can handle many thousands of predictors it is often 
computationally expensive to do so. Additionally, models with many predictors are 
very hard to interpret. Therefore, we aim to reduce the number of variables we use in 
modeling via feature selection. Feature selection removes redundancy and noise from 
data leaving only the most discriminatory features while reducing problems of 











4 Method selection 
After selecting features to include in the analysis, or planning the feature selection 
techniques to use alongside modeling, the modeling algorithm must be selected. The 
choice of algorithm is important and should be tailored to the question you are 
looking to answer and the data you have. Do you have more predictor variables than 
samples? Some methods (for example support vector machines (SVMs)) are good at 
coping with high dimensionality datasets with a small number of samples, however 
this may require large amounts of computer memory. Do you have balanced training 
data? Some methods, such as SVMs and decision trees, are sensitive to imbalance in 
the training dataset and should therefore be avoided if you have unbalanced data. 
Where possible it is preferable to test a number of classifiers to identify the most 
appropriate choice for the specific problem. 
4.1 Supervised vs. unsupervised machine learning 
The most common types of machine learning algorithms are supervised learning and 
unsupervised learning. Supervised learning takes a set of examples that are labelled 
and creates a set of rules to classify samples where the status is unknown. In contrast, 
unsupervised learning models a set of inputs where labelled examples are not 
available. The algorithm finds a way of clustering the data based upon the known 
features and then provides descriptions for these clusters.  
In this section we will introduce some vital concepts before discussing some 
supervised and unsupervised algorithms that are amongst the most commonly used 
within the field of bioinformatics. 
165
Box 1: Supervised learning example 
Predicting whether a non-synonymous SNP (nsSNP) is disease related is a question 
that can be addressed via machine learning methods. Supervised 
learning is appropriate because the aim is to assign an nsSNP to one of 
a number of classes. It is possible to use a set of nsSNPs where the 
disease status is known as a training set to form a set of rules. These 
rules can then be used to make a prediction for nsSNPs where the 
function is unknown.  
 
4.2 Important concepts 
4.2.1 Training, testing and validation 
A common problem of supervised learning methods is over-fitting. An algorithm can 
be trained for too long on one particular data set so that it fails to generalise the 
information learned to similar data sets. A number of methods are available for 
evaluating machine learning results and showing the results are general enough to be 
applied to other data (Hand et al., 2001). To successfully train a supervised learning 
algorithm, one should aim to generate three data sets from the original data set. 
- A training set: used to train the algorithm. 
-  A validation set: to track how well the algorithm is generalizing and to 
perform parameter tuning. 
-  A test set: an unseen data set on which the finalised algorithm’s 
performance is tested. 
As machine learning algorithms require substantial training data, the usual 
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distribution of the training, validation and testing sets is 2:1:1. However, in the case of 
limited data availability, different cross-validation (CV) methods can be employed. 
4.2.2 Cross validation 
In cross-validation the data is divided into a number (n) of ‘folds’. Each fold is treated 
as the validation dataset in turn, with the remaining n-1 folds being used as training 
data. CV is especially useful for smaller datasets (Kohavi, 1995). The performance of 
the classifier on each fold is measured and then a final accuracy is calculated based 
upon the average of all n folds.  
4.2.3 Bootstrap 
Sampling from a whole dataset, with replacement, creates a bootstrap sample. The 
bootstrap sample is the same size as the original dataset and contains, on average, one 
third of all observations in the whole dataset. The observations not included in the 
bootstrap sample are called the out of bag (OOB) data. As sampling with replacement 
creates the bootstrap sample, it can contain repeated instances (Efron & Tibshirani, 
1994).  
Bootstrapping is a useful tool to maintain the size of your training dataset while also 
creating validation data. The performance of the classifier is calculated by averaging 
the accuracy from the OOB data of each bootstrap sample. 
4.2.4 Hyper-plane 
A hyper-plane is a subspace with one less dimension than the whole space under 
consideration. This is easiest to imagine in small dimensions. For example, if we 
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consider a problem in two dimensions (for example, plotting age against height) a 
hyper-plane is any one-dimensional line running through the space. Similarly, if we 
consider a problem in three dimensions (for example, plotting age against height and 
weight) a hyper-plane is any two-dimensional plane. 
4.3 Unsupervised methods 
Unsupervised learning has a long and distinguished history within modern 
epidemiology. For example, John Snow a physician in the mid-19th century is famous 
for discovering the source of Cholera outbreaks, which were at the time believed to be 
due to ‘bad air’. To achieve this he used an unsupervised data analysis method. 
During the 1854 Cholera outburst in Soho, London, John Snow recorded the location 
of deaths onto a map of Soho, showing that deaths were clustered around an 
intersection of Broad Street. He later identified the source as an infected water pump 
(Johnson, 2006).  
 
Unsupervised machine learning extends the concept of looking for patterns to 
complex multidimensional datasets. Like John Snow’s map it seeks to identify 
patterns within datasets. Patterns extracted from data using unsupervised machine 
learning can also be used later in supervised approaches to identify the underlying 
causes of various patterns, analogous to John Snow adding information on water 






4.3.1 Principal components analysis (PCA) 
A commonly used unsupervised approach to data analysis is Principal Components 
Analysis (PCA). For example, PCA is often used in genetic epidemiology to take into 
account population stratification and systematic differences in allele frequencies that 
are often due to ancestry (Price et al., 2006). It can also be invaluable for visualizing 
outliers (Price et al., 2006) and batch effects (Alter et al., 2000) in high-dimensional 
datasets, for example whole genome gene expression data. As such, it is often used as 
part of the important ‘quality control’ process. 
 
PCA takes a set of possibly correlated variables and returns a set of Principal 
Components (PCs), which are orthogonal hyper-planes that explain maximal variance 
in the predictors. A useful feature of the PCs is that they are given in rank order for 
the proportion of total variation they explain; PC 1 explains more of the variation in a 
dataset than PC 2 does. A useful consequence of this is that it is often possible to 
summarise a large proportion of the total variance using only 2 or 3 principal 
components allowing high-dimensional datasets to be summarised in 2D or 3D plots. 
For example Figure 1 shows the effect of ancestry on PCA applied to genetic data. 
The proportion of variance that each PC explains can be visualised in a ‘scree plot’, 
helping you to choose the number of PCs to use for plotting or further analysis. More 




Box 2: Principal components analysis example 
Figure 1 – Principal Components Analysis of 125 Ancestry Informative Markers 
(AIMs). Scatterplots are shown comparing the first three Principal 
Components. Individuals are represented by one circle in each 
scatterplot. The first 3 Principal Components summarise the majority 
of the variability in ancestry, and help to distinguish individuals of 
European, African-American, Hispanic and Asian descent. Figure 
generated by Dr William S Bush, Assistant Professor at Case Western 











  We are grateful to Dr Bush for permission to reproduce this figure, 







Methods such as PCA can be used to summarise variability in a dataset, often 
showing that data points can be divided into ‘groups’ or ‘clusters’. The general 
definition of a cluster is that objects within a cluster are more similar to each other 
than they are to objects outside of that cluster. But how do you automate the 
assignment of data points to clusters? And how many clusters exist? 
 
The problem of assigning data points to clusters is an unsupervised machine learning 
problem, for which many different approaches exist. One of the most commonly used 
approaches is hierarchical clustering, which generates a hierarchy tree with a data 
point lying at the end of every branch (Ward, 1963). The branches for the most 
similar data points are connected first, and this is repeated until eventually all data 
points are connected. Data points are separated into clusters by applying a threshold 
to the tree. The problem with this approach is that as branches are combined one at a 
time, the final grouping may not always be optimal. 
 
A common alternative to hierarchical clustering is called K-means (Jain, 2010). This 
involves looking for K clusters in the data, where K is a number. The K-means 
procedure proceeds as follows: 
- Data points are randomly assigned into K different clusters. 
- The mean of each cluster is calculated. 
- Each data point is assigned to belong to the cluster whose mean it is closest to. 
- Steps 2 – 3 are repeated until an acceptable solution is reached.  
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K-means solutions are often more optimal than a hierarchical clustering solution. 
However, to perform K-means, a ‘mean’ must be definable for your dataset. Where 
this is not possible, alternatives such as K-centres or affinity propagation can be used. 
 
For both approaches, you need to specify a threshold or a number of clusters in 
advance. A commonly used approach to find the optimal number or threshold is the 
silhouette plot, which provides a visualization of the quality of clusters (Rousseeuw, 
1987).  
	
4.4 Supervised methods 
4.4.1 K nearest neighbours (KNN) 
K nearest neighbours (KNN) is arguably the simplest supervised learning method 
(Altman, 1992). The basic idea is that a new observation is classified to the modal 
class of the k closest observations from the training data (where k is some integer). 
There are a number of methods to define what we mean by ‘closest’ but these are not 
discussed here. The example given in Box 3 should clarify this idea. In order to 
perform an analysis using this method we must choose a suitable value for k. This is 
known as parameter tuning and is usually performed by using several rounds of cross-
validation to choose the value that gives the best results. If k is too low the model can 
over-fit to the training data and conversely, if k is too high, the model may under-fit. 
Although KNN provides a method with very simple intuition the model fit can be 
hard to interpret; it is solely based on training data so there is no description of the 
model. Furthermore, it can become computationally expensive on large datasets. 
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Box 3: KNN example 
We have a group of patients presenting with memory impairment; they have been 
classified as having either dementia or short-term memory loss. 
Suppose that for each of them we have only two pieces of clinical 
information: age and hippocampal volume from an MRI scan. We 
could plot this information and colour code by the subject’s 
classification. When a new patient enters the clinic presenting with 
memory impairment and with these two measures available we can add 
them to the plot. We can consider the 5 patients who are closest to the 
new patient on the graph and output the most common class from these 
5 subjects as the classification. 
 
4.4.2 Decision tress  
Decision trees are supervised classifiers composed of a graph (tree structure) of 
decisions (Quinlan, 1993). Each point in the tree where a decision is made is called a 
node and the result of each decision determines which branch to follow. The decisions 
are usually simple single attribute tests to divide the data. A leaf represents the 
predicted class based on values at the nodes on the path from the root (the first 
decision point). Decision trees have an advantage over many classifiers in that they 
produce interpretable rules. Once a tree has been built new instances can be classified 
by starting at the root and following a path down to a leaf. An example of a decision 
tree can be seen in Figure 2 where a patient is classified as being at high or low risk of 
psychosis based on a number of attributes. 
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Box 4: Decision tree example 
Figure 2: An example of a decision tree used to classify a patient as being at high or 
low risk of psychosis. The diagram shows decisions at the nodes and 















When the attribute at a node is categorical, there will be one branch for each attribute 
value. If the attribute is continuous, a decision will be made based on whether the 
instance is above or below a specific cut-off value. There are a number of methods for 
deciding which attribute should be used at each node but they are not discussed here.  
A decision tree is complete when some criterion about the terminal nodes has been 















At this point the tree is often ‘pruned’ to prevent it being too specific to the training 
dataset. The aim is to produce a tree that is general enough to be applied to any new 
instances that require classification, avoiding over-fitting. The algorithms are efficient 
and therefore able to handle large volumes of data. However, one drawback to this 
approach is that the partitioning can cause interesting relationships between attributes 
to be lost. 
4.4.3 Random forests (RF) 
Random forest (RF) is a supervised classifier consisting of multiple decision trees 
(Breiman, 2001). The final class assigned to an observation is the modal class selected 
by the multiple decision trees. RF combines two machine learning methods: bootstrap 
sampling and random feature selection. Each tree is created from a bootstrap sample 
of the training data. OOB data is used to obtain an unbiased estimate of the error 
during the training. However, rather than using all features, RF randomly selects a 
subset of input variables to decide what decision should be made at each node of the 
tree. Advantages of random forest classifiers include the fact that the error can be 
balanced when the class population sizes are imbalanced and over-fitting can be 
avoided. There are also good methods available for handling missing data.  
4.4.4 Partial least squares (PLS) 
Partial least squares (PLS) modelling is very similar to PCA. Where PCA looks for 
orthogonal hyper-planes that explain maximal variance in the predictors, PLS looks to 
explain maximal covariance between the predictors and the outcome (Wold, 2004). It 
is this reliance on the outcome measure that means PLS modelling is supervised and 
is particularly suited for prediction problems. PLS modelling is useful when the 
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number of predictors is greater than the number of samples as it reduces the size of 
the predictor space by creating components. 
4.4.5 Support vector machines (SVMs)  
Support vector machines (SVMs) are a supervised learning classifier developed by 
Corte & Vapnik (1995). They have been shown to be very accurate in many 
disciplines including bioinformatics, benefitting from the ability to handle high 
dimensional data with a small number of instances, finding a good balance between 
training set accuracy and test data error. For a given set of training vectors labelled 
with two classes, a SVM can find the optimal linear hyper-plane that maximizes the 
margin between the two classes. An example of SVM classification in two 
dimensions is given in Figure 3. 
SVMs can be extended to provide non-linear classification through the application of 








Box 5: Support vector machine example 
Figure 3: An example of a SVM classifying between two classes (circles and crosses). 












5 Training a classifier 
The process of building a model with initial data is called training.  
An important point to consider when training a classifier is the presence (or lack 
thereof) of balanced data. The number of instances belonging to each class in the 
training set may be imbalanced resulting in a danger that the classifier will have a 
preference for selecting the most populated class because the classifier assumes that 
there is a greater chance of an instance belonging to this class (Barandela et al., 
2003). The result is that performance is reduced for the minority dataset. However, it 
may be the case, such as when detecting fraudulent telephone calls for example, that 












6 Drawing conclusions from modelling 
It is necessary to summarise the results of model testing using informative metrics. 
These metrics should quantify how well a model fits the test data. 
6.1 Accuracy, sensitivity and specificity 
There are four possible scenarios that could arise when classifying a new observation 
using a trained classifier. In this case we consider the example of a diagnostic test.  
- A person with the disease is correctly classified as having the disease. 
- A person without the disease is correctly classified as not having the disease. 
- A person with the disease is misclassified as not having the disease. 
- A person without the disease is misclassified as having the disease. 
These are the four key features that determine how well a classification test has 
performed and they can be summarised using three metrics. The accuracy is defined 
as the percentage of all patients who are correctly classified and is perhaps the most 
intuitive and general of these metrics. It is can be split into the percentage of patients 
with the disease who are correctly classified as having the disease (sensitivity) and the 
percentage of patients without the disease who are correctly classified as not having 
the disease (specificity). 
It is important to look at all three of these metrics, as often a high sensitivity will 
coincide with a low specificity and vice versa. However, the nature of your question 
will determine which of these metrics is most important. When interpreting accuracy, 
179
sensitivity and specificity remember that these metrics are not affected by the 
prevalence of a disease.  
Box 6: Diagnostic test example  
Consider a diagnostic test where we have results for 100 patients. 
	
 True diagnosis 
Disease No disease 
Diagnostic test Disease 30 5 
No disease 20 45 
	
Accuracy = (30 + 45) /100 = 75% 
Sensitivity = 30/50 = 60% 
Specificity = 45/50 = 90% 
Positive predictive value = 30/35 = 85.7% 
Negative predictive value = 45/65 = 69.2% 
 
6.2 Negative predictive value (NPV) and positive predictive 
values (PPV) 
Two further metrics are often used to describe the performance of a classifier: 
negative predictive value (NPV) and positive predictive value (PPV). 
- PPV: the percentage of positive predictions that are true positives 
- NPV: the percentage of negative predictions that are true negatives 
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Unlike accuracy, sensitivity and specificity, NPV and PPV will change if the 
prevalence of a disease changes. PPV will fall as the prevalence of a disease decreases 
while NPV will rise. This should make sense as a lower prevalence means, over the 
whole population, a positive result is less likely (Loong, 2003). 
6.3 Receiver operating characteristic (ROC) analysis 
In most cases, when a classifier is built the underlying method works by creating a 
probability of assigning a sample to a certain class. If this probability is above a pre-
defined threshold then the sample is allocated to the class in question. It is therefore 
interesting to vary the threshold to see if we can create a test that best answers the 
question we are studying. A good way to visualise the effect of changing this 
threshold is through a receiver operating characteristic (ROC) plot. These plots 
usually have the false positive rate (1 – specificity) on the x-axis and the true positive 
rate (sensitivity) on the y-axis. They are often summarised by measuring the area 
under the curve (AUC). A perfect test would have sensitivity and specificity of 1 
meaning the AUC would also be 1, as we create a unit square. We therefore look to 
maximise the AUC to get as close to this perfect test as possible. It is useful to 
remember that a test that is randomly guessing between two classes should, by 




Box 7: Example of an ROC curve 
Figure 4: An example of an ROC curve generated from a random forest model. The 
model uses gene expression data to classify subjects as having 


















































Genes AUC  = 0.724
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Continuous NAB against IgM split by APOE genotype (Controls only)

























Dichotomised NAB against PPY split by APOE genotype
Supplementary Figure 3: Dichotomised NAB against PPY split by APOE genotype
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Supplementary Tables
Supplementary Table 1: Control population demographics
Total P-value High A  burden Low A  burden P-value
N = 120 N = 43 N = 77
Gender (% female) 49.2 0.488 41.9 53.2 0.258
APOE status (% of APOE ✏4 positive) 50.8 0.029 62.8 44.2 0.059
APOE load 0.017 0.094
% with load 0 49.2 37.2 55.8
% with load 1 46.7 55.8 41.6
% with load 2 4.2 7.0 2.6
Median age [IQR] (years) 70 [13] <0.001 75 [12.5] 68 [11] <0.001
Median MMSE score [IQR] 29 [2] 0.966 29 [2] 29 [2] 0.744
Global CDR status (% ¿ 0) 7.5 0.341 8.3 6.5 0.720
Individuals are positive for APOE ✏4 if at least one APOE ✏4 allele is seen in their genotype.
APOE ✏4 load is the number of ✏4 alleles seen in a subjects genotype.
IQR = Inter Quartile Range.
Overall p-value is a result of the Kendall tau test for dependence between SUVR and the demographics variable.
Kruskal Wallis Chi-Squared was used to test between high and low groups for continuous data.
Fishers exact was used to test between high and low groups for categorical data.
Supplementary Table 2: Discovery analysis (included on disc).
Supplementary Table 3: Non-AIBL candidates single protein analysis (included on disc).
Supplementary Table 4: AIBL candidates single protein analysis (included on disc).
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Appendix D




Section 1: PLAGE in detail (Tomfohr et al., 2005)
1. The expression profile of each gene is bought to a common scale by ensuring a distribution
of mean zero and variance one.
2. For each pathway a matrix Y is created only containing gene expression data from the
genes included in the pathway. In the matrix Y each column represents a sample and
each row represents a gene.
3. We perform the singular value decomposition of matrix Y. This involves writing Y in the
form:
Y =WDC
W = Matrix of eigenvectors ordered by size of corresponding eigenvalue. Each column is
an eigenvector.
D = Diagonal matrix of eigenvalues ordered from largest to smallest.
C = Matrix of weights. Each column is a vector of coe cients for one sample indicating
the overall level of each pathway.
4. The pathway scores for one pathway in all samples are given by the first row of C. The
row corresponding to the largest eigenvalue and hence explaining the most variation in
the pathway across the samples.
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Section 2: Data analysis in detail
To build the gene model and pathway model the batch 1 data was bootstrapped 100 times. The
bootstrap samples were of the same size as the batch 1 data and sampled with replacement.
For each bootstrap sample a RF model was built using 5 fold cross validation to tune the model
parameter mtry (Liaw & Wiener, 2002). mtry is the number of variables randomly selected
for consideration at each split in the decision tree. The model parameter that determined the
number of trees created within each model ntree was set to 501 throughout; an odd ntree was
used to account for any ties. The change in Gini index was used to create variable importance
scores. These were ranked across all variables per model and then summed across all bootstrap
samples. Variables were ordered by this metric and plotted. The variable importance plot
plateaued after approximately 5% of variables and consequently the top 5% of variables were
taken forward to the next stage (See Supplementary Figures 1 and 2).
Recursive feature elimination (RFE) was performed on this subset of variables in the original
batch 1 data for the pathway model and gene model. Building of the demographic model began
at this stage using all variables. The feature elimination was again based on a RF model with
ntree = 501 and investigated subsets of variables of all possible sizes. Carets pickSizeTolerance
function was used (tolerance = 5%) to identify a further subset of variables. This function finds
a smaller set of variables while maintaining model accuracy (Kuhn et al., 2015). If this subset
matched the RFE optimal set, the RFE model was taken forward. Otherwise, the optimum
variables were selected using the selectVar function in caret and a final RF model was built.
RF models were used throughout for their non-parametric, non-linear properties. Further,
the use of bootstrapping in RF modelling and random selection of variables at each decision
point decreases the dependence of these models on noise.
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Supplementary Figures
Supplementary Figure 1: Pathway variable importance
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Supplementary Figure 4: Accuracy for 1000 random pathway sets
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P−value ~  0.126
Supplementary Figure 5: Permutation testing of variable importance measures for selected
pathways
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Supplementary Figure 5 continued: Permutation testing of variable importance measures for
selected pathways
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Supplementary Figure 6: Misclassification rates
200
Supplementary Figure 7: Misclassification in AD subjects and controls with memory complaints
against years since onset
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Pre-processing of metabolite data
The following pipeline was used to process the metabolic feature data once it had been extracted
from netCDF files using the R package ‘XCMS’ (Smith et al., 2006).
1. Metabolic features that eluted before 1 minute or after 35 minutes were removed.
2. Per sample, per metabolic feature outliers were identified as values outside of 6 standard
deviations of the mean metabolic feature value and set to missing.
3. Metabolic features not present in at least 80% of samples were removed.
4. Samples that did not have data from at least 80% of metabolic features were removed.
5. Missingness was investigated per batch. In this study batches were the groups of samples
split by QC samples.
6. Each metabolic feature was autoscaled (by subtracting the mean value and dividing by
the standard deviation) as suggested by van den Berg et al. (2006).
7. In order to remove any negative values created by autoscaling (necessary for the remaining
processing steps) each value was increased by 6.
8. The distribution of each metabolic feature was tested for normality using the Shapiro-
Wilks test.
9. The data was subject to a log base 2 transformation.
10. Batch e↵ects were removed using ComBat (Johnson et al., 2007).
11. Probabilistic principal components analysis (pPCA) was performed to ensure QC samples
clustered and to identify any outlier samples.
12. Missing data was imputed using 10 nearest neighbors.
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Supplementary Tables
Supplementary Table 1: Continuous NAB cohort demographics
Total P-value
N = 76
Median NAB SUVR [IQR] 1.3 [0.9] -
Plasma sample median days in storage [IQR] 1354.5 [568] 0.454
Median number of days di↵erence between sample collection and scan [IQR] 18.5 [73] 0.376
Median age [IQR] 64.91 [10.79] 0.939
Median MMSE [IQR] 26 [6] < 0.001






APOE ✏4 status (%) 0.019
0 57 (75)
1 19 (25)





AD = Alzheimers Disease; FTD = Fronto-temporal dementia; HC = Healthy controls; MCI = Mild cognitive impairment.
IQR = Inter-quartile Range; MMSE = Mini Mental State Exam; NAB = Neocortical Amyloid Burden.
SUVR = Standardized Uptake Value Ratio.
P-value: result of the Kendall tau test for dependance between SUVR and the demographics variable.
Supplementary Table 2: Continuous NAB single metabolite results (included on disc).
Supplementary Table 3: Dichotomous NAB single metabolite results (included on disc).
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Candidate metabolites (ADNI 1 only)
Metabolite data was available for 853 blood serum samples in ADNI 1. Twenty-four individuals
had two samples included in the study. Targeted metabolomic analysis was performed using
the AbsoluteIDQ p180 assay requiring 10µl of serum per sample. The samples were run in
11 batches with two pooled QC samples present in each batch: one run before the samples
and one afterwards. The metabolite data was processed according to the pipeline described by
Voyle et al. (2016b). In order to reduce multiple testing burden and over-fitting, one candidate
metabolite is used in this study: PCaa36.6 was identified by Voyle et al. (2016b) in the only
study, to date, investigating associations between metabolites and A . The study identified
a panel of 5 metabolites that predicted dichotomised A  but PCaa36.6 is the only one also
identifiable in ADNI.
Candidate protein assays (ADNI 1 only)
ADNI 1 blood proteomics data is provided by the Biomarkers Consortium Plasma Proteomics
Project for Rules-Based Medicine (RBM) multiplex data. In short, blood plasma samples
were analysed on the human discovery map; a 190 analyte immunoassay panel developed by
RBM. The panel was designed to include plasma proteins thought to be involved in cancer,
cardiovascular disease, metabolic disorders, inflammation and AD (Ray et al., 2007). Samples
were selected for proteomic analysis based on additional biomarker endpoints being available.
In particular, control samples were chosen to have baseline CSF A  levels above the median
of all control participants. This study considers one candidate protein that has shown some
replicability in other proteomic studies: pancreatic polypeptide (PPY) as reviewed in Voyle
et al. (2015) (Burnham et al., 2013; Kiddle et al., 2012). Fibrinogen gamma chain (FGG) has
also shown some replication (Ashton et al., 2015) but the RBM probe for FGG is known to
also bind to alpha and beta chains so is not used in this analysis (Kiddle et al., 2012).
The data was checked for outliers, defined as values greater than 6 standard deviations from
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the mean, and none were found. The data was approximately normally distributed (Shaprio-
Wilks test p-value = 0.67) so no data transformation was performed.
Gene expression
EDAR
The EDAR gene expression data (N = 115) was generated on a Illumina HT-12 v4.0 ex-
pression beadchip and processed using the pipeline previously used by Voyle et al. (2016a)
(http://bit.ly/1vjyKNo). In short, raw expression data was subject to a model based back-
ground correction for bead array (Ding et al., 2008). The data was then log base 2 transformed
and robust spline normalized. Outlying samples were iteratively identified using fundamental
network concepts and removed (Oldham et al., 2012). Technical artefacts were accounted for
by principal components analysis and the use of ComBat (Johnson et al., 2007). Finally, the
data was subset to probes that could be reliably detected in at least 80% of samples in at least
one diagnostic group. After processing gene expression data was available for 109 individuals.
ADNI 2
Gene expression data was collected for 811 ADNI subjects on the A↵ymetrix Human Genome
U219 Array. The array contains 530,467 probes for 49,293 transcripts mapped and annotated
with reference to the human genome (hg19). The publicly available data has been processed
using robust multi-chip averaging (RMA) and gender checked (Irizarry et al., 2003). Additional
processing was performed to ensure the data was as similar as possible to that from EDAR,
despite the di↵erences between A↵ymetrix and Illumina arrays. The processing steps were:
1. Identification of non-expressed probes: probes whose mean expression level was in the
lowest 20th percentile for all diagnostic groups.
2. Removal of outlier samples using network concepts (Oldham et al., 2012).
3. Adjustment for continuous batch e↵ects using linear regression models (RIN and 260\230
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ratio of nucleic acid purity) and discrete batch e↵ect using ComBat (plate and sex)
(Johnson et al., 2007).
4. Removal of probes identified as non-expressed in step 1.
This pipeline is adapted from http://bit.ly/1vjyKNo to be compatible with an A↵ymetrix array.
Gene Expression Risk Score (GERS)
GERS were calculated using a method based on that presented by Bret et al. (2012) for all
109 individuals from the EDAR study with gene expression data. In short, all expression
probes were regressed against A  burden using a LASSO regression model. This method
selects a subset of probes by shrinking the estimates of non-informative variables to zero. The
regularization parameter (lambda) in the LASSO regression was tuned using 10 fold cross-
validation (CV). In order to choose the simplest informative model we selected the largest
lambda that gave a CV error within 1 standard deviation of the minimum CV error. The
subset of probes were then tested for prognostic significance using the Wilcoxon rank statistic
through the R function ‘Maxstat’ (Hothorn, 2015). This produced a gene expression cut-o↵
that best di↵erentiated between high and low A  burden for each probe. The cut-o↵ was
converted to a rank based metric to enable application to other datasets, possibly generated
on alternative chips. The per subject GERS was calculated by summing the coe cients from
the LASSO regression weighted by +1 if a signal was greater than the cut-o↵ value defined by
maxstat, and -1 if the signal was less than or equal to the cut-o↵. The scores were built in the
EDAR cohort and the estimates, and rank based cut-o↵s, applied to create the GERS in ADNI
2. Supplementary Figure 1 outlines the steps used to create both the GERS and the PGRS.
In this study, the LASSO regression used to generate the GERS maintained non-zero es-





Models of dichotomized A  burden were built using 5 fold cross-validation in ADNI 1 (N =
222). A standardized PGRS and measurements of PPY and PC.aa.36.6 were included in the
modelling. Demographics of the population are given in Supplementary Table 1 and results in
Supplementary Table 3.
Analysis 2
Models of dichotomized A  burden were built in EDAR (N = 47) and tested in ADNI 2 (N =
38). A standardized PGRS and a GERS were included in the modelling. Demographics of the
population are given in Supplementary Table 2 and results in Supplementary Table 4.
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Supplementary Tables
Supplementary Table 1: ADNI 1 cohort demographics ANALYSIS 1
Overall Normal CSF A  Abnormal CSF A  P-value
(N=222) (N=95) (N=127)
Median age [IQR] 74.15 [8.7] 74 [8.45] 74.7 [9.75] 0.816
Gender (%)
0.672Female 35.6 33.7 37
Male 64.4 66.3 63
Median years in education [IQR] 16 [4] 16 [4.5] 16 [4] 0.821
Median MMSE [IQR] 28 [3] 29 [2.5] 27 [3] < 0.001
Diagnosis (%)
< 0.001CTL 22.5 52.6 0
MCI 77.5 47.4 100
APOE (%)
< 0.0010 54.5 84.2 32.3
1 45.5 15.8 67.7
Standardized PGRS [IQR] -0.567 [2.150] -0.595 [2.214] -0.557 [0.157] 0.01
PC.aa.36.6 [IQR] 2.534 [0.281] 2.541 [0.253] 2.530 [0.337] 0.868
PPY [IQR] 2.055 [0.480] 2.045 [0.441] 2.072 [0.503] 0.114
Kruskal Wallis chi-squared was used to test between normal and abnormal groups for continuous demographic variables.
Fishers exact was used to test between normal and abnormal groups for categorical demographic variables.
APOE status is 1 if an individuals genotype contains any e4 alleles, and 0 otherwise.
IQR = Inter-quartile range; CSF = Cerebrospinal Fluid; MMSE = Mini Mental State Exam;
MCI = Mild Cognitive Impairment; CTL = Control; PGRS = Polygenic risk score; PPY = Pancreatic Polypeptide.
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Supplementary Table 2: Cohort demographics ANALYSIS 2
EDAR
Overall Normal CSF A  Abnormal CSF A  P-value
(N=47) (N=24) (N=23)
Median age [IQR] 69 [10.5] 65 [11] 69 [10.5] 0.088
Gender (%)
0.371Female 36.2 29.2 43.5
Male 63.8 70.8 56.5
Median years in education [IQR] 12 [6.5] 14 [4.25] 11 [6.5] 0.08
Median MMSE [IQR] 27 [3] 28 [4] 27 [3] 0.203
Diagnosis (%)
> 0.999CTL 10.6 12.5 8.7
MCI 89.4 87.5 91.3
APOE (%)
0.080 44.7 58.3 30.4
1 55.3 41.7 69.6
Standardized PGRS [IQR] 0.142 [1.689] -0.058 [1.341] 0.484 [1.380] 0.202
GERS [IQR] 0.184 [5.679] -2.883 [2.660] 3.025 [3.211] < 0.001
ADNI 2
Overall Normal CSF A  Abnormal CSF A  P-value
(N=38) (N=22) (N=16)
Median age [IQR] 69.5 [11.3] 67.7 [11.5] 73.75 [11.1] 0.048
Gender (%)
0.325Female 50 59.1 37.5
Male 50 40.9 62.5
Median years in education [IQR] 16 [4] 16 [2.75] 16 [4] 0.553
Median MMSE [IQR] 29 [2.75] 29 [2] 27.5 [2.25] 0.103
Diagnosis (%)
0.675MCI 81.6 63.6 87.5
CTL 18.4 36.4 12.5
APOE (%)
0.5110 57.9 63.6 50
1 42.1 36.4 50
Standardized PGRS [IQR] 0.0002 [1.246] 0.089 [1.323] -0.221 [1.127] 0.554
GERS [IQR] -0.821 [3.968] -1.297 [3.999] 0.078 [3.429] 0.117
Kruskal Wallis chi-squared was used to test between normal and abnormal groups for continuous demographic variables.
Fishers exact was used to test between normal and abnormal groups for categorical demographic variables.
APOE status is 1 if an individuals genotype contains any e4 alleles, and 0 otherwise.
IQR = Inter-quartile range; CSF = Cerebrospinal Fluid; MMSE = Mini Mental State Exam;
MCI = Mild Cognitive Impairment; CTL = Control; PGRS = Polygenic risk score; GERS = Gene expression risk score.
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Supplementary Table 3: Results for ANALYSIS 1
Model Informative priors? Accuracy Sensitivity Specificity AUC ROC
Demographics NO 0.6576 0.7148 0.5926 0.767
Demographics YES 0.5182 0.5362 0.4896 0.5312
Demo + Protein NO 0.387 0.5434 0.1852 0.4368
Demo + Protein YES 0.4956 0.1414 0.9676 0.4344
Demo + Metabolite NO 0.3692 0.5434 0.142 0.3398
Demo + Metabolite YES 0.4864 0.1244 0.9676 0.4328
Demo + PGRS NO 0.4598 0.252 0.7316 0.4198
Demo + PGRS YES 0.441 0.5162 0.3614 0.4626
Demo + Protein + Metabolite NO 0.4282 0 1 0.5686
Demo + Protein + Metabolite YES 0.4282 0 1 0.656
Demo + Protein + PGRS NO 0.4282 0 1 0.4224
Demo + Protein + PGRS YES 0.518 0.2592 0.8656 0.6398
Demo + Metabolite + PGRS NO 0.5714 0.7708 0.3162 0.6346
Demo + Metabolite + PGRS YES 0.4282 0 1 0.6078
Demo + Protein + Metabolite + PGRS NO 0.5714 0.7708 0.3162 0.4912
Demo + Protein + Metabolite + PGRS YES 0.4282 0 1 0.5264
PGRS = Polygenic Risk Score
AUC ROC = Area under the Receiver Operating Characteristic Curve
Supplementary Table 4: Results for ANALYSIS 2
Model Informative priors? Accuracy Sensitivity Specificity AUC ROC
Demographics NO 0.421 [0.263; 0.592] 0.625 0.273 0.315
Demographics YES 0.5 [0.334; 0.666] 0.625 0.409 0.415
Demo + PGRS NO 0.579 [0.408; 0.737] 0.625 0.545 0.661
Demo + PGRS YES 0.395 [0.24; 0.566] 0.438 0.364 0.347
Demo + GERS NO 0.474 [0.31; 0.642] 0.688 0.318 0.472
Demo + GERS YES 0.342 [0.196; 0.514] 0.375 0.318 0.27
Demo + PGRS + GERS NO 0.579 [0.408; 0.737] 0.688 0.5 0.636
Demo + PGRS + GERS YES 0.474 [0.31; 0.642] 0.562 0.409 0.42
AUC ROC = Area under the Receiver Operating Characteristic Curve.
PGRS = Polygenic Risk Score; GERS = Gene expression risk score.
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Supplementary Table 5: Probes in GERS in ANALYSIS 2
Entrez ID LASSO coe cient (3dp) Gene name
10077 0.053 TSPAN32 : Tetraspanin 32
10425 0.01 ARIH2 : AriadneRBR E3 ubiquitin protein ligase 2
10961 2.297 ERP29 : Endoplasmic reticulum protein 29
1861 0.003 TOR1A: Torsin family 1, member A
212 -0.273 ALAS2 : 5’-aminolevulinate synthase 2
3126 0.022 HLA-DRB4 : Major histocompatibility complex, class II, DR beta 4
3543 -0.177 IGLL1 : Immunoglobulin lambda-like polypeptide 1
4069 0.321 LYZ : Lysozyme
51024 -0.203 FIS1 : Fission, mitochondrial 1
51312 -0.09 SLC25A37 : Solute carrier family 25 (mitochondrial iron transporter), member 37
51399 0.873 TRAPPC4 : Tra cking protein particle complex 4
54807 0.043 ZNF586 : Zinc finger protein 586
55766 0.489 H2AFJ : H2A histone family member J
57222 -0.136 ERGIC1 : Endoplasmic reticulum-golgi intermediate compartment 1
6228 0.255 RPS23 : Ribosomal protein S23
65264 -0.078 UBE2Z : ubiquitin conjugating enzyme E2Z
80162 0.448 ATHL1 : Acide trehalase-like 1
8349 0.553 HIST2H2BE : Histone cluster 2
84273 0.035 NOA1 : Nitric oxide associated 1
84447 -0.105 SYVN1 : Synoviolin 1
84545 -0.405 MRPL43 : Mitochondrial ribosomal protein L43
8546 0.53 AP3B1 : Adaptor-related protein complex 3, beta 1 subunit
89790 -0.299 SIGLEC10 : Sialic acid binding Ig-like lectin 10
973 -0.297 CD79A
997 -0.036 CDC34 : Cell division cycle 34
GERS = Gene expression risk score; dp = decimal places.
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Supplementary Figures
Supplementary Figure 1: Overview of PGRS and GERS for ANALYSIS 2
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